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Prokaryotic organisms employ various mechanisms for defending against parasitism by 
viruses and other mobile genetic elements. One form of defense comprises the adaptive 
immune systems derived from clustered, regularly interspaced, short palindromic 
repeat (CRISPR) loci and CRISPR-associated (cas) genes. CRISPR-Cas immune systems 
enable the acquisition of heritable resistance to specific mobile genetic elements on the 
basis of nucleic acid sequence recognition, but do not necessarily discriminate between 
target elements which are burdensome and those which are beneficial. My thesis is 
concerned with the consequences of CRISPR-Cas immunity directed at a particular 
breed of bacterial DNA viruses, known as temperate phages, which cause both harmful 
(lytic) and benign (lysogenic) infections under different conditions.  
Initial studies investigating prokaryotic CRISPR-Cas immunity seemed to indicate that 
functional, DNA-targeting systems cannot stably co-exist with their target elements in 
vivo. For example, in studies where immunity was directed at temperate phages, DNA-
targeting CRISPR-Cas systems were found to prevent both lysogenic and lytic infections 
except when targeting was altogether abrogated via mutation or inhibition of the 
CRISPR-Cas system. The first part of my thesis work includes in vivo experiments which 
challenged the generality of this view, with regard to the different types of DNA-
targeting CRISPR-Cas systems. Namely, I demonstrated that a staphylococcal branch of 
the ‘type III’ CRISPR-Cas systems is capable of tolerating lysogenic infections by 
specific temperate phages which are otherwise targeted during lytic infections. I further 
established that the capacity for conditional temperate phage tolerance results from a 
transcription-dependent targeting modality which was not anticipated for this 
particular DNA-targeting type III system. In contrast, I observed only the expected 
genetic escape outcomes when temperate phages were targeted by a ‘type II’ CRISPR-
Cas system with a transcription-independent (Cas9-based) DNA targeting modality. 
These findings laid the groundwork for subsequent studies of CRISPR-Cas immunity to 
phages in Staphylococcus aureus hosts, and guided my colleagues towards in vitro 
characterization of the type III system’s transcription-dependent targeting mechanism.  
CRISPR-Cas systems have been identified in about 50% of sequenced bacterial 
genomes, and the factors which influence this distribution are still not fully understood. 
My description of conditional tolerance by a staphylococcal, type III CRISPR-Cas 
system illustrated that, in principle, these particular systems could stably co-exist with 
their temperate phage target elements in lysogenic hosts while maintaining their ability 
to protect against lytic infections. During the second part of my thesis work, I set out to 
define additional phenotypic consequences for the lysogenized lineages of S. aureus 
which maintain conditional tolerance, in an effort to better understand how this 
phenomenon might influence the distribution and stability of type III systems among 
natural isolates. Notably, I found that the maintenance of certain temperate-phage-
targeting systems can incur fitness costs in lysogenic populations. I showed, 
furthermore, that these costs are potentially greater if more than one temperate phage is 
targeted in populations of double lysogens, but that they can be alleviated by mutations 
which do not abrogate phage targeting during lytic infections. Collectively, these 
findings imply that long-term maintenance of type III systems in natural populations of 
lysogens might require additional evolutionary fine-tuning, particularly among lineages 
which are prone to multiple infection. 
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CHAPTER 1: INTRODUCTION 
1.1 Implications of Horizontal Gene Transfer for prokaryotic evolution 
The ‘vertical’ transfer of a genome from parent to progeny during reproduction can 
result in the stochastic alteration of its sequence content via mutation. Mutations are a 
source of genetic variation and may give rise to novel adaptive genotypes that can be 
selected for during evolution. However, mutations occurring at random are more likely 
to be deleterious than beneficial. According to Muller’s ratchet mechanism (Muller, 
1932, 1964), genomic degeneration occurring via random mutation can drive an 
organism to extinction in the absence of a recombination process to increase the chance 
of reconstructing fully functional genomes (Felsenstein, 1974). This fate may be averted 
through sexual recombination, as it is exhibited in extant eukaryotes (Figure 1-1A). 
Moreover, sexual recombination offers an additional mechanism for generating novel 
genotypes during reproduction, but it has evolved with reproductive barriers that help 
to moderate the variation produced by ensuring that genetic exchanges occur between 
closely related genomes (for example, within a species) (Seehausen et al., 2014). By 
contrast, recombination can occur between more distantly related genomes through 
horizontal gene transfer (HGT), which constitutes another key avenue for genome 
diversification (Keeling and Palmer, 2008; Thomas and Nielsen, 2005). 
2 
Figure 1-1. Genome evolution can result from vertical or horizontal transmission of 
DNA. 
(A) Schematic summary of genome evolution in a unicellular and haploid eukaryote 
that reproduces sexually. Mutation can generate novel, mutant alleles (brown lines with 
stars) within chromosomes during DNA replication, which may be either deleterious or 
beneficial. Recombination between homologous chromosomes (yellow or blue) can 
occur during a tetraploid zygotic stage, before any cellular division. Sexual 
recombination in this manner provides opportunities for the removal of deleterious 
alleles (red lines) as well as for the introduction of beneficial alleles (green lines). Both 
processes occur vertically during reproduction. (B) Schematic summary of genome 
evolution in a haploid and unicellular prokaryote that reproduces asexually. Mutation 
may once again generate mutant alleles (shown as brown lines with stars) vertically 
during reproduction of the prokaryote’s chromosome (blue); however, recombination  
with exogenous sources of DNA (yellow) must occur through horizontal processes that 
are not tied to reproduction. 
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Broadly speaking, HGT refers to the transmission of genetic material from one 
organism to another, through processes that are not tied to reproduction. Following 
physical transport into the recipient organism, genetic material may be incorporated 
into the genome through recombination with the chromosome (or chromosomes) or 
through autonomous replication as an episome. Evidence for HGT in eukaryotes has 
accumulated over the years, but most reports involve free-living protists and fungi, or 
endosymbionts inhabiting the cytosol of multicellular organisms (Dunning Hotopp, 
2011; Keeling and Palmer, 2008). Meanwhile, the mammalian nuclear genome appears 
to be well insulated from HGT, and this has been suggested to result from the isolation 
of their germline cells in the gonads (Andersson et al., 2001). One could further 
speculate that this represents an evolutionary strategy that helps to preserve genomic 
fitness in mammalian lineages, as HGT can introduce deleterious mutations in addition 
to those generated vertically and might be superfluous if sufficient recombination and 
genetic variation is already achieved through sexual reproduction. However, for 
unicellular, asexually reproducing organisms such as prokaryotes, HGT provides an 
avenue for recombination that, in theory, can operate like sexual recombination in 
averting Muller’s ratchet (Takeuchi et al., 2014), in addition to providing genomic 
variation (Figure 1-1B). Stricter definitions of HGT, also known as lateral gene transfer 
(LGT), may distinguish it from gene transfers that result in gene conversion or repair at 
homologous loci (Ochman et al., 2000; Vos, 2009). In other words, HGT/LGT may be 
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defined in certain contexts as only those transfers that introduce non-homologous (also 
known as heterologous) sequences to a genome. When recombinations with 
exogenously derived donor DNA are considered, however, both heterologous DNA 
insertions and gene conversions/repair at homologous loci can result from the same 
molecular processes (e.g., homologous recombination between related segments of 
DNA) (Johnston et al., 2014; Vos, 2009). Therefore, the term ‘horizontal DNA transfer’ 
(HDT) can also be employed to describe, more precisely, the transfer of DNA from one 
organism to another without distinguishing between outcomes (Croucher et al., 2016). 
In practice, because relatively little is known about horizontal RNA transfer in 
prokaryotes, the less stringent definition of HGT/LGT often invoked in the prokaryotic 
literature (and throughout this work) is essentially synonymous with HDT. Sequencing 
of diverse prokaryotic phyla and comparative genome analyses suggest the virtual 
ubiquity of HGT, as well as its potential to drive rapid genome evolution through the 
acquisition of novel genes en bloc (Dobrindt et al., 2004; Koonin and Wolf, 2008). 
Notably, HGT appears to be a common route through which evolving pathogens 
acquire particular traits, including resistance to antibiotics (Croucher et al., 2011). 
Nevertheless, in the absence of reproductive barriers, the risk of introducing deleterious 
information into the genome is theoretically greater with HGT than with conventional 
sexual reproduction. For example, HGT can introduce mobile genetic elements (MGEs) 
from unrelated organisms — such as transposons, viruses or plasmids — which can, in 
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turn, parasitize the genome (Doolittle and Sapienza, 1980; Orgel and Crick, 1980). This 
matter is further complicated by the fact that MGEs are themselves often vectors of 
HGT in the prokaryotic domain, as I explain below. 
Molecular mechanisms for prokaryotic HGT have been established using various 
experimental systems, beginning with the discovery of pneumococcal capsule 
acquisition (Griffith, 1928). Overall, three major categories have been studied 
extensively in bacteria: conjugation, transduction and natural transformation. 
Conjugation involves the direct transfer of DNA from a donor to a recipient cell during 
physical contact through pili (Llosa et al., 2002) or pore-like structures (Grohmann et al., 
2003). It is typically orchestrated by conjugative plasmids or transposons that carry the 
necessary genetic functions to ensure their own transfer through this process. 
Transduction refers to the transfer of non-viral DNA encapsulated in viruses or virus-
like particles. During lytic infections, the viruses of bacteria (known as phages) can 
package parts of the lysing host genome into a few of their particles, and this DNA may 
then be delivered to distant cells (Weinstock, 2002; Zinder and Lederberg, 1952). 
Natural transformation involves the uptake of free DNA from the environment and 
occurs after the recipient cell enters a physiological state known as ‘competence’ 
(Johnston et al., 2014). Although natural transformation of competent bacteria is a host-
encoded process and usually results in unbiased DNA uptake, most known examples of 
conjugation and transduction are tied to the activity of MGEs that need not benefit the 
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host and can even be detrimental. Unlike typical genes that rely strictly on a host 
genome for carriage, mobile genetic elements can propagate independently of host 
replication. Therefore, their presence in genomes could reflect parasitism rather than 
natural selection for their phenotypic contributions to host survival (Orgel and Crick, 
1980). For example, although conjugative plasmids and transposons can carry adaptive 
traits such as genes for antibiotic resistance that promote survival, horizontal 
dissemination of these elements can occur even when they burden their hosts with 
extraneous genetic cargoes that do not promote fitness or vertical transmission. Lytic 
phages represent an extreme form of genomic parasitism in that they immediately 
dispose of their host after the process of self-amplification. Hence, molecular barriers 
that limit the spread of MGEs can directly contribute to prokaryotic survival (Labrie et 
al., 2010; Makarova et al., 2013; Thomas and Nielsen, 2005). Some barriers, such as 
abortive infection systems, offer highly selective resistance to lytic infection by certain 
phages or classes of phages (Chopin et al., 2005; Depardieu et al., 2016; Labrie et al., 
2010). When considering the potential benefits of HGT, there appear to be tradeoffs 
associated with generalized versus selective resistance mechanisms. For example, 
although selective barriers do not necessarily offer resistance to diverse types of 
elements, they are less likely to interfere with HGT outright. Among the known 
prokaryotic defense mechanisms, restriction–modification (R–M) and CRISPR–Cas 
(clustered, regularly interspaced short palindromic repeat–CRISPR-associated proteins) 
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systems are distinct in that they can resist diverse MGEs while still offering selectivity. 
Thus, both systems can safeguard against genomic parasitism without necessarily 
interfering with HGT. These properties, furthermore, provide a central basis for the 
comparisons to mammalian immunity discussed in this work. 
1.2 Prokaryotic immune systems are optimized for selective resistance to MGEs 
Across all domains of life, the fitness of an organism may be threatened by parasitic 
interactions with foreign elements. Accordingly, organisms have evolved several 
biological barriers that aid in the defense against parasitism. Physical barriers, such 
as the cellular envelope and those at the surface of mammalian skin and mucosal 
linings, repel foreign elements rather indiscriminately (McGuckin et al., 2011; Proksch et 
al., 2008). Immune systems, by contrast, offer the potential to repel particular target 
elements while tolerating others and can thus function as highly selective barriers. 
However, the balance of selectivity must be well calibrated when relying on active 
means of surveillance and resistance; a system that is too selective risks evasion by 
pathogens, whereas one that is unselective risks damaging the host organism through 
immunopathology. In this regard, the mammalian immune system serves as an 
excellent example, with innate and adaptive activities (Medzhitov, 2007) that are 
optimized to reliably combat parasitism and generally tolerate host constituents. 
Prokaryotic R–M and CRISPR–Cas systems resemble the mammalian immune system in 
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their ability to actively resist infectious elements with a high degree of selectivity, as 
well as in their capacity for tolerance (Barrangou and Marraffini, 2014; Goren et al., 
2012; Tock and Dryden, 2005). In the following two subsections, I describe the core 
mechanisms through which these systems achieve selectivity and ‘self’ tolerance via 
nucleic acid surveillance within the cell. Analogy to features of mammalian immunity is 
also considered in more detail. 
1.2.1 Restriction-Modification systems 
A minimal R–M system encodes enzymes with two activities: a restriction endonuclease 
(REase), which cleaves double-stranded DNA upon recognition of specific target 
sequences, and a methyltransferase (MTase), which modifies these sites through 
methylation to prevent cleavage (Tock and Dryden, 2005). Depending on the type of 
system, these activities may be associated with separate proteins, a complex, or a single 
protein (for a comprehensive review on their nomenclature, see (Roberts et al., 2003)). 
Recognition sites for an R–M system are typically palindromic sequences of 4–8 bp in 
length — short enough to occur frequently in the genome of a prokaryotic organism at 
random. Hence, without a nuclear envelope to insulate their genetic material from the 
cytoplasm, prokaryotes use methylation to protect their chromosome and other native 
DNA elements from attack by the REase. Meanwhile, the REase can provide immunity 
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against invading genetic elements that have not had sufficient exposure to the MTase of 
the cell, including the DNA of phages and plasmids (Arber and Linn, 1969) (Figure 1-2). 
Figure 1-2. Schematic summary of antiviral defense mediated by Restriction–
Modification systems.  
(A) Intracellular restriction endonuclease enzymes (REases; shown in red) cleave 
injected viral DNA (black double helix) at short sequence motifs known as recognition 
sites (pink boxes). Meanwhile, methyltransferase enzymes (MTases; shown in blue) can 
modify DNA at the same recognition sites (appended with blue boxes) to prevent 
cleavage by their cognate REase. The sequence specificity of a REase is hardwired for a 
particular recognition site and thereby offers innate immunity to unmodified phages 
that harbor these sites in their DNA. Whereas unmodified invading DNA is rarely 
methylated fast enough to receive protection from restriction, modification is generally 
effective in preventing cleavage of the host chromosome (bottom) and thus allows for a 
rudimentary form of self and non-self discrimination. 
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Thus, methylation provides the R–M system with an intrinsic basis for distinguishing 
self from non-self, and each system is hardwired for surveillance of a particular 
recognition sequence, similarly to pattern recognition by mammalian pattern 
recognition receptors (Medzhitov, 2007). In these regards, R–M activities are akin to 
mammalian innate immune functions and may have an analogous role in the resistance 
against viruses and other MGEs (see (Vasu and Nagaraja, 2013) for a review on 
additional functions that have been described for some of these systems). 
R–M systems have been identified in about 75% of sequenced prokaryotes, 
averaging roughly two systems per genome (Oliveira et al., 2014). As alluded above, the 
relative ubiquity of their recognition sequences in DNA dictates that the selectivity of 
the R–M system for foreign target elements must be primarily informed by methylation 
patterns (although underrepresentation of recognition sequences can also occur (Rocha 
et al., 2001)). However, this rudimentary mechanism for self and non-self discrimination 
is particularly susceptible to host mimicry evasion paradigms (Damian, 1964); even 
exogenous DNA may bypass restriction if it arrives pre-methylated (for example, 
through modification in a neighbouring cell possessing the same MTase) (Bertani and 
Weigle, 1953; Korona and Levin, 1993). In this scenario, the methylated foreign DNA is 
effectively tolerated as a self-component and recognized by the host MTase during 
subsequent rounds of replication. Therefore, an infectious MGE can propagate freely in 
spite of REase surveillance once it manages to achieve methylation. In parallel, 
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prokaryotic organisms may acquire resistance to these infectious elements through 
other defense mechanisms, such as their CRISPR–Cas systems (Dupuis et al., 2013; 
Hynes et al., 2014). 
1.2.2 CRISPR-Cas systems 
Among the two major classes of CRISPR-Cas systems, six distinct types (I-VI) and 19 
subtypes (A-U) have now been defined (Makarova et al., 2015; Shmakov et al., 2017), 
but they all share two key genetic components: a CRISPR locus and a set of genes that 
encode Cas proteins. Cas proteins include nucleases that can degrade invading DNA or 
RNA targets, and they identify their targets via base pair complementarity using small 
RNA guides known as CRISPR RNAs (crRNAs) (Brouns et al., 2008; Gasiunas et al., 
2012; Jinek et al., 2012; Zhang et al., 2012). Depending on the class of CRISPR-Cas 
system, crRNAs can function as guides in complex with a single effector protein or with 
a multiprotein effector complex (Shmakov et al., 2017; van der Oost et al., 2014). Class I 
CRISPR-Cas systems include the type I and type III systems that utilize a multiprotein 
effector complex, while Class II CRISPR-Cas systems include the type II, type V, and 
type VI that utilize a single protein effector. The crRNAs themselves are derived from 
transcription of one or more CRISPR loci, which are structured as arrays of short 
palindromic repeat sequences (~40 bp in length) that are intercalated with unique 
sequences of a similar length, known as spacers (Figure 1-3). After being processed into 
12 
Figure 1-3. Schematic summary of antiviral defense mediated by CRISPR–Cas 
systems. 
(A) CRISPR arrays are composed of alternating units of repeat sequences (black 
squares) interrupted by unique spacer sequences (colored diamonds). Newly 
encountered phage DNA sequences (boxed in red) can be incorporated as spacer DNA 
within the host CRISPR array through the process of CRISPR adaptation, which 
provides a genetic memory of past infection. Transcription of the CRISPR array 
provides primary transcripts, known as pre-CRISPR RNAs (pre-crRNAs), which are 
processed into short, mature species that each include a single spacer sequence. During 
CRISPR–Cas targeting, Cas protein complexes are guided by individual mature crRNAs 
to mediate the destruction of invading nucleic acids that harbor a matching target 
sequence. By virtue of sequences in their flanking repeat elements, spacer DNA of the 
CRISPR array is intrinsically spared from CRISPR–Cas targeting to prevent 
autoimmunity (Marraffini and Sontheimer, 2010a; Shmakov et al., 2017; Wiedenheft et 
al., 2012). 
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minimal, mature species, each crRNA contains a single spacer sequence that specifies a 
target for its Cas nuclease complex (Brouns et al., 2008; Carte et al., 2008; Charpentier et 
al., 2015; Hatoum-Aslan et al., 2011). In this way, Cas nucleases can be programmed to 
recognize diverse DNA or RNA targets, according to the spacer sequence of their 
crRNA. Importantly, the spacer content of a CRISPR locus can be actively modified 
through a process known as CRISPR adaptation (Barrangou et al., 2007) (reviewed in 
(Amitai and Sorek, 2016; Jackson et al., 2017)). During this process, spacer DNA can be 
acquired directly from an invading element for incorporation into the CRISPR locus 
(Figure 1-3). This provides the cell with a novel target sequence for its Cas nucleases as 
well as a genetic memory of the encounter to pass on to daughter cells. In this manner, 
CRISPR–Cas function is particularly analogous to mammalian adaptive immunity. 
However, it should be emphasized that memory acquired through CRISPR is fully 
heritable, whereas newborn mammals are only thought to receive short-lived, 
maternally derived passive immunity (Grindstaff et al., 2003). Furthermore, whereas the 
mammalian immune system relies heavily on clonal deletion and anergy of self-reactive 
cells to establish central tolerance (Kyewski and Klein, 2006), CRISPR–Cas systems do 
not require such mechanisms because spacer sequence diversity is not randomly 
generated but instead derived from invading genetic elements in an apparent 
Lamarckian evolutionary fashion (Barrangou and Marraffini, 2014; Haerter and 
Sneppen, 2012). Nevertheless, given that the spacer sequences in CRISPR loci are 
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themselves perfect matches for the crRNAs they encode, additional mechanisms are 
required to protect the CRISPR locus DNA from autoimmune responses (Marraffini and 
Sontheimer, 2010b; Shmakov et al., 2017; Wiedenheft et al., 2012). In this sense, CRISPR 
loci can be viewed as immune-privileged regions of the genome. 
The majority of naturally occurring spacer sequences with known targets match 
to viral elements, although matches to plasmids and other MGEs are also observed 
(Brodt et al., 2011). A growing body of experimental work indicates that CRISPR–Cas 
systems are indeed capable of resisting a wide range of MGEs targeted by their spacers 
(Barrangou et al., 2007; Edgar and Qimron, 2010; Marraffini and Sontheimer, 2008; 
Tamulaitis et al., 2014). Unlike R–M systems, which discriminate targets primarily 
through methylation, CRISPR–Cas systems derive their selectivity first and foremost 
from an exquisitely specific sequence recognition capability based on crRNA 
complementarity. On the one hand, the spacer sequence of a typical mature crRNA is 
20–40 nucleotides—presumably long enough to discriminate different target elements 
on the basis of sequence alone. Accordingly, a phage- or plasmid-derived spacer 
sequence is unlikely to specify targeting of the host’s own chromosome (generally not 
exceeding ~5 Mbp for a prokaryotic genome (Koonin and Wolf, 2008)). On the other 
hand, it has been shown that spacers engineered to specifically target the chromosome 
appear to be lethally self-reactive (Bikard et al., 2014; Jiang et al., 2013a), so the 
observation that self-targeting spacers rarely occur in nature might be explained by the 
15 
immediate culling of cells that acquire such spacers — in a manner akin to clonal 
deletion. Interestingly, however, experimental evidence indicates that spacer acquisition 
is biased towards extra-chromosomal sequences from the outset (that is, even in the 
absence of CRISPR–Cas target degradation), despite the overrepresentation of 
chromosomal DNA by mass (Levy et al., 2015; Modell et al., 2017; Yosef et al., 2012). 
Evidently, this bias helps to ensure that CRISPR–Cas surveillance processes display a 
selective preference for foreign genetic elements, given that many types of HGT events 
do not involve physical linkage of foreign DNA to the chromosome. The phenomenon 
known as ‘primed’ CRISPR adaptation may also help to ensure that the adaptation 
machinery is selectively directed towards foreign elements, and that robust immunity is 
achieved in the face of recurring infections (Datsenko et al., 2012; Fineran et al., 2014; 
Jackson et al., 2017; Musharova et al., 2017). This phenomenon is analogous to affinity 
maturation and class-switching of antibodies in the mammalian immune system (Wabl 
and Steinberg, 1996), in the sense that it can refine the CRISPR repertoire to ensure more 
effective resistance during subsequent infections. Perhaps one distinction here, 
however, is that antibody development can be driven by antigen-presenting cells 
(Medzhitov, 2007) even after a particular infection is cleared, whereas primed CRISPR-
Cas adaptation still requires re-exposure to the infectious element(s). 
As discussed in section 1.1, while the uptake of DNA from exogenous sources 
can introduce parasitic MGEs that compromise host fitness, it can also introduce 
16 
beneficial genes (Croucher et al., 2016). Four of the six (I-VI) types of CRISPR-Cas 
systems which have been classified to date (Makarova et al., 2015; Shmakov et al., 2017) 
include systems that cleave the DNA of their target elements (Jinek et al., 2012; Samai et 
al., 2015; Westra et al., 2012; Zetsche et al., 2015). It was therefore proposed that 
resistance to foreign DNA elements by CRISPR-Cas systems could jeopardize the 
survival of bacterial hosts which rely heavily on horizontal gene transfer (HGT) 
(Marraffini and Sontheimer, 2008), and in turn promote the evolution of strains that do 
not harbor CRISPR-Cas systems (Marraffini, 2013; Palmer and Gilmore, 2010). CRISPR-
Cas systems are indeed absent from ~50% of sequenced bacterial genomes (Touchon et 
al., 2016), despite evidence that they can be transferred horizontally (Chakraborty et al., 
2010; Godde and Bickerton, 2006; Horvath et al., 2009; Seed et al., 2013) and function in 
heterologous hosts (Bikard et al., 2012; Brouns et al., 2008; Heler et al., 2015). Moreover, 
the potential for genetic loss of CRISPR-Cas systems has been clearly demonstrated in 
laboratory settings. For example, population bottlenecks imposed by antibiotics were 
found to select for mutant or deleted CRISPR-Cas systems when a target element 
carrying resistance to the antibiotic was introduced prior to treatment (Edgar and 
Qimron, 2010; Fischer et al., 2012; Goldberg et al., 2014; Gudbergsdottir et al., 2011; 
Jiang et al., 2013b). In this manner, tradeoffs associated with targeting of favorable 
genetic elements could influence the distribution of CRISPR-Cas systems in wild 
populations. It should be emphasized, however, that CRISPR-Cas systems were not 
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found to impose a general barrier to HGT when evolutionary timescales were 
considered in silico (Gophna et al., 2015)—perhaps owing to their optimizations toward 
selectivity. 
Fitness costs associated with the maintenance of CRISPR-Cas systems, including 
those that result from ‘immunopathological’ self-targeting, have also been proposed to 
influence the distribution of these systems (Goldberg and Marraffini, 2015; van Houte et 
al., 2016; Vercoe et al., 2013). As mentioned above, previous studies have demonstrated 
that chromosomal targeting by CRISPR-Cas systems in bacteria is severely detrimental 
to growth and potentially lethal (Jiang et al., 2013b; Vercoe et al., 2013). Therefore, high 
rates of CRISPR-Cas adaptation are potentially detrimental to the host, insofar as they 
engender a greater risk of acquiring self-targeting spacers (Heler et al., 2017). In certain 
cases, immunopathology may result from CRISPR-Cas immunity directed at temperate 
phages that integrate into their host’s chromosome during lysogeny (Cady et al., 2012; 
Edgar and Qimron, 2010; Goldberg et al., 2014). ‘Temperate’ phages are distinct from 
strictly lytic ‘virulent’ phages in that they can establish an alternative infection state, 
known as lysogeny (Lwoff, 1953), wherein the host is spared from lysis. Integrative 
temperate phages, such as lambda-like (lambdoid) temperate phages, integrate into 
their host’s chromosome as a so-called prophage upon establishment of a lysogenic 
infection (Figure 1-4). The difference between the lambdoid temperate phage’s infection 
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Figure 1-4. Summary of phage λ’s alternate infection pathways.  
(A) Following injection and circularization of the λ genome (red), infection can follow 
either a lysogenic or lytic pathway. During a lytic cycle, λ genomes are propagated and 
packaged into phage particles, which are ultimately released via lysis of the host cell. 
During a lysogenic cycle, the host is spared from lysis via repressor-mediated 
immunity, and the λ genome is integrated into the bacterial chromosome (blue) as a so-
called prophage. Subsequent rounds of cell division allow passive replication of the 
prophage within the chromosome. During a process known as ‘prophage induction’, 
phage λ can excise from a lysogen’s chromosome and re-enter the lytic cycle. 
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states reflects changes in its transcriptional activity within the host, rather than 
alterations of its DNA sequence (Johnson et al., 1981). Therefore, when CRISPR-Cas 
immunity is directed at an integrative temperate phage, targeting of phage DNA may 
occur at prophage loci in the event of lysogenization. In the next section, I briefly 
summarize the transcriptional regulation that determines a lambdoid phage’s infection 
state, as well as some other relevant features of lambdoid temperate phage biology. 
1.3 Lambdoid temperate phages 
Typically, the term ‘lambdoid’ is used to describe temperate phages of Escherichia coli 
that are similar to phage λ (lambda) (Brüssow et al., 2004; Gottesman and Weisberg, 
2004). The mechanisms of gene regulation (Dodd et al., 2005) and site-specific 
integration (Kotewicz et al., 1977) that that are central to phage lambda’s lytic and 
lysogenic life cycles have been characterized in extensive detail. However, these life 
cycles are not specific to temperate phages infecting E. coli, and lambda’s mechanisms 
therefore serve as more general models for understanding certain types of temperate 
phages. In this work, I consider a temperate phage lambdoid if its prophage integrates 
site-specifically, and if its life cycle decisions are principally determined by a cI-/cro-like 
regulatory mechanism, or ‘genetic switch’, akin to that of phage lambda (Johnson et al., 
1981; Ptashne, 2011). 
20 
Under typical laboratory conditions, the majority of lambda infections give 
rise to a lytic cycle. A proportion of these infections, however, will lead to establishment 
of a lysogenic cycle and prophage integration (Figure 1-4). This occurs when lambda’s 
cI-encoded repressor accumulates early during infection to sufficient levels that repress 
transcription of cro, a gene required for establishment of the lytic cycle (Casjens and 
Hendrix, 2015). During lysogeny, cI expression remains on, and its repressive action 
ensures that transcription of cro (and also as a consequence most of the phage genome) 
remains off (Ptashne, 2011). In cases where cro was not sufficiently repressed, a lytic 
cycle ensues. Under these conditions, the cro gene product—also a repressor—
accumulates to sufficient levels that prevent cI transcription, and thereby ensures that 
expression of the other early-transcribed lytic genes can proceed. In turn, some of these 
early-transcribed lytic genes include regulators that allow transcription of late genes 
and subsequent completion of the lytic cycle (Casjens and Hendrix, 2015). 
In order to exert their regulatory control early during infection, CI and Cro 
repressors compete for binding at two regions on the lambda genome, known as 
operators, which each possess three binding sites. The right operator (OR) is located 
between the oppositely oriented cI and cro ORFs, and serves as the primary site of 
action for determining the decision between lytic and lysogenic life cycles (Johnson et 
al., 1981). Although CI and Cro can occupy each of the three OR binding sites (OR1, OR2, 
and OR3), they have evolved with distinct preferences that allow differential 
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accumulation at each site. Thus, CI and Cro can preferentially repress their partner’s 
transcription without completely repressing their own transcription up front (Figure 1-
5). The molecular details of transcriptional regulation by CI and Cro are discussed 
elsewhere in more depth (Dodd et al., 2005). 
Figure 1-5. Schematic diagram summarizing transcriptional regulation that stabilizes 
phage λ’s decision between lysogenic and lytic life cycles.  
(A) During infections, the cI and cro ORFs (thick purple and orange arrows, 
respectively) can be transcribed from the PRM and PR promoters, respectively (grey bent 
arrows). Homodimers of their gene products (CI and Cro, respectively) can bind at each 
of the three operator binding sites (solid grey rectangles). Cro’s preference for OR3 and 
OR2 over OR1 allows it to dominate the operator such that cI transcription is turned off 
while cro’s can initially remain on; a lytic cycle ensues (right). Meanwhile, CI’s 
preference for OR1 and OR2 over OR3 allows it to dominate the operator such that cro 
transcription is turned off while cI’s can remain on; a lysogenic cycle ensues (left). 
Features of the diagram are scaled arbitrarily. 
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In temperate phages with related genomic architecture, similar operators can 
be found between divergently transcribed cI- and cro-like ORFs. Later in the text, I’ll 
refer to such regions more generally as early lytic control regions (ELCRs) for simplicity. 
Another region, which I’ve termed the late lytic control region (LLCR), refers to a 
conserved region that was identified within various temperate phages infecting gram 
positive bacteria (Ferrer et al., 2011; Quiles-Puchalt et al., 2013).  As its name implies, 
this latter region appears to be specifically involved in regulating transcription of late 
lytic genes and completion of the lytic cycle, but it is not directly controlled by the CI- or 
Cro-like proteins. 
Unlike toxic lytic infections, lysogenic infections do not necessarily reduce 
host fitness and can even be advantageous (Brüssow et al., 2004; Dykhuizen et al., 1978; 
Edlin et al., 1977). In addition, they provide immunity to lytic superinfections by the 
same phage, because the CI(-like) repressors expressed from a resident prophage 
during lysogeny can also suppress lytic development of an injected phage in trans 
(Casjens and Hendrix, 2015). However, this is not always a stable arrangement: 
functional lambdoid prophages retain the ability to re-initiate the lytic cycle and excise 
from the chromosome, both stochastically and in response to DNA damage or other 
signals (Bailone et al., 1979; Johnson et al., 1981; Little and Michalowski, 2010; Schubert 
et al., 2007). This process arises from derepression via autoproteolytic cleavage of the 
prophage’s CI(-like) repressors, and is known as ‘prophage induction’ (Figure 1-4). CI(-
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like) repressors possess an intrinsic serine protease activity, but their autoproteolysis 
only occurs efficiently in the presence of activated RecA (RecA*) co-factors (Erill et al., 
2007; Livny and Friedman, 2004; Mo et al., 2014). Host-encoded RecA becomes activated 
when it associates with ssDNA, typically arising via DNA damage. Accumulation of 
RecA* triggers the host’s ‘Save-Our-Ship’ (SOS) stress response, and in turn leads to 
upregulation of RecA precursors (Erill et al., 2007). Once a threshold of RecA* 
accumulates, prophage induction is also triggered. These processes can be stimulated 
with DNA-damaging treatments such as UV light or Mitomycin C (MMC). When 
lambdoid lysogens are grown in the absence of overt DNA-damaging stimuli, 
‘spontaneous’ prophage induction can still occur at a moderate to low frequency 
(Nanda et al., 2015). However, even spontaneous prophage induction appears to be 
largely dependent on RecA*, because its frequency becomes almost undetectably low in 
host backgrounds that have lost their SOS-responsiveness (Fuchs et al., 1999; Little and 
Michalowski, 2010; Nanda et al., 2015). 
Whereas superinfection of a lambdoid lysogen by identical or closely related 
phages is prevented if the prophage utilizes the same repressor-mediated immunity 
module, superinfection by divergent phages that do not share the immunity module—
known as ‘heteroimmune’ phages—can still occur. During infection by a heteroimmune 
phage, a lysogenic host can become lysogenized with more than one prophage, or 
‘polylysogenized’. In these cases, induction of more than one prophage can still be 
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coordinated via the SOS response, but intracellular competition and/or cross-talk within 
the host may result in asymmetric propagation of one prophage over another (Refardt, 
2011). 
Among certain bacteria with pathogenic lifestyles, such as Staphylococcus 
aureus, polylysogeny is a common phenomenon (Brüssow et al., 2004). For example, one 
screen of 291 S. aureus clinical isolates based on site-specific integrase typing 
determined that most (87%) harbored one or more prophage, and about half (51%) 
contained two or more (Goerke et al., 2009). Similar to lambda and other lambdoid 
phages, the temperate phages of S. aureus have typically been identified as Siphoviridae 
with genome sizes of ~39-43 kbp (Xia and Wolz, 2014). Many of S. aureus’s prophages 
are predicted or confirmed to contribute to their host’s pathogenicity (Xia and Wolz, 
2014). In the next section, I elaborate on some examples relevant to this work. 
1.4 Examples of temperate phages that contribute to staphylococcal
pathogenicity 
In cases where lysogenization is associated with a phenotype independent of repressor-
mediated immunity, the phenomenon can be referred to as ‘lysogenic conversion’ 
(Bondy-Denomy and Davidson, 2014). This was first described for the ability to produce 
diphtheria toxin conferred by lysogenization with certain phages (Groman, 1955). 
Numerous other examples of phages (and in particular prophages) contributing to 
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bacterial pathogenicity have been documented in the literature, and are reviewed 
elsewhere (Brüssow et al., 2004; Canchaya et al., 2003; Casjens, 2003). Lysogenization by 
integrative temperate phages results in two principle genomic alterations: disruption of 
the integration site locus, and incorporation of a heterologous stretch of DNA—the 
prophage. Either alteration can result in lysogenic conversion phenotypes (Bondy-
Denomy and Davidson, 2014). These phenotypes are highly homogeneous in cases 
where the temperate phage reliably integrates into a specific locus. Likewise, the 
prophage itself may encode functions that reliably confer a phenotype. For example, 
temperate phages can harbor seemingly extraneous segments of DNA that are not 
required for their lytic or lysogenic functions, known as ‘morons’ (Brüssow et al., 2004; 
Cumby et al., 2012; Juhala et al., 2000). Moron DNA may include toxin or virulence 
genes, and even promoter elements that allow for their efficient expression during 
lysogeny. In certain cases, processes which occur during prophage induction may also 
contribute to lysogenic conversion phenotypes (Tyler et al., 2013). For example, toxin 
expression can be enhanced via coordinated upregulation of phage late promoters 
during the lytic cycle (Wagner et al., 2002). In addition, it has been shown that lysis can 
allow for efficient release of toxins which accumulate in the periplasm of gram-negative 
bacteria (Shimizu et al., 2009). In the following two subsections, I outline some phages 
and phage-like elements that are proposed or confirmed to contribute to staphylococcal 
pathogenicity in various ways. 
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1.4.1 β-hemolysin-converting phages 
Lysogenization with the β-hemolysin-converting phages of Staphylococci, also known as 
Sa3int phages, is found to simultaneously disrupt the β-hemolysin (hlb) gene harboring 
their integration site and also provide morons—including a cluster within the 3’ end of 
their genomes (Coleman et al., 1989; van Wamel et al., 2006; Verkaik et al., 2011; Xia and 
Wolz, 2014). This ‘immune evasion cluster’ (IEC) can encode for several secreted 
proteins: staphylococcal enterotoxin A (SEA) (Dohlsten et al., 1993), staphylokinase 
(SAK) (Jin et al., 2004), chemotaxis inhibitory protein of S. aureus (CHIPS) (de Haas et 
al., 2004), and staphylococcal complement inhibitor (SCIN) (Rooijakkers et al., 2005). 
Some of these ORFs were found to be upregulated at the transcriptional level in various 
strains, following prophage-inducing treatments with Mitomycin C (Cao et al., 2012; 
Goerke et al., 2006; Sumby and Waldor, 2003). In addition, such treatments were found 
to increase the extracellular concentrations of SEA released by certain strains (Cao et al., 
2012). However, it remains to be clarified whether the process of prophage-mediated 
lysis itself can contribute to the release of functional IEC proteins (or other secreted 
proteins) from S. aureus lysogens. Given that canonical processing of signal peptides 
requires secretion across the plasma membrane (Schneewind and Missiakas, 2012), it’s 
possible that rapid cell lysis via induction could even diminish the release of functional 
secreted proteins by disrupting the integrity of plasma membranes prematurely. 
Whereas the ɸ13 phage of NCTC8325 appears to be fully functional (Goerke et al., 2006; 
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Iandolo et al., 2002; van Wamel et al., 2006), other β-hemolysin-converting prophages 
appear to be at least partially defective (Bae et al., 2006; Holt et al., 2011; Sumby and 
Waldor, 2003; van Wamel et al., 2006). For instance, S. aureus Newman-derived single 
lysogens harboring the ɸNM3 prophage (‘TB3’) do not produce infective particles (Bae 
et al., 2006). S. aureus Newman has been studied as a model clinical isolate in numerous 
works, and its pathogenicity has also been investigated in animal models (Baba et al., 
2008). In addition to its ɸNM3 prophage, Newman harbors three other prophages: 
ɸNM1, ɸNM2, and ɸNM4 (Figure 1-6A). All four prophages integrate site-specifically at 
distinct loci (Figure 1-6B & C). Unlike the ɸNM3 prophage, ɸNM1, ɸNM2, and ɸNM4 
represent functional temperate phages that can form infective particles (Bae et al., 2006). 
They are also ‘pac’ phages that utilize a headful packaging mechanism, and are 
therefore capable of generalized transduction (Chen et al., 2015a; Chen and Novick, 
2009; Chen et al., 2015b). When a S. aureus Newman transposon insertion screen was 
used to look for virulence genes required in a nematode killing assay, one candidate 
ORF was identified in ɸNM3 (separate from the IEC), and five were identified among 
Newman’s three pac prophages (Bae et al., 2004). The mechanistic basis for this remains 
unclear to me. No precise molecular function was ascribed to any of the candidate 
ORFs; and, all three of Newman’s pac prophages were found to be dispensable for 
pathogenesis in a mouse liver abscess model (Bae et al., 2006). However, various pac 
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Figure 1-6. Summary of S. aureus Newman’s four prophages (ɸNM1, ɸNM2, ɸNM3, 
and ɸNM4) and their integration sites within the host chromosome.  
(A) Schematic summary of the predicted ORF (thick arrow) positions and orientations 
in each prophage genome. ORFs are color-coded according to tentatively assigned 
functions (listed at the bottom). The sea, sak, chp, and scn ORFs at the 3’ end of ɸNM3 
constitute its immune evasion cluster. Other virulence determinants (red) were 
identified in a transposon insertion screen for mutants defective in nematode killing, 
and are numbered according to locus tags (SAV numbers) of S. aureus Mu50 prophage 
homologues originally used as a reference (prior to the complete sequencing of 
Newman). Dashed lines indicate that ɸNM3’s cell wall hydrolase ORF is truncated, and 
that its xis ORF is missing, although these are intact within the other prophages. (B) 
Summary of the prophage positions (black triangles) along S. aureus Newman’s 
chromosome; the Mu50 genome was used as a reference. ‘L’ and ‘R’ denote the relative 
position of attL and attR attachment arms at each prophage (and thereby denote the 
relative orientation of prophage insertions at each locus). Positions of the chromosomal 
origin of replication (ori) and replication termination site (ter) are also indicated, with 
oppositely oriented black arrows used to denote bi-directional DNA synthesis. (C) 
Schematic summary as in ‘B’, but zoomed in to show relevant genomic regions in 
Newman that contain the integration sites for each of its prophages. Where a predicted 
function could not be assigned, ORFs were labeled according to their SAV numbers 
from the Mu50 annotation originally used as a reference. hlb, encodes β-haemolysin; 
geh, encodes glycerol ester hydrolase. Figure elements were reprinted from (Bae et al., 
2006) with permission. 
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phages of S. aureus— including Newman’s—have been found to mobilize S. aureus 
Pathogenicity Islands (SaPIs) (Chen and Novick, 2009; Chen et al., 2015b; Dearborn and 
Dokland, 2012; Penades et al., 2015). SaPIs are a natural repository for putative and 
confirmed superantigen toxin genes (Penades et al., 2015; Sloane et al., 1991). Therefore, 
even when pac phages do not carry genes that contribute to pathogenesis directly, they 
can indirectly contribute to pathogenicity by functioning as ‘helper’ phages that spread 
SaPIs. 
1.4.2 SaPIs and their SaPI-mobilizing ‘helper’ phages 
SaPI helper phages include many of the well-studied S. aureus phages, such as ɸ11 and 
80α (Xia and Wolz, 2014). Whereas 80α is thought to represent a laboratory recombinant 
(Christie et al., 2010; Lindsay et al., 1998), ɸ11 is derived from a prophage of the 
NCTC8325 isolate (Iandolo et al., 2002; Novick, 1967). Similar to phage lambda, both 
prophages encode cI-like repressors, and can be induced by treatment with DNA-
damaging agents (Ferrer et al., 2011; Penades et al., 2015; Quiles-Puchalt et al., 2013). 
The ELCR of ɸ11 was also confirmed to include binding sites for its CI-like repressor in 
vitro (Ganguly et al., 2009). When a SaPI-containing strain is lysogenized with a helper 
phage for its SaPI, the SaPI genome can be excised, replicated, and packaged during 
prophage induction. In a sense, this phenomenon represents a SaPI-dependent 
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lysogenic conversion phenotype. Below, I provide a coarse-grained summary of how 
SaPIs interact with—and apparently parasitize—their helper phages. 
SaPIs are small prophage-like elements (~15 kbp) found in the genomes of many 
S. aureus isolates (Novick et al., 2010; Penades et al., 2015). Their mobility is regulated by 
master repressor ‘Stl’ proteins (Figure 1-7), similar to how the lytic activity of lambdoid 
temperate phages is regulated by CI-like repressors (Johnson et al., 1981). Unlike 
phages, however, SaPIs do not encode the full complement of genes required for 
infection, and therefore rely on helper phages for packaging and transmission. 
Moreover, whereas the lytic cycle of many bona-fide prophages can be induced in 
response to host signals alone (Little and Michalowski, 2010; Nanda et al., 2015; Refardt, 
2011), induction of SaPIs requires interactions with helper-phage-encoded antirepressor 
proteins (Penades et al., 2015; Tormo-Mas et al., 2010). Helper phages express SaPI 
antirepressors during their lytic cycle, such that SaPI induction only occurs during 
infection or prophage induction. Various SaPI antirepressor proteins have been 
described, such as the Dut (dUTPase) and Sri proteins found in 80α, ɸNM1, and ɸNM2 
(Dearborn and Dokland, 2012; Tormo-Mas et al., 2010). Once a SaPI is de-repressed, it 
expresses proteins that allow it to excise from the chromosome, replicate, and hijack its 
helper phage’s packaging machinery (Figure 1-7A). Hijacking is mediated by SaPI-
encoded ‘interference’ proteins (Ram et al., 2012; Ram et al., 2014) which ensure 
32 
Figure 1-7. Summary of helper-phage-mediated SaPI mobilization and transfer.  
(A) Schematic summary of SaPI mobilization in lysogens during induction of a helper 
prophage. SaPI induction is normally repressed by its master repressor, ‘Stl’. Once the 
lytic cycle of a cohabiting helper prophage is induced (e.g., via the host’s SOS-response  
(Erill et al., 2007; Nanda et al., 2015)), phage-encoded antirepressor proteins are 
expressed, and relieve repression by Stl. SaPI excision and replication ensues, while 
expression of SaPI-encoded interference proteins ultimately re-directs the phage’s 
packaging machinery to concatemeric SaPI genomes for encapsidation. Packaging of 
phages can still occur, albeit inefficiently. In some cases, SaPI interference involves 
proteins that modify phage capsids such that they are ~1/3 the size and therefore too 
small to package complete phage genomes (Christie and Dokland, 2012). This too can 
reduce the maximal yield of infective (phage) particles. (B) Schematic summary of SaPI 
transfer via modified phage particles, which are large enough to encapsidate a typical 
complete SaPI genome. Following injection, the SaPI can be site-specifically integrated 
into the host chromosome via attS (SaPI) and attC (chromosomal) attachment sites, 
where it is maintained by Stl-mediated repression. (C) Same as in ‘A’, except that SaPI 
mobilization is licensed by an infecting helper phage; note that this may occur before 
Stl-mediated repression of an injected SaPI was ever established. Figure adapted from 
(Novick et al., 2010) with permission. 
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preferential packaging of the SaPI in phage or modified phage particles (Christie and 
Dokland, 2012) that are ultimately released upon completion of the helper phage’s lytic 
cycle. These include proteins which prevent the phage’s small terminase (TerSɸ) 
subunit from recognizing of its own genome during packaging, and thereby allow the 
SaPI’s alternative small terminase (TerSSP) subunit to re-direct capsids to the SaPI 
genome (Chen et al., 2015b; Penades et al., 2015). Upon transfer into a new host that 
lacks active helper phages, SaPIs may once again be established within the chromosome 
via site-specific integration and Stl-mediated repression (Figure 1-7B). 
 By impeding the packaging of helper phage genomes, SaPI-encoded interference 
proteins can substantially reduce the helper phage’s infective burst size (Lindsay et al., 
1998). Importantly, this effect can provide the SaPI-containing host with a survival 
advantage by preventing plaque formation. Functional SaPIs, therefore, offer a highly 
selective form of defense against (helper) phages, but operate more like abortive 
infection systems (Chopin et al., 2005; Depardieu et al., 2016; Labrie et al., 2010) than 
CRISPR-Cas systems in the sense that they do not rescue the viability of infected cells. 
Meanwhile, by allowing for lysis during infection or prophage induction, SaPIs permit 
both the transfer of host genes via generalized transduction pathways and the efficient 
transfer of their own genomes (Chen et al., 2015b). Accordingly, it was recently 
proposed that this feature of SaPIs could offer a unique advantage over CRISPR-Cas 
systems, and perhaps explain the relative abundance of SaPIs (and scarcity of CRISPR-
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Cas systems) in S. aureus populations which are thought to benefit heavily from 
frequent horizontal gene transfer (Ram et al., 2014). This idea is compelling, but seems 
to disregard the contributions of helper-phage-mediated mobilization and transfer of 
SaPIs, which might be sufficient to explain their relative abundance in temperate-
phage-rich populations of S. aureus. Furthermore, while type III-A CRISPR-Cas systems 
in S. aureus genomes display signatures of recent horizontal acquisition (Cao et al., 2016; 
Golding et al., 2010; Kinnevey et al., 2013), intrinsic mobility has yet to be demonstrated 
for any extant CRISPR-Cas system (Beguin et al., 2016; Krupovic et al., 2014). Hence, the 
relative immobility of extant CRISPR-Cas systems could also explain their scarcity 
among S. aureus genomes. A recent PCR-based screen of 636 S. aureus clinical isolates 
derived from four Chinese hospitals determined that only 6 isolates contained type III-
A CRISPR-Cas systems (Cao et al., 2016). Despite this scarcity, type III-A systems are 
relatively well-represented among Staphylococci compared to other CRISPR-Cas 
systems, and my advisor Dr. Marraffini first noticed this while browsing the available 
genomes and CRISPR database (Grissa et al., 2007a, b). In the next section, I summarize 
some additional developments that led us to embark on our study of type III-A systems 
in S. aureus hosts, about five and a half years ago. 
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1.5  Rationale for the study of type III-A CRISPR-Cas systems in S. aureus hosts 
Although the first experimental demonstration of a CRISPR-Cas system’s adaptive 
immune functionality was carried out with Streptococcus thermophilus and virulent 
phages, prior in silico analyses of these systems and their CRISPR spacer content 
(Bolotin et al., 2005; Mojica et al., 2005; Pourcel et al., 2005) seemed to suggest that they 
would also be capable of defending against other classes of mobile genetic elements, 
such as plasmids. A seminal study led by Dr. Marraffini subsequently confirmed this 
prediction, in showing that a CRISPR-Cas system in Staphylococcus epidermidis RP62a 
(Gill et al., 2005) can target DNA (plasmid) elements, and thereby prevent horizontal 
gene transfer (Marraffini and Sontheimer, 2008). Staphylococci are thought to engage in 
frequent horizontal transfer of mobile genetic elements and accessory genes (Lindsay 
and Holden, 2004), and in this light the implications of Dr. Marraffini’s findings were 
particularly intriguing. Apparently, by preventing horizontal gene transfer, CRISPR-
Cas immunity could be detrimental to bacteria in certain circumstances. Negative 
selection operating on CRISPR-Cas systems that target favorable elements might 
therefore explain their scarcity among S. aureus genomes, and perhaps even explain 
their absence from about 50% of bacterial genomes overall (Grissa et al., 2007a, b), and 
Dr. Marraffini conveyed this intriguing notion to me once I’d begun work in his 
laboratory. Dr. Marraffini also pointed out that spacers matching to temperate phages 
could be identified among the CRISPR loci of type III-A systems in sequenced 
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Staphylococci, suggesting these systems do indeed interface with temperate phages in 
the wild, and presumably protect their hosts from them. For example, the second spacer 
in RP62a’s type III-A system matches to the CNPH82 temperate phage of S. epidermidis 
(Daniel et al., 2007). Moreover, whereas plasmid or non-phage integrative elements in S. 
aureus were often found to confer antibiotic resistance, temperate phage or phage-like 
elements in S. aureus were often found to confer putative or confirmed virulence traits 
(Lindsay and Holden, 2006). Targeting of temperate phages by type III-A systems in S. 
aureus, therefore, might be expected to present a barrier to virulence acquisition, in the 
same sense that antibiotic resistance acquisition could be prevented by plasmid 
targeting. Consistent with this idea, CRISPR-Cas targeting of a fully functional 
temperate phage (lambda) had been tested in one study, and it was found to resist 
lysogenic infections (Edgar and Qimron, 2010). In two other studies, resistance to lytic 
infection by a virulent mutant of lambda (λvir) had also been shown (Brouns et al., 2008; 
Sapranauskas et al., 2011). The time was ripe for testing whether CRISPR-Cas targeting 
of temperate phages in S. aureus would license a similar state of genetic incompatibility. 
There were practical reasons for working with type III-A systems in S. aureus as 
well. In December 2011, my colleague Wenyan showed that the type III-A system from 
S. epidermidis RP62a could license anti-conjugative-plasmid immunity in S. aureus hosts, 
once cloned on an autonomously replicating plasmid vector. This provided a proof of 
principle that targeting by a type III-A system could operate as expected in 
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heterologous staphylococcal hosts, and allowed us to readily modify the system’s 
CRISPR array and cas genes via standard plasmid cloning manipulations. Modification 
of S. epidermidis RP62a and its derivatives, meanwhile, is less trivial, and we were 
initially lacking a phage that could infect these strains. By contrast, a variety of S. aureus 
phages were available to us, and Dr. Marraffini recommended that I begin work with 
the three functional temperate phages of S. aureus Newman: ɸNM1, ɸNM2, and ɸNM4. 
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CHAPTER 2: INVESTIGATION OF CRISPR-CAS IMMUNITY IN S. AUREUS
REVEALS AN UNEXPECTED MECHANISM FOR CONDITIONAL
TEMPERATE PHAGE TOLERANCE 
When this work was begun, the type I-E CRISPR-Cas system’s potential to resist both 
lytic and lysogenic infections by phage lambda or its derivatives had been 
demonstrated in Escherichia coli (Brouns et al., 2008; Edgar and Qimron, 2010; 
Sapranauskas et al., 2011), but little else was known about CRISPR-Cas immunity to 
temperate phages in bacteria. Spacers matching to temperate phages had been 
identified in various CRISPR-Cas systems, including type III-A systems of Staphylococci 
(Gill et al., 2005; Golding et al., 2010). However, a phage-defense function for CRISPR-
Cas immunity in staphylococcal hosts had yet to be demonstrated experimentally. 
Enabled by my colleague Wenyan’s recent cloning of the S. epidermidis RP62a type III-A 
system on a plasmid vector, I set out to characterize the genetic outcomes of temperate 
phage targeting by type III-A systems in S. aureus. The plan involved reverse-
engineering of our type III-A system’s upstream CRISPR locus, such that it would 
contain spacers matching to the functional temperate phages of S. aureus Newman 
(ɸNM1, ɸNM2, and ɸNM4). The spacer in position 1 of this CRISPR locus had already 
been shown to license immunity to plasmids that bore a matching nickase (nes) target 
sequence, so it was conceivable that temperate-phage-matching spacers, once 
engineered, would also be able to license anti-phage immunity. By working with three 
40 
heteroimmune temperate phages, moreover, I could presumably emulate the effects of 
CRISPR-Cas targeting in natural S. aureus populations, where infection by multiple 
(pro)phages is not uncommon (Brüssow et al., 2004; Goerke et al., 2009). Most of the 
phage- and prophage-targeting experiments described in sections 2.1, 2.2, and 2.3 were 
initially carried out with the ‘TB4’ host or its derivatives (Bae et al., 2006). TB4 is a 
prophage-cured derivative of S. aureus Newman that can be re-infected with ɸNM1, 
ɸNM2, or ɸNM4, and thereby serves as a native host background for these phages. This 
strain and its lysogenic derivatives lack endogenous CRISPR-Cas systems, but can be 
readily transformed with plasmids miniprepped from S. aureus RN4220—a restriction-
deficient and prophage-cured laboratory derivative of NCTC8325 which also lacks an 
endogenous CRISPR-Cas system (Nair et al., 2011). Once it was clear that RN4220 could 
be used to reproduce the core findings directly, however, I focused on conducting 
experiments with this more genetically tractable host. The majority of the data 
presented in Chapter 2—and ultimately included for publication (Goldberg et al., 2014) 
—was therefore derived from experiments with RN4220. 
2.1 Initial demonstration of CRISPR-Cas immunity to phages in S. aureus 
My work on this project began with the isolation of ɸNM1, ɸNM2, and ɸNM4 phage 
stocks. Supernatants from overnight cultures of S. aureus Newman contain a mixture of 
spontaneously induced infective particles derived predominantly from ɸNM1 and 
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ɸNM2 (Bae et al., 2006). Single plaques were isolated by plating the supernatant mixture 
on a sensitive soft agar lawn, and then genotyping plaques with primers specific for 
each phage. This allowed for the direct identification of ɸNM1 and ɸNM2 plaques, 
which were then propagated to produce high-titer lysates. Temperate phages such as 
these do not produce completely clear soft agar lawns upon lysis. Rather, lawns become 
‘turbid’ because a high proportion of cells are lysogenized during initial infections, 
which then survive subsequent infections via prophage repressor-mediated immunity. 
In turn, lysogens can be isolated by re-streaking from a region of turbid lysis. I obtained 
TB4::ɸNM1 and TB4::ɸNM2 single lysogens in this manner, which were genotyped 
using my original phage-specific primers. A TB4::ɸNM1+ɸNM2 double lysogen was 
subsequently constructed by infecting TB4::ɸNM1 with ɸNM2, and re-streaking from a 
region of turbid lysis in the same way. This double lysogen allowed me to identify 
ɸNM4 plaques from S. aureus Newman supernatants, because it counter-selects against 
ɸNM1 and ɸNM2 phages. Finally, a TB4::ɸNM4 single lysogen was similarly obtained 
during propagation of ɸNM4 on sensitive lawns. 
Shortly after I began work on the phage isolations, I started working to re-
engineer the CRISPR locus of Wenyan’s type III-A CRISPR-Cas plasmid, which he 
called pWJ30β. In order to readily replace the native phage-targeting spacer in position 
2 of this plasmid with engineered spacers targeting S. aureus Newman’s phages, I 
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needed to create a new plasmid lacking all repeats and spacers downstream of its nes 
spacer in position 1. This new plasmid, pGG3 (Figure 2-1), served as the parent 
Figure 2-1. Plasmid-borne type III-A CRISPR-Cas systems for initial experiments in 
S. aureus. 
(A) Schematic representations of the pWJ30β (left) and pGG3 (right) type III-A CRISPR-
Cas plasmids. pWJ30β harbors the wild type system from S. epidermidis RP62a, 
including its conserved leader sequence (‘L’, dark grey box) immediately upstream of 
the CRISPR array. To construct pGG3, the CRISPR array of pWJ30β was reduced to a 
single repeat-spacer element (middle). pC194 backbones include a chloramphenicol 
acetyltransferase (cat) gene conferring resistance to chloramphenicol, which is also 
depicted alongside cas genes in the plasmid diagrams. 
vector for my initial phage-targeting constructs. It was immediately apparent that the 
pGG3 plasmid in TB4 did not prevent infection by the Newman phages. In fact, TB4 
derivatives harboring pGG3 were arbitrarily used for propagation during some of my 
initial lysogen isolations (once it was cloned), probably because this allowed me to 
prophylactically treat the culturing media with an antibiotic (chloramphenicol). 
Accordingly, the effects of phage-targeting spacers could be subsequently tested 
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relative to this isogenic and phage-sensitive background. PCR-based methods using our 
standard oligo sizes (~ 60 bp) allowed for one-step addition of repeat-spacer units to the 
pGG3 backbone, with the phage-targeting spacer introduced at position 2 but lacking a 
downstream repeat. Dr. Marraffini pointed out to me that this should not present an 
issue, because single repeat-spacer units were found to be sufficient for anti-plasmid 
immunity in conjugation assays (Hatoum-Aslan et al., 2011). In addition, Dr. 
Marraffini’s previous work with the type III-A system had demonstrated that excessive 
matching between the 5’ tag of the crRNA and the corresponding flanking sequence in 
the target would prevent immunity (Marraffini and Sontheimer, 2010b), so I designed 
my spacers to avoid this, as per his recommendation. Beyond this, it was not known 
whether there would be additional requirements for type III targeting, such as the 
PAMs which had been described for type I and type II systems (Deveau et al., 2008; 
Semenova et al., 2011). It had been pointed out to me, furthermore, that previous 
reports seemed to indicate CRISPR-Cas systems could provide immunity to phages and 
plasmids regardless of the DNA strand or genomic context targeted (Barrangou et al., 
2007; Deveau et al., 2008; Garneau et al., 2010; Marraffini and Sontheimer, 2008). I 
naïvely doubted that I would not encounter further constraints on the type III-A (DNA) 
targeting mechanism, even with spacers engineered to match their targets perfectly. In 
any event, I reasoned that I could satisfy my own skepticism by designing a few 
different spacers; if there really were no other targeting constraints, I should be able to 
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Figure 2-2. Summary of target positions and spacer design for type III CRISPR-Cas 
immunity directed at ɸNM1 (or other S. aureus Newman phages) in Chapter 2.  
(A) Schematic representation of the ɸNM1 genome’s rightward-oriented (golden) and 
leftward-oriented (purple) ORFs, scaled in accordance with their annotated lengths 
(Accession number: NC_008583.1). The target positions for various type III spacers with 
crRNAs complementary to the top (‘T’) or bottom (‘B’) strand of the genome are also 
indicated. Oppositely oriented bent grey arrows represent the PcI (leftward) and Pcro 
(rightward) promoters found within the early lytic control region (ELCR) designated for 
ɸNM1. (B) Base-pairing potential between the spacer 16B or 16T crRNAs and the DNA 
of perfectly conserved target regions in ɸNM1, ɸNM2, and ɸNM4, as indicated by 
vertical lines between the sequences. The 5’ crRNA tag is an 8 bp sequence derived from 
the CRISPR repeat that must be sufficiently mismatched with the target’s flanking 
sequence in order to license immunity. (C) Plaquing efficiency of ɸNM1 on lawns of 
RN4220 harboring pGG3- or pGG3-BsaI-derived type III CRISPR-Cas plasmids with 
different phage-targeting spacers. High plaquing efficiency implies that the CRISPR-Cas 
plasmid did not provide immunity to infection; the functionality of these plasmid 
backbones was verified in at least one independent CRISPR-Cas targeting assay prior to 
publication (Goldberg et al., 2014), such as the pG0400 conjugation assay (Figure 2.3). 
Dotted line represents the limit of detection under these assay conditions. Error bars, 
mean ± s.d. (n = 3, technical replicates). 
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provide CRISPR-Cas immunity with virtually any spacer matching to a phage’s 
genome. Moreover, in perhaps equally naïve fashion, I attempted to increase my odds 
of encountering such constraints by initially designing spacers that match to all three 
phages (ɸNM1, ɸNM2, and ɸNM4). Besides these considerations, the first spacer I 
successfully cloned, 16B, was arbitrarily designed with a sense sequence matching to 
one of the rightward-oriented ORFs (gp16 in ɸNM1, numbered ‘866’ in Figure 1-6) 
reported to encode a conserved nematode virulence determinant (Bae et al., 2006; Bae et 
al., 2004). When considering the rightward-oriented ORFs in these phages (e.g., those 
encoding various lytic genes), sense spacers produce crRNAs with complementarity to 
the ‘bottom’ strand, hence the ‘B’ (Figures 2-2A & 2-2B). The 16B spacer did not 
detectably reduce plaque formation by any of these phages. Representative data from 
experiments with ɸNM1 are shown in Figure 2-2C. I next designed three additional 
spacers (2B, 19B, and 56B) targeting different regions of the phage genomes, even 
though we expected that DNA targeting by CRISPR-Cas systems would provide anti-
phage immunity regardless of the target’s genomic context. For consistency, sense 
spacers were again designed to target the bottom strand of conserved sequences. 
However, I made a point to include a spacer targeting a gene in the lysogeny region, 
because I surmised that targeting of this region would be more likely to have distinct 
functional consequences. This was made possible by the well-conserved, rightward-
oriented excisionase ORF (gp2) present in the lysogeny region of each phage. Although 
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the 19B and 56B spacers matching to lytic regions did not reduce plaque formation, the 
2B spacer did. Again, representative data from experiments with RN4220 and ɸNM1 are 
shown in Figure 2-2C. Meanwhile, all three of these strains exhibited anti-plasmid 
immunity when I tested them as conjugative plasmid recipients in control assays 
(Figure 2-3), owing to the nes spacer retained at position 1 of their CRISPR. The 
conjugation efficiencies I observed are comparable to published values reported by our 
lab for pG0400 and pG0mut (Hatoum-Aslan et al., 2013; Jiang et al., 2013b; Marraffini 
and Sontheimer, 2008): efficiency is only reduced for the pG0400 plasmid with a wild 
type target for the nes spacer. The rare pG0400 transconjugants I observed were 
presumed to represent CRISPR-inactive genetic escapers, since, at this time, my 
colleagues Wenyan and Inbal were well under way with their characterization of 
similar transconjugants in S. epidermidis RP62a, which they found to be genetic escapers 
in all cases (Jiang et al., 2013b). Evidently, however, we still didn’t fully understand the 
requirements for phage targeting by type III-A systems in plaque assays, because 3 of 
my first 4 spacers failed to license anti-phage immunity by otherwise functional 
CRISPR-Cas systems. Given that these particular phage-targeting spacers were all 
engineered, it initially seemed plausible to me that the non-functional spacers could be 
lacking in target recognition capacity, or were poorly expressed in our host background. 
I hadn’t, for example, considered their predicted RNA-DNA hybridization potential 
when designing them, or assessed crRNA abundance. Moreover, a requirement for 
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Figure 2-3. Integrity of pGG3 backbones can be functionality validated using 
conjugation assays.  
(A) Schematic diagram depicting the conjugative transfer of pG0(400 or mut) plasmids 
conferring mupirocin resistance from S. aureus RN4220 donors to TB4 recipients 
containing pGG3 or pGG3-derived CRISPR-Cas plasmids with the native nes-targeting 
spacer in position 1. The solid white rectangle on pG0 signifies the presence of a perfect 
or partially matching target for the nes spacer in pGG3. The wild type (pG0400) and 
mutated (pG0mut) target site sequences are shown on the right, with red lettering used 
for mutated bases. (B) Conjugation assays for validating the functionality of CRISPR-
Cas plasmids conferring resistance to chloramphenicol. In this example dataset, 
recipients harbor type III CRISPR-Cas plasmids with one of the four indicated phage-
targeting spacers, or the pGG3 parent vector (C). After filter mating with either pG0400 
or pG0mut donors, recipient and transconjugant concentrations (CFU / ml) were 
quantified as described in the methods. Dotted line represents the limit of detection 
under these assay conditions. Conjugation efficiencies denote the ratio of 
transconjugants to recipients measured in each experiment.  
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previously unidentified target flanking motifs, such as PAMs, had still not been 
rigorously ruled out. In any case, it was easy for me to suspend judgment on this matter 
rather than attempting to pursue these ideas directly, since there were other 
experiments to be done. For example, Dr. Marraffini had pointed out that the rare 
plaques which arise on immune lawns with the 2B spacer are probably caused by 
escaper mutant phages (Barrangou et al., 2007; Deveau et al., 2008; Semenova et al., 
2011), and he recommended that I isolate some of these phages to determine whether 
they had target site mutations. He also recommended that I begin by picking some big 
and some small plaques. Presumably, this could increase our odds of sampling different 
phages (i.e., with different plaque size phenotypes). These endeavors ultimately proved 
fruitful, as I explain below. 
2.2 Initial characterization of phages and lysogenic hosts that escape type III-A 
CRISPR-Cas immunity via genetic means 
Plaques picked from CRISPR-immune lawns can be re-plated on the same lawns to 
ensure additional counter-selection against residual wild type phage particles. In this 
manner, I initially isolated six ɸNM1 mutants, two ɸNM2 mutants, and six ɸNM4 
mutants. My colleague Wenyan had used the Greek letter, β, to distinguish his pWJ30β 
plasmid from its pWJ30 predecessor, so I initially adopted a similar practice when 
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Figure 2-4. Preliminary genotyping of spacer 2B escaper phages (γ-series). 
(A) Schematic diagram depicting a relevant genomic region of ɸNM1, scaled according 
to its reference annotation (Accession number: NC_008583.1). The integrase and 
excisionase (xis) ORFs correspond to gp1 and gp2, respectively. Grey rectangle denotes 
the position of the xis target sequence. Dashed line denotes the location of target region 
PCRs initially attempted with primers oGG25 and oGG26. (B) Same as in ‘A’, except the 
schematic depicts a relevant genomic region of ɸNM2, scaled according to the ɸNM2 
(NC_028913.1) reference annotation. (C) Same as in ‘A’, except the schematic depicts a 
relevant genomic region of ɸNM4, scaled according to the ɸNM4 (NC_028864.1) 
reference annotation. 
naming my phage mutants. For example, the spacer 2B escapers were the first phages 
which I provided with a ‘γ’ designation, in order to help distinguish them from wild 
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type. To genotype these ‘γ-series’ mutants, I initially attempted to PCR-amplify small 
regions which include the conserved xis target for spacer 2B (Figure 2-4). After repeated 
attempts at this PCR, I was only successful at reproducibly amplifying from one of my 
ɸNM1 mutants, ɸNM1γ6, but Sanger sequencing confirmed that its amplicon lacked 
mutations (data not shown). Incidentally, this was the only one of my γ-series mutants 
which exhibited a small plaque phenotype when plating on spacer 2B lawns (Figure 2-
5A). Importantly, this reduction in plaque size was not observed when control lawns 
were infected with ɸNM1γ6 (Figure 2-5B); and, a ‘clear-plaque’ phenotype was readily 
apparent on these lawns (Figure 2-5C). This indicated that, although its plaque size 
Figure 2-5. ɸNM1γ6 plaque phenotypes. 
(A-B) Plaque formation by a ɸNM1γ6 lysate spotted on lawns of TB4 harboring the 
spacer 2B CRISPR-Cas system (A) or the pGG3 parent vector (B). Pictures are 
representative of at least two experiments performed under the same assay conditions. 
(C) Comparison of ɸNM1 (turbid) and ɸNM1γ6 (clear) phenotypes by spotting of high 
phage titers on a sensitive lawn. Picture is representative of at least four technical 
replicates. 
phenotype was CRISPR-dependent, the ɸNM1γ6 phage did have heritable alterations—
elsewhere—that could produce a clear-plaque phenotype even in the absence of 
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CRISPR-Cas targeting. In contrast, all of my other γ-series mutants escaped targeting 
with apparently wild type plaque sizes, regardless of whether they also exhibited clear-
plaque phenotypes. I began to surmise that the small-plaque phenotype of ɸNM1γ6 
could reflect incomplete escape of the 2B spacer, or partial targeting, enabled by the 
presence of its intact target sequence. The complete escape observed with the other 
mutants for whom an intact target sequence could not be amplified, meanwhile, might 
be explained by deletions at the target region which included one or more annealing 
site for my PCR primers. Consistent with this notion, I was generally able to PCR-
amplify wild type amplicons when I used my original ɸNM1-, ɸNM2-, or ɸNM4-
specific primer sets that did not encompass the target region. 
At this stage, the source of the ɸNM1γ6 phenotypes was still quite puzzling. 
Regarding clear-plaque phenotypes, Dr. Bikard explained to me that this can arise if the 
phage is incapable of establishing lysogeny. Indeed, the few surviving colonies I was 
able to isolate after clearance of lawns with high titers of pure ɸNM1γ6 were never 
found to be lysogenized. These survivors were presumed to have acquired CRISPR-
independent resistance mutations, since no expansion of CRISPR arrays was observed 
even when the infected lawn harbored a type III-A CRISPR-Cas plasmid (data not 
shown). Growth phenotypes were also observed in some cases while re-streaking these 
survivors in the absence of phage, which would not be expected for CRISPR-adapted or 
lysogenized lineages. 
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In a separate experiment, I characterized a few clones that survived infection by 
one of my other clear mutants, ɸNM4γ4. In this case, the infected lawn also harbored 
the spacer 2B CRISPR-Cas plasmid, which is fully escaped by the ɸNM4γ4 mutant. 
Although I was again unsuccessful at isolating type III-A CRISPR-adapted clones here, 
two of my isolates had apparently become lysogenized (Figure 2-6A), as determined by 
PCR-amplification with my original ɸNM4-specific primer set. One of these lysogenic 
survivors, ɸNM4γ4-S1, appeared to have an altered CRISPR region in its spacer 2B 
plasmid, given that I could not amplify its CRISPR array with my standard primers. 
The other survivor, ɸNM4γ4-S2, still had an intact CRISPR array amplicon. In both 
cases, the xis target region could be amplified, but the ɸNM4γ4-S2 isolate gave a 
shortened product (Figure 2-6A). Sanger sequencing revealed an 81 bp deletion, 
confined within the ORF, which included 23/35 base pairs of the original target 
sequence (Figures 2-6B & C). Aside from allowing CRISPR-escape, this deletion did not 
appear to produce a phenotype, since I could isolate plaques from lysogen 
supernatants, and use them to re-lysogenize TB4. Evidently, this mutant was distinct 
from ɸNM4γ4. Soon afterwards, I realized that the ‘ɸNM4γ4’ stock used for infection in 
this particular experiment had not been purified to homogeneity, because I was able to 
amplify faint, wild type products from the xis target region (indicative of 
contaminating, parental ɸNM4 phages). Therefore, these lysogenic survivors were 
probably derived from residual wild type phages in the lysate which ultimately 
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Figure 2-6. Characterization of two ɸNM4-derived lysogens that genetically escaped 
prophage targeting by spacer 2B.  
(A) PCR amplification from two clones that survived ɸNM4γ4 infection on TB4 lawns 
with the spacer 2B CRISPR-Cas plasmid (‘S1’ and ‘S2’). After re-streaking, a single 
colony lysate from each isolate was used to template three different PCRs using primers 
for the xis target region (middle), primers for amplifying the CRISPR array (right), or 
primers for amplifying from ɸNM4 phages at a separate locus (left). Note the shorter 
size of the xis amplicon derived from the S2 isolate, and the lack of CRISPR array 
amplification from the S1 isolate. Control amplification (C) from the CRISPR array of 
the pGG3 parent vector lacking spacer 2B is shown in lane 10. Size markers of 3 kbp and 
0.5 kbp in lane 1 are indicated. Additional replicates were not performed on the original 
isolates. Lanes 2, 3, 6 and 7 were used for other experiments. (B) Sequence of the xis 
target region in ɸNM4 and ɸNM4γ4-S2. Red highlighting denotes sequences from the 
xis ORF; target sequences matching the 2B spacer are boxed in grey. Note that while 
only 12 bp of the original target sequence remain in ɸNM4γ4-S2, the deletion 
regenerated a ‘T’ immediately downstream (dotted yellow box). (C) Schematic diagram 
as in Figure 2-4C, with the position of the ɸNM4γ4-S2 deletion indicated (Δ81 bp). PCR 
amplification with the oGG25/oGG26 primer set (dashed line) produces a shortened 
product size of 364 bp. 
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protected their hosts from superinfection by ɸNM4γ4 mutants. Indeed, none of my 
clear mutants were capable of superinfecting their respective lysogens, even when high 
titers were spotted on lysogen lawns around the time of initial isolation (data not 
shown). Notwithstanding, this result seemed to provide at least one example of how a 
type III-A CRISPR-Cas system could select for temperate phage mutants that 
completely evade immunity—even during lysogeny—via target sequence deletions. 
This mutational, or genetic form of CRISPR-escape seemed to mirror what my 
colleagues had found in conjugation experiments (and also what had been reported 
previously on temperate phage targeting in E. coli (Edgar and Qimron, 2010)), where 
functional CRISPR-Cas systems do not co-exist with their DNA target elements. 
Consistent results were obtained in transformation assay pilot experiments where I 
electroporated the spacer 2B CRISPR-Cas plasmid into S. aureus Newman (which 
harbors 3 prophage targets). Although S. aureus Newman was comparably transformed 
with pGG3 and spacer 16B CRISPR-Cas plasmids (data not shown), only a single 
transformant was isolated from the two experiments where I attempted to introduce the 
spacer 2B plasmid. This transformant maintained an intact CRISPR array, but was 
presumed to have lost its CRISPR-Cas targeting functionality by other means (e.g., via 
mutation of one or more cas gene), in part because I was able to amplify from all four of 
its prophages using PCR. Accordingly, I saved the strain but proceeded with other 
experiments described below, under the assumption that this putative escaper would 
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Figure 2-7. Spacers matching to conserved sequences in ɸNM1, ɸNM2, and ɸNM4 
can license type III-A CRISPR-Cas immunity to all three phages.  
(A) Schematic representations of the ɸNM1, ɸNM2, and ɸNM4 genomes; ORF (thick 
arrow) lengths were scaled according to their respective NCBI annotations 
(NC_008583.1, NC_028913.1, and NC_028864.1). Colored ORFs contain a conserved or 
partially conserved target for spacer 2B (red), spacer 32T (blue), or spacer 61T-1 (green).  
(B) Schematic summary of the CRISPR arrays in CRISPR-Cas plasmids used for initial 
phage-targeting experiments in TB4 hosts. The 2B, 32T, and 61T-1 spacers are color-
matched to their target ORFs shown in panel ‘A’. CRISPR-Cas plasmids with a phage-
targeting spacer in position 2 were derived from pGG3 as described in the methods. The 
spacer 32T∆nes CRISPR-Cas plasmid is a derivative of the spacer 32T CRISPR-Cas 
plasmid, and was isolated by miniprepping from a pG0400 transconjugant that escaped 
mupirocin counter-selection via loss of the nes spacer in position 1. (C) Quantification of 
plaque-forming potential (PFU / ml) measured for lysates of ɸNM1, ɸNM2, or ɸNM4 
plated on soft agar lawns of S. aureus TB4 harboring one of the five CRISPR-Cas 
plasmids summarized in ‘B’. Lawns with the pGG3 parent vector plasmid lack phage-
targeting spacers and thus serve as a sensitive control in this assay. Data represents 
single biological replicates; for each phage, the same lysate was used for plating on the 
five lawns. Dotted line represents the limit of detection under these assay conditions. 
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not offer particularly novel insights (about six months later, I confirmed that the strain 
had indeed lost CRISPR-Cas targeting functionality in a pG0400 conjugation assay; data 
not shown). 
Meanwhile, additional phage escaper data corroborating these preliminary 
results was promptly procured, once I’d found two additional spacers, 32T and 61T-1, 
which reduced plaque formation by the three Newman phages (Figure 2-7). The first 
was the 32T spacer, which was originally identified as a naturally occurring spacer in 
the type III-A CRISPR-Cas locus of S. argenteus MSHR1132 (Holt et al., 2011). Dr. 
Marraffini, and also my colleague Wenyan, brought this spacer to my attention when 
they found that it partially matches to the Newman phages I was working with. Partial 
complementarity between this spacer’s crRNA and the Newman phage target regions is 
illustrated in Figure 2-8. In parallel, I constructed two variants (32T*A and 32T*B) which 
perfectly matched their targets in ɸNM1/ɸNM2 and ɸNM4, respectively, because it was 
unclear at the time whether the naturally occurring mismatches would abrogate 
immunity. Ultimately, all three spacers were found to provide immunity. Having been 
generally advised on the pitfalls of studying engineered systems, however, I 
endeavored to work with the unmodified 32T spacer whenever possible. Using this 
spacer, I isolated three ɸNM2 and three ɸNM4 escaper plaques, which I designated as 
‘α-series’ mutants to distinguish them from escapers of spacer 2B. Unlike the 2B spacer, 
which targets the bottom strand of Newman phage genomes, spacer 32T targets their 
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Figure 2-8. Partial complementarity between the spacer 32T crRNA and its DNA 
target regions in ɸNM1/ɸNM2 or ɸNM4.  
(A) Vertical lines denote base-pairing potential between sequences of the 32T crRNA 
and the DNA of conserved ɸNM1/ɸNM2 target regions; G:U base-pairing potential was 
not considered. The 5’ crRNA tag is an 8 bp sequence derived from the CRISPR repeat 
that must be sufficiently mismatched with the target’s flanking sequence in order to 
license immunity. (B) Same as in ‘A’, but with base-pairing potential to DNA of the 
ɸNM4 target region depicted instead. 
 ‘top’ strands, hence the ‘T’. Having now found, somewhat fortuitously, that I could 
obtain immunity with spacers targeting either strand, I designed four additional spacers 
(61B-1, 61B-2, 61T-1, and 61-T2) matching a separate region of the genome, this time 
with deliberate targeting of both strands. I was initially unsuccessful at cloning the 61-
T2 spacer. However, among the other three spacers which I promptly cloned, the 61T-1 
spacer was the only spacer which provided immunity. Using this 61T-1 spacer, I again 
isolated some escaper plaques, and designated them as ‘τ-series’ mutants. Two ɸNM1 
mutants, and one ɸNM2 mutant, were isolated. None of these α- or τ-series escapers 
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were found to produce wild type PCR amplicons at their target regions, and in some 
cases I was able to map deletions which included all or part of their target sequences. 
Aside from their CRISPR-escape phenotypes, however, they were generally 
indistinguishable from wild type. One exception was the ɸNM2τ1 phage, which 
exhibited a small plaque phenotype (Figure 2-9A). Unlike the ɸNM1γ6 phenotype, 
however, the ɸNM2τ1 plaque phenotype was observed even on control lawns (Figure 
2-9B), and was therefore deemed to be CRISPR-independent and not studied further. 
Figure 2-9. CRISPR-independent, small-plaque phenotype of ɸNM2τ1. 
(A-B) Plaque formation by a ɸNM2τ1 lysate spotted on lawns of TB4 harboring the 
spacer 61T-1 CRISPR-Cas system (A) or the pGG3 parent vector (B). Pictures are 
representative of at least two experiments performed under similar assay conditions. 
Given that this phage had escaped CRISPR-Cas targeting of the parental tail fiber gene, 
I presumed its plaque phenotype to reflect impaired phage particle functionality (such 
as a defect in adsorption) resulting from a deletion in that target region. Taken together, 
these putative and confirmed deletion escapers stood in stark contrast to the ɸNM1γ6 
escaper, which did not possess target site mutations and appeared to only partially 
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evade targeting by spacer 2B. I initially considered the possibility that ɸNM1γ6 had in 
some way acquired a general CRISPR-escape phenotype, but this was promptly ruled 
out by plating on lawns harboring the spacer 32T CRISPR-Cas plasmid. Representative 
results from experiments with RN4220 are depicted in Figure 2-10A, and demonstrate 
that ɸNM1γ6’s plaquing efficiency was reduced appreciably by the 32T spacer, but not 
the 2B spacer. Somehow, the heritable changes in ɸNM1γ6 that allowed for partial 
escape were still ostensibly specific to targeting by spacer 2B. Unfortunately, I could not 
also investigate the ɸNM1γ6 CRISPR-escape phenotype in the context of a lysogenic 
infection (i.e., chromosomal targeting by spacer 2B), because it apparently didn’t form 
lysogens. It was now clear to both me and Dr. Marraffini that full genomic sequencing 
of this phage would likely provide additional insight into its phenotypes (which were 
not lost upon passaging in the absence of CRISPR, as one might expect for an epigenetic 
form of escape (Bertani and Weigle, 1953; Korona and Levin, 1993)). We had also 
discussed plans to produce a more thorough characterization of my various escaper 
mutations, which in many cases still hadn’t been mapped by PCR, so I was already 
considering the prospect of sequencing entire phage genomes. Meanwhile, Dr. Bikard 
was isolating phages in separate experiments, and plans were conceived to pool our 
phages together in a multiplexed, next-generation sequencing run at the Rockefeller 
University Genomics Core. Both phenotypes of ɸNM1γ6 would ultimately be 
explained, but it was some time before this sequencing was completed. In the interim, I 
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Figure 2-10. ɸNM1γ6 can escape type III targeting of the bottom strand to the left of 
the ELCR, owing to a SNP that reduces leftward transcription from its PcI promoter. 
(A) Plaquing efficiency of ɸNM1γ6 on lawns of RN4220 harboring pGG3- or pGG3-
BsaI-derived type III CRISPR-Cas plasmids with different phage-targeting spacers. 
Dotted line represents the limit of detection under these assay conditions. Error bars, 
mean ± s.d. (n = 3, technical replicates). (B) Consensus sequences of the leftward-
oriented PcI promoter within the ELCR of ɸNM1 and ɸNM1γ6. The SNP found in 
ɸNM1γ6’s –10 element is shown in clay-red lettering. A putative transcription start site 
(+1) is indicated by the bent grey arrow for ɸNM1. (C) Schematic diagram depicting a 
relevant genomic region of ɸNM1γ6 that includes the ORF2 (xis) and ORF4 (cI-like 
repressor) target regions, as well as the ELCR. Open black rectangles denote the 
approximate positions of spacer 2B/2T and 4B/4T target sequences. The location of the 
SNP in PcI is marked by a clay-red vertical line. Rightward-oriented bent grey arrow 
represents the intact Pcro promoter. (D) Comparison of phage transcription profiles from 
cells infected with ɸNM1 (grey lines) or ɸNM1γ6 (clay-red lines), 15 min post-infection. 
Phage-derived transcripts are plotted in reads per million total-mapped reads (RPM) 
relative to their position on the genome (only the first 5 kbp are shown). To improve 
readability, curves were smoothened by plotting average reads per million values over 
a 500 bp sliding-window. Arrows up top indicate the direction of transcription plotted 
in each graph; the vertical dotted line marks the position of the ELCR. 
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was conducting experiments with lysogens and the spacer 32T CRISPR-Cas plasmid, 
which also proved fruitful. 
2.3 Initial evidence for co-existence between functional type III CRISPR-Cas 
systems and their DNA target elements in S. aureus lysogens 
As explained in section 2.2, my analysis of two lysogenic clones which survived the 
infection by ɸNM4(γ4) in a spacer 2B lawn seemed to suggest that type III-A CRISPR-
Cas targeting could select for genetic escape outcomes in the event of lysogenization by 
a lambdoid, chromosomally integrated prophage (Figure 2-6). In order to demonstrate 
this more clearly without the need for co-infecting ɸNM4 wild type and ɸNM4γ4 
mutant phages, Dr. Marraffini recommended that I take advantage of the lysogenic 
conversion phenotype associated with ɸNM4 integration to screen for lysogenized 
clones, by plating cells on egg yolk-supplemented agar after a brief infection. Upon site-
specific integration into TB4’s glycerol ester hydrolase (geh) locus, the ɸNM4 prophage 
disrupts expression of this secreted lipase, and thereby reduces the visible breakdown 
of lipids caused by colonies formed on egg yolk agar plates (Bae et al., 2006). The 
unmodified, 32T spacer was initially tested in this ‘egg-yolk screen’. Approximately 
1000 colonies were plated, and two were found to be geh- (that is, displaying reduced 
lipid clearance on the egg yolk agar). A representative image of the two lysogenic 
isolates plated on egg yolk agar is presented in Figure 2-11A alongside lysogenic and 
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Figure 2-11. Characterization of ɸNM4 lysogens isolated from the egg yolk screen 
with spacer 32T or 61T-1 CRISPR-Cas plasmids.  
(A) Visualization of TB4-derived strains grown on egg yolk-supplemented agar. 
Integration of ɸNM4 within the host’s geh locus results in strongly reduced breakdown 
of lipids in the media, enabling a screen for ɸNM4 lysogenization. Right-most lanes 
display two lipase-negative isolates (‘L1’ or ‘L2’) from the spacer 32T lysogenization 
screen; left-most lanes display lipase-negative and lipase-positive control strains, 
respectively (according to the labeling above). Picture is representative of at least five 
technical replicates for each strain. (B) ɸNM2-sensitivity assay for the strains shown in 
‘A’ (arranged in the same order from left to right). Single colonies were streaked 
through the ɸNM2-seeded region from top to bottom. The ɸNM4 lysogen harboring 
pGG3 and the non-lysogen harboring spacer 32T streaked in the two left-most lanes 
serve as sensitive and insensitive controls, respectively. Picture is representative of 
three technical replicates for each strain. (C) ɸNM2 plaquing efficiency on soft agar 
lawns of the strains analyzed in ‘A’ and ‘B’, calculated by comparison with plaquing on 
non-lysogenic lawns of TB4 harboring the pGG3 plasmid. (D) PCR amplification from a 
lipase-negative isolate (‘L3’) of the spacer 61T-1 lysogenization screen, or from control 
templates that produce wild type amplicon sizes (C). A colony lysate from the L3 isolate 
was used to template three different PCRs using primers for the spacer 61T-1 target 
region (right), primers for amplifying the CRISPR array (left), or primers for amplifying 
from Newman phages at a separate, xis, locus (left). Size markers of 3 kbp and 0.5 kbp 
in lane 1 are indicated. Additional replicates were not performed. Lanes 4, 5, 6, 7, 10, 11, 
12, and 13 were used for other experiments. (E) ɸNM1 sensitivity assay for the 61T-1(L3) 
egg yolk isolate characterized in ‘D’. The ɸNM4 lysogen harboring pGG3 in the left-
most lane serves as a sensitive control. Single colonies were streaked through the 
ɸNM1-seeded region from top to bottom. Additional replicates were not performed. 
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non-lysogenic controls displaying geh- and geh+ phenotypes, respectively. After 
determining by PCR and Sanger sequencing that both isolates maintained intact 
CRISPR arrays, I proceeded with more functional testing. Firstly, I confirmed that each 
of the isolates maintained (CRISPR-dependent) immunity to ɸNM1 in plaque assays 
(data not shown). In other words, these isolates hadn’t genetically inactivated their 
spacer 32T CRISPR-Cas systems. I next investigated whether the resident prophage was 
still wild type, by collecting supernatants with spontaneously induced PFU and re-
plating them on both spacer 32T lawns and control lawns. Although some plaquing was 
observed on control lawns, none was observed on spacer 32T lawns (data not shown). 
This indicated that the phages derived from each lysogen were indeed still wild type, or 
at least the majority of them were. While examining these isolates again prior to 
publication (Goldberg et al., 2014), I confirmed that both are also resistant to ɸNM2 
infection (as expected for strains with an intact spacer 32T CRISPR-Cas system). 
Representative experiments with ɸNM2 are depicted in Figures 2-11B & C. Shortly after 
the original egg yolk screen with spacer 32T, I repeated the screen under similar 
conditions using the 61T-1 or 2B spacers. Although no colonies were identified in the 
spacer 2B screen, in the 61T-1 screen, one geh- colony was again identified among the 
~1000 colonies plated. I determined by PCR that this isolate had wild type amplicon 
sizes at both its CRISPR array and prophage target region, and subsequently confirmed 
its resistance to ɸNM1 by the streak-test method (Figures 2-11D & E). I also analyzed 
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the spontaneously induced PFU derived from this isolate, and found that while some 
plaques were formed on control lawns, none were formed on 61T-1 lawns (data not 
shown). Again, this finding seemed to suggest that its resident prophage was wild type. 
The results of these egg yolk screens seemed to indicate that, at least with certain 
spacers, functional CRISPR-Cas systems could co-exist with non-mutant prophage 
targets within lysogenic isolates. I noticed, however, that the number of spontaneously 
induced PFU derived from these isolates appeared to be reduced relative to that of wild 
type ɸNM4 lysogens. In my mind, this phenotype was reminiscent of the ɸNM1γ6 
escape phenotype: co-existence between a functional CRISPR-Cas system and intact 
target sequence occurred at least transiently, but not without evidence of a partial 
interaction (presumably targeting). Corroborating the lysogeny results, I found 
transformation of TB4::ɸNM4 single lysogens with spacer 32T CRISPR-Cas plasmids to 
be moderately efficient. In one experiment, four transformants were confirmed by PCR 
to have both their CRISPR array and target region amplicons intact (Figure 2-12A). 
However, seemingly conflicting results were again obtained via electroporation of 
spacer 2B CRISPR-Cas plasmids, this time into TB4::ɸNM1 single lysogens instead of 
Newman. Of the nine transformants that were found in one experiment, 8/9 had lost 
their CRISPR-Cas targeting functionality, as assessed by sensitivity to ɸNM4 infection 
in the streak-test assay (Figure 2-12B). The remaining ɸNM4-resistant transformant was 
noted to have lost its ɸNM1 prophage, although it’s unclear from my notes how this 
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Figure 2-12. Transformation of single lysogens with type III CRISPR-Cas plasmids.  
(A) PCR amplification from four randomly selected transformants isolated via an 
electroporation of TB4::ɸNM4 lysogens with the spacer 32T CRISPR-Cas plasmid. After 
re-streaking, a single colony lysate from each transformant was used to template two 
different PCRs using primers for the 32T target region (left) or primers for amplifying 
the CRISPR array (right). Size markers of 3 kbp and 0.5 kbp in lanes 1 and 10 are 
indicated. Additional replicates were not performed on these isolates. (B) ɸNM4-
sensitivity assay for the nine transformants isolated via an electroporation of 
TB4::ɸNM1 lysogens with the spacer 2B CRISPR-Cas plasmid. After re-streaking, single 
colonies were streaked through the ɸNM4-seeded region from top to bottom. A 
TB4::ɸNM1 lysogen harboring pGG3 and a TB4 non-lysogen harboring spacer 2B were 
streaked in the two left-most lanes as sensitive (-C) and insensitive (+C) controls, 
respectively. Additional replicates were not performed on these isolates. (C) 
Transformation of RN4220::ɸNM1 lysogens with different CRISPR-Cas plasmids as 
indicated. The pGG3 plasmid was transformed as a control (C). Transformation 
efficiencies were calculated as the number of CFU per nanogram of miniprepped DNA 
used for electroporation. Error bars, mean ± s.d. (n = 3, technical replicates).  
71 
was assessed at the time. Plausibly, the strain was found to be sensitive to one of my 
ɸNM1-derived spacer 2B escapers, such as ɸNM1γ1 or ɸNM1γ6, or that the ɸNM1 
prophage simply could not be detected by colony PCR. Representative transformation 
efficiency data, later collected with RN4220::ɸNM1 lysogens, are shown in Figure 2-
12C. 
At this point, I was piecing together a model that could account for the various 
results. On the one hand, immunity to lytic infection was licensed by spacers targeting 
either strand of the phage genomes (2B, or 32T and 61T-1). On the other hand, the 2B 
spacer exhibited a distinct phenotype from the 32T and 61T-1 spacers in the context of 
lysogeny (Figures 2-6 & 2-12). Meanwhile, most of the sense-oriented spacers that had 
been tested so far (16B, 19B, 56B, 61B-1 and 61B-2) all failed to license immunity. The 2B 
spacer is distinct from other bottom-strand-targeting spacers in that its target is located 
within a cluster of leftward-oriented ORFs to the left of the ELCR (Figure 2-2). At least in 
part, ORF orientations are predicted to reflect differences in the directionality of 
transcription throughout phage genomes. Based on these predictions, I reasoned that a 
directional transcription requirement for type III-A targeting could explain functional 
consequences associated with the orientation of spacers relative to their target region(s). 
In other words, if type III-A immunity required that targets are transcribed in the 
antisense orientation relative to a spacer’s crRNA, this could explain why the 2B, 32T, 
and 61T-1 spacers were all functional, while the others were not. An apparent 
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inconsistency here was that the wild type nes spacer is sense-oriented relative to its 
target ORF, but was shown to license pG0400 targeting in conjugation assays 
(Marraffini and Sontheimer, 2008). However, my colleague Wenyan had also found that 
an antisense-oriented spacer complementary to the opposite strand of this target 
sequence (but arbitrarily also shifted 2 bp upstream; ‘nes3’) could provide immunity to 
pG0400 (personal communication). Therefore, the results would still be explained if this 
nes target region is bi-directionally transcribed, such that the sense-oriented wild type 
spacer would in fact be complementary to a non-template strand when considering 
transcription from downstream. Given that the downstream ORF was oriented in the 
opposite direction, this seemed plausible. Also note that my model assumed the 
directional transcription requirement to be a pre-requisite for DNA targeting, which, 
would not necessarily distinguish between whether the sequence was coding or non-
coding, and instead distinguish directionality on the basis of whether the strand was 
templating or non-templating for an RNA polymerase. Thus, the rightward-oriented 
reading frame of xis would not necessarily impact targeting by 2B. Moreover, evidence 
was mounting that type III systems could directly cleave complementary RNAs (Hale et 
al., 2012; Hale et al., 2009; Zhang et al., 2012), and this did not go unnoticed by our lab. 
RNA transcripts, naturally, are produced from transcribed DNA, and the strand 
polarity of a given transcript is derived from the directionality in which it is transcribed. 
I reasoned, therefore, that it would not be entirely unprecedented if our type III-A 
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system could also in some way respond to the polarity of transcriptional events 
(possibly, but not necessarily, via the RNA transcripts—even if this were to ultimately 
result in DNA targeting). Importantly, a directional transcription requirement for type 
III-A targeting could account for the various results I was observing with lysogens. 
During lysogenic infections, lambdoid prophages repress transcription of most lytic 
genes, but can sustain transcription of one or more genes required for maintenance of 
lysogeny (Casjens and Hendrix, 2015; Ptashne, 2011). Targets of the 32T and 61T-1 
spacers lie within lytic regions of the Newman phage genomes and were presumably 
repressed during lysogeny, whereas the spacer 2B target lies within a small intervening 
region of the lysogeny genes downstream of the cI-like repressor, just before int. 
Conceivably, the 2B target could be transcribed in lysogens by read-through from an 
upstream promoter, such as the leftward PcI promoter found in the ELCR (Figures 2-2). 
In other words, chromosomal targeting would occur in lysogens where a target in the 
proper orientation falls within an actively transcribed region, but not necessarily where 
a repressed lytic gene is targeted. Although sustained integrase expression is not 
required for lysogenic maintenance in phage λ (Casjens and Hendrix, 2015), there are 
noticeable differences in the genomic organization of λ and the Newman phages, so it 
was reasonable to suspect that their transcriptional patterns would also differ. For 
example, in lambda, the xis ORF is oriented in the same direction as int, but they’re 
oppositely oriented in the Newman phages. Furthermore, the possibility that targeting 
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was licensed by even low levels of transcriptional read-through in this region could not 
be excluded (i.e., regardless of whether the transcription was functionally relevant to int 
expression), and would perhaps explain why lytic infection was blocked by the 2B 
spacer despite the position of its target between lysogeny genes. Finally, I reasoned that 
the ɸNM1γ6 CRISPR-escape and clear-plaque phenotypes might also be explained if its 
mutation(s) disrupts leftward transcription of the lysogeny genes: weakened leftward 
transcription could both reduce the chance of DNA targeting by the spacer 2B CRISPR-
Cas system during lytic infections, and also prevent the establishment of lysogeny. 
A number of these points were still hypothetical of course, so I conceived some 
plans to test the model further. In particular, I wanted to confirm the directional 
transcription requirement using an inducible promoter system (ideally carried on a 
plasmid, for ease of manipulation) where I could insert a target sequence in both 
orientations relative to the promoter, and then assay for targeting upon induction. 
When I shared these ideas with Wenyan, he excitedly agreed that, if confirmed, the 
directional transcription requirement would nicely explain the phage results, and 
perhaps other findings as well. For example, in some of his early experiments where he 
designed a few chromosome-targeting spacers for the type III-A system in S. epidermidis, 
only the antisense-oriented spacers seemed to offer strong targeting. Furthermore, 
when we looked into some of the naturally occurring, temperate-phage-targeting 
spacers that had been sequenced, all of them (including the 32T spacer) appeared to be 
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antisense-oriented relative to their target ORFs. At the time, however, no one in the lab 
had been working with tightly regulated inducible systems (which I assumed might be 
valuable in this case), so we consulted Dr. Marraffini to discuss the logistics. When I 
proposed the idea, he suggested that I use one of the pCL55-derived integrative vectors 
we had received from Angelika Gründling, which were already designed for inducible 
expression. These were the IPTG- and (Anhydro)tetracycline-inducible vectors referred 
to as pCL55-iSpac and pCL55-iTET, respectively. The pCL55-iTET plasmid, I now 
presume, refers to the pitet plasmid published previously (Grundling and Schneewind, 
2007). My CRISPR-Cas plasmids contained the same chloramphenicol resistance 
marker, so Dr. Marraffini pointed out that I would simply need to replace the resistance 
marker on one of these pCL55-based vectors. Moreover, because these vectors allow 
plasmid manipulations to be carried out in E. coli, cloning with them was expected to be 
straightforward (and indeed, at least for the pCL55-iTET vector, generally was). 
Ultimately, although chromosomal targeting of these integrative vectors imposed 
certain experimental limitations, it provided the answers we were looking for, and 
nicely emulated the prophage-targeting scenario encountered during lysogeny. 
Both the design and results of these inducible targeting experiments, along with 
additional evidence which confirmed the directional transcription requirement for type 
III targeting, are described in the following section (2.4). Before these experiments were 
completed, however, the data from our phage sequencing was received and proved to 
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be highly encouraging. I owe a great many thanks to Dr. Bikard for procuring free 
software to analyze this data in a timely fashion (including SAMtools (Li et al., 2009) 
and IGV (Robinson et al., 2011), and later also ABySS (Simpson et al., 2009) for de novo 
assembly). Quite excitingly, ɸNM1γ6 turned out to harbor a SNP at a crucial position of 
the -10 element in a leftward promoter immediately upstream of its cI-like repressor 
gene (Figure 2-10B). Although this SNP was located ~1700 bp away from the target 
sequence (Figure 2-10C), presumably, it would reduce leftward transcription and allow 
escape from spacer 2B (as well as reducing the phage’s ability to lysogenize). The 
remaining CRISPR-escape mutants that hadn’t been mapped by PCR were confirmed to 
harbor target site deletions. Preliminary analyses for 14 deletion mutants (Figure 2-13A) 
were presented along with the results of Figure 2-7 at the Bacteria, Archaea, & Phages 
Meeting in Cold Spring Harbor (August 2012). Among these was the ɸNM4γ4 clear 
mutant that was ultimately adopted by my colleagues for type II adaptation 
experiments (Heler et al., 2015; McGinn and Marraffini, 2016; Modell et al., 2017), and 
which infects RN4220 somewhat more robustly than my ɸNM1γ6 clear mutant. In 
addition to its 2784 bp deletion in the lysogeny cluster, ɸNM4γ4 harbored a stretch of 
sequences (~3101 bp) in its late structural/lytic gene cluster that mapped more closely to 
other phages, such as bacteriophage ROSA (Accession: AY954961.1), than to ɸNM4 or 
any of the Newman phages. Presumably owing to the potential for recombination 
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Figure 2-13. Summary of γ-series, α-series, and τ-series phage mutants that escaped 
type III CRISPR-Cas targeting via target site deletions.  
(A) Schematic diagrams depicting a relevant genomic region of ɸNM1 and ɸNM4 
phages that includes the spacer 2B (xis) target region. (B) Same as in ‘A’, except for the 
spacer 32T target region escaped by three ɸNM2 and four ɸNM4 phages. The ɸNM4ω8 
phage was originally isolated from a lysogen that escaped pG0400 conjugation, 
following ɸNM4 infection of TB4 cultures harboring the spacer 32T CRISPR-Cas 
plasmid. Sequencing revealed a 656 bp target site deletion that was also found in two 
ɸNM4 α-series escapers. (C) Same as in ‘A’, except for two ɸNM1 and one ɸNM2 
escaper of the 61T-1 spacer. In each case, deleted sequences are delimited by vertical 
lines, and their sizes are denoted on the far right (Δ). ORFs were labeled according to 
their predicted gene products (where applicable), and target ORFs were color-coded as 
in Figure 2-7. Open black rectangles denote location of the 35- or 36-bp target sequence. 
In some cases, incomplete deletion of the target sequence was sufficient for evasion of 
the CRISPR-Cas system. 
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during co-infection, phage ‘mosaicism’ appears to be a common phenomenon (Brüssow 
et al., 2004; Martinsohn et al., 2008), and was assumed to explain the finding. Although 
we do not work with phage ROSA, it is not inconceivable that a contaminating phage 
from our lab environment, related to ROSA, could have produced this recombination 
event. However, if such a recombination did occur in our lab, it likely happened prior to 
the initial CRISPR selection step(s), because my other ɸNM4-derived escaper phages 
also harbored the same recombinant sequence at this region. Verifying the ɸNM4 
prophage sequence at this region in our Newman isolate, or in our original ɸNM4 
single lysogen isolate, might help to tease out this point. The ɸNM1γ1 mutant, 
meanwhile, was found to harbor a 396 bp deletion which included the integrase start 
codon but did not disrupt the cI-like repressor ORF upstream. This offered an 
explanation for why I was never able to isolate stable lysogens of ɸNM1γ1, despite its 
turbid plaques (data not shown). In other words, ablation of its integrase function 
appears to have resulted in an ‘abortive lysogeny’ phenotype (Gottesman and 
Weisberg, 2004). Regarding the escapers of spacer 32T, three out of my four ɸNM4 
mutants harbored the same 656 bp deletion at the target region, whereas my three 
ɸNM2 mutants harbored three different deletions. The 656 bp deletions appear to have 
utilized 12 bp direct repeat microhomologies that flank the 32T target in ɸNM4. The 
downstream repeat is absent from ɸNM1 and ɸNM2, which may explain why the 656 
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bp deletion was not observed in ɸNM2 mutants, and perhaps also why the frequency of 
escape was found to be much higher for ɸNM4 than for ɸNM1 or ɸNM2 (Figure 2-7C). 
On top of the phage sequencing results, I was further encouraged by a result that 
I obtained at this time using the pG0 conjugation assay, which seemed to support the 
notion of a directional transcription requirement for type III targeting in general. 
Previously, I had cloned a spacer called nes-γ(B) which was intended to target pG0mut 
on the same strand as the wild type nes spacer, but ~1000 bp upstream of the engineered 
SNPs (Figure 2-14A). However, this sense-oriented spacer never provided immunity. 
Once I began noticing the strand requirement pattern in my plaque assays, I finished 
cloning the inverted, antisense-oriented equivalent of this spacer (nes-γT) and found 
that it indeed prevented conjugation by pG0mut (Figure 2-14B). I interpreted this to 
mean that inverse-oriented transcription from the downstream ORF might not read all 
the way through to the nes-γB target. In hindsight, this result should be interpreted with 
additional caution, because the two-spacer CRISPR arrays I was using still contain the 
wild type nes spacer in position 1 (see Figure 2-7B for an example). Therefore, the wild 
type nes spacer might license some effect on pG0mut at the mismatched target site 
downstream, even though it does not reduce conjugation efficiency in the presence of 
these mismatches. For example, type III-A systems were eventually found to cleave 
complementary target RNAs 
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Figure 2-14. Apparent directional transcription requirement for type III targeting of 
pG0mut at a nickase sequence upstream of its mutations.  
(A) Schematic diagram depicting a relevant genomic region of the pG0mut plasmid, 
including its nickase target gene and oppositely oriented downstream gene encoding an 
LtrC-like protein, scaled according to their ORF annotations in pGO1 (Accession 
number: NC_012547.1). The location of the pG0mut SNPs at the target of the native type 
III-A nes spacer in CRISPR position 1 are marked with a solid red rectangle. Along with 
the native nes spacer target, the nes-γB (sense) and nes-γT (antisense) targets ~1000 bp 
upstream are also indicated. (B) Conjugation assays performed with pG0mut as in 
Figure 2-3. In this dataset (single experiments), recipients harbor type III CRISPR-Cas 
plasmids with the nes-γB or nes-γT spacers in position 2, or the pGG3 parent vector 
harboring only the nes spacer in position 1 (C). Conjugation efficiencies denote the ratio 
of transconjugants to recipients measured in each experiment.  
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(Samai et al., 2015; Staals et al., 2014; Tamulaitis et al., 2014), and this even occurs in the 
presence of partial mismatching (Staals et al., 2014; Tamulaitis et al., 2014). Thus, the 
wild type nes spacer might potentially license cleavage of antisense transcripts 
originating from downstream. However, it’s unclear whether this effect could result in 
sufficiently diminished transcriptional read-through to the nes-γB spacer’s target, or 
whether some other less-expected effect(s) might arise from the mismatching. 
2.4  Demonstration of a directional transcription requirement for in vivo targeting 
by a type III CRISPR-Cas system 
Prior to working with the pCL55-iTET vector, I had attempted to amplify from the 
pCL55-iSpac vector in unrelated PCR experiments, but was unsuccessful. This time, I 
set out with parallel efforts to replace the antibiotic resistance marker on both of these 
integrative vectors. Although I was again unsuccessful at amplifying from the pCL55-
iSpac vector, I managed to replace the pCL55-iTET’s chloramphenicol resistance marker 
with a kanamycin resistance marker to create pKL55-iTET. Using this vector, I designed 
my first chromosomal targeting system around the 16B/16T spacer pair (Figures 2-2 and 
2-15A), since it was the first pair of phage-targeting spacers I had designed to be the 
exact inverse of each other. The 61B-1/61T-1 and 61B-2/61T-2 pairs, for example, were 
still slightly off-set from one another (Table 2-1). Therefore, I could readily design 
targets for the 16B/16T spacers that were the exact inverse of one another, and insert 
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them downstream of the inducible promoter. In previously published work, 
chromosomal targeting by CRISPR-Cas systems was shown to be toxic, and perhaps 
even lethal (Edgar and Qimron, 2010). Generally, transformation experiments in the lab 
thus far had yielded similar outcomes (including Wenyan and Dr. Bikard’s initial 
Figure 2-15. Transformation of strains containing first-generation integrative target 
vectors with type III CRISPR-Cas plasmids harboring spacer 16T or 16B.  
(A) Schematics summarizing the orientation of spacer 16T or 16B crRNAs (orange and 
blue arrows) relative to a forward (left) or reversed (right) target sequence downstream 
of the Pxyl/tet promoter in first-generation integrative vectors. Leftward-oriented arrows 
(depicted above) represent crRNAs with complementarity to the non-template strand 
relative to rightward Pxyl/tet transcription; rightward-oriented arrows (depicted below) 
represent crRNAs with complementarity to the template strand. (B) Transformation of 
RN4220-derived strains with spacer 16T or 16B CRISPR-Cas plasmids in the presence of 
ATc. Electrocompetent cells possessed either the ‘Targetless’ parent vector insertion, the 
forward ‘Target’ vector insertion, or the ‘Reverse’ target vector insertion, and were 
transformed using the same miniprep for either CRISPR-Cas plasmid cloned in RN4220. 
A constant volume of each miniprep was electroporated across experiments, and the 
concentration of transformants (CFU / ml) recovered after electroporation was 
quantified by selective plating. Error bars, mean ± s.d. (n = 2, technical replicates).  
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genome editing experiments (Jiang et al., 2013a) with type II systems in Streptococcus 
pneumoniae, unpublished at the time). It was therefore intuited that a growth and/or 
transformation efficiency reduction in the presence of ATc could likewise be used as a 
readout for CRISPR-Cas targeting of my inducible vectors in the chromosome. 
Although this targeting setup provided a preliminary proof-of-principle that type III-A 
spacers could be either targeting or non-targeting depending on their orientation 
relative to a nearby promoter (Figure 2-15B), this particular system was not inducible 
(i.e., when targeting occurred, it occurred even in the absence of the ATc inducer for at 
least one of the two spacer-target orientations). In order to more definitively 
demonstrate a transcriptional requirement for type III-A targeting, I endeavored to 
reproduce these results with a more tightly-regulated inducible promoter system. 
Ideally, my spacers and targets might co-exist in the absence of the transcriptional 
inducer, as they could in lysogens. The Pxyl/tet promoter architecture employed in pCL55-
iTET is also found in pKOR (Bae and Schneewind, 2006), and was originally designed as 
an engineered promoter system for Bacilli (Geissendorfer and Hillen, 1990). By default, 
this Pxyl/tet promoter in pWH353 had a single tetO operator and was known to be 
relatively leaky, but various modifications—including addition of a second tetO 
operator downstream—have been shown to reduce its leakiness (Geissendorfer and 
Hillen, 1990; Helle et al., 2011). The modified promoter system I ultimately selected was 
based on the pRAB12 architecture described previously (Helle et al., 2011), because it 
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was shown to promote virtually undetectable expression levels in the absence of 
inducers, while still offering moderate expression levels in their presence. Its overall 
regulatory architecture is similar, with divergently transcribed PtetR- and Pxyl/tet-based 
promoters, but it includes various modifications which I introduced into pKL55-iTET in 
Figure 2-16. Modification of pKL55-iTET to create pKL55-iTET-RC12 second-
generation target insertion vectors.  
(A) Scaled representations of the ATc-inducible promoter region found within pCL55-
iTET-derived vectors between the tetR start codon (left) and the multiple cloning site 
beginning with AvrII (right). The pKL55-iTET first-generation architecture is 
schematized at the top. Three-step modification produced the pKL55-iTET-RC12  
second-generation architecture (bottom) based off pRAB12 (Helle et al., 2011). The 
additional 17 bp in pKL55-iTET-RC12 creates a new TetR binding site (‘tetO3’) 
downstream of Pxyl/tet*. Meanwhile, the TetR binding site that overlaps the PtetR promoter 
(‘tetO1’) is disrupted at the modified promoter, PtetR*. Bent arrows denote the 
approximate positions of transcriptional start sites for each promoter; dashed bent 
arrows signify that their promoter ’s consensus is predicted to drive weaker constitutive 
transcription relative to its first- or second-generation counterpart.   
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three steps (Figure 2-16). Firstly, I introduced the two pRMC2 (Corrigan and Foster, 
2009) SNPs which are thought to strengthen tetR expression by improving its 
promoter’s –10 consensus, and perhaps also disrupting the consensus of its overlapping 
tetO operator (Stary et al., 2010). In turn, stronger expression of the tetR repressor gene 
is thought to reduce leakiness from Pxyl/tet-based promoters. In the next step, I weakened 
the Pxyl/tet promoter by introducing a SNP into its –10 consensus. Finally, I introduced a 
second tetO operator downstream to strengthen the potential for repression. The 
resulting pKL55-iTET-RC12 vector with sequences matching to pRAB12 (Helle et al., 
2011) was used in downstream manipulations. 
In parallel efforts, I continued to clone spacers that would corroborate the strand-
biased pattern of type III phage targeting. These included the 4B, 4T, 32B, 43B, and 43T 
spacers (Figure 2-2). The 4B/4T spacers matched to ɸNM1’s cI-like repressor gene, while 
the 43B/43T spacers matched to its “head protein” gene (Table 2-1). By designing these 
additional ɸNM1-targeting spacers, I was able to further characterize the ɸNM1γ6 
escape phenotype. For example, the 4B spacer was escaped by ɸNM1γ6, while the 4T, 
16T, 43T and 61T-1 spacers were not (Figure 2-10A). Assuming a directional (i.e., non-
template strand) transcription requirement for type III-A targeting, this was consistent 
with a reduction in leftward transcription across the spacer 2B and 4B targets that is 
predicted to result from the upstream promoter SNP (Figure 2-10C). In addition, the 
spacer 4B CRISPR-Cas plasmid—which provides immunity to wild type ɸNM1 in 
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plaque assays (Figure 2-2C)—was found to reduce lysogen transformation efficiency to 
a similar degree as the spacer 2B plasmid (Figure 2-12C). In this case, the reduced 
transformation efficiency observed solely with these 2B and 4B spacers would be 
explained if their targets are the only among those that I tested which are actively 
transcribed in the proper orientation within lysogens. Meanwhile, the other spacers 
target ɸNM1 within lytic regions, or within the same lysogeny region but on the 
template strand of transcripts arising from the leftward promoter upstream of its cI-like 
repressor. The original 2T spacer (2Told) was also cloned at this time, but provided 
virtually no targeting in my plaque and transformation assays. It was later realized that 
the exact inverse of the 2B spacer (found in this original 2Told construct) contained 
excessive 5’ handle complementarity which probably prevented type III targeting. This 
spacer was therefore re-cloned with a 2 nucleotide shift (Table 2-1) that produced the 
expected targeting behavior in efficiency of plaquing (Figure 2-2C) and transformation 
efficiency assays (Figure 2-12). However, transformants harboring this adjusted 2T 
CRISPR-Cas system generally exhibited a small-colony phenotype. Given what I had 
observed with my leaky first-generation chromosomal target vectors, where small 
colonies were observed in one of the orientations even in the absence of ATc, but not at 
all in the other (data not shown), it seemed plausible that this could reflect low levels of 
chromosomal targeting. It also seemed plausible that this could result, specifically, from 
low levels of rightward transcription across the xis ORF in lysogens. At this point, we 
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were still basing our interpretation of these results on various transcriptome predictions, 
largely inferred from the directionality of predicted ORFs within the ɸNM1 annotation. 
It was clear that actual transcriptome data from ɸNM1-infected cells could serve to 
validate these interpretations, so I discussed plans with Dr. Marraffini to obtain this 
using ‘stranded’ RNA-seq. Wenyan was also planning an RNA-seq experiment to study 
plasmid targeting at the time, so we ended up pooling a few samples together in what 
was assumed to be a mere pilot run. Ultimately, the stranded transcriptome analysis for 
one of the samples in this run—a logarithmically growing RN4220::ɸNM1 single 
lysogen—was used for publication (Goldberg et al., 2014). It confirmed, among other 
things, that there is indeed a slightly higher peak of rightward transcription across the 
spacer 2B/2T target region, relative to other target regions (Figure 2-17). Another 
sample from this run with ɸNM1-infected non-lysogens harvested 15 minutes post-
infection also looked promising, and so I made plans to repeat this with four time 
points in succession, and also include two equivalent early time points with ɸNM1γ6. 
In additional parallel efforts, I was cloning a type II CRISPR-Cas plasmid for 
targeting of ɸNM1 that I figured would be useful as a control for CRISPR-Cas targeting 
of lytic regions in S. aureus lysogens. In other words, I wanted to show that a 
presumably transcription-independent CRISPR-Cas system would prevent lysogeny in 
this host background even if type III systems targeting the same lytic region(s) did not. 
The first type II spacer I designed (16B-tII) overlapped the 16B/16T target region, and 
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was intended to be able to target my ‘first-generation’ chromosomal target insertions in 
either orientation, regardless of the ATc inducer’s presence or absence. My colleague 
Wenyan had already cloned the entire S. pyogenes SF370 type II-A CRISPR-Cas system 
on pWJ40, so I made plans to modify its CRISPR array, similar to as I had done for 
Figure 2-17. ɸNM1 prophage transcription profiles from a logarithmically growing 
lysogen.  
(A) Rightward and leftward expression values are plotted as golden and purple lines, 
respectively, in reads per million (RPM). The position of relevant spacer targets are 
indicated with vertical solid lines. The dotted line with divergent arrowheads marks the 
position of the early lytic control region (ELCR) with divergently oriented PcI and Pcro 
promoters. To improve readability, curves were smoothened by plotting average reads 
per million values over a 500 bp sliding-window. Noticeable leftward expression 
originates from the ELCR and a few upstream regions that presumably encode functions 
involved in lysogenic maintenance and/or prophage morons (Brüssow et al., 2004; 
Cumby et al., 2012). Rightward transcription was weaker than leftward transcription as 
expected, but not absent, and includes a peak that overlaps the xis ORF targeted by the 
2B/2T spacers. 
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 pWJ30β. The first step involved reducing the CRISPR array of pWJ40 to a single repeat, 
creating pGG32. Type II systems were not known to function without a downstream 
repeat flanking their spacer(s) of interest, so I would have to construct the 16B-tII 
CRISPR-Cas plasmid in two steps using my blunt ligation method, without drastically 
increasing my primer lengths. The first step would add the spacer, and the second 
would add the downstream repeat. By the time this construct was cloned, I had already 
elected to use a different target region in my ‘second-generation’ chromosomal 
targeting vectors (explained below). Fortunately, Dr. Bikard was cloning his first type II 
parent vectors with a single placeholder spacer containing two oppositely oriented BsaI 
restriction sites. These allow for 1-step replacement of the placeholder spacer with 
annealed oligo pairs containing a (spacer) sequence of interest. My subsequent cloning 
of type II CRISPR-Cas plasmids utilized this method, along with Dr. Bikard’s parent 
vectors. Therefore, although the pGG33 construct with spacer 16B-tII was capable of 
targeting ɸNM1, it was never included in my published work. However, along with the 
ɸNM4γ4 clear mutant (lytic) phage I had isolated, the pGG32 (single repeat) precursor 
ultimately proved useful for my colleague, Robert Heler, in some of his type II 
adaptation experiments (Heler et al., 2015). Meanwhile, after learning of the BsaI 
cloning method, I adopted it to construct subsequent type III CRISPR-Cas plasmids as 
well. This was initially accomplished with a new type III parent vector called pGG3-
BsaI, which I created by introducing the same placeholder spacer from Dr. Bikard’s 
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vectors at position two of the CRISPR array (just as I had previously introduced my 
phage-targeting spacers into pGG3). 
When designing my second-generation chromosomal targeting system, I elected 
Figure 2-18. Transformation of strains containing second-generation integrative 
target vectors with type III CRISPR-Cas plasmids harboring spacer 43T or 43B.  
(A) Schematics summarizing the orientation of spacer 43T or 43B crRNAs (orange and 
blue arrows) relative to a forward (left) or reversed (right) target sequence downstream 
of the Pxyl/tet* promoter in second-generation integrative vectors. Leftward-oriented 
arrows (depicted above) represent crRNAs with complementarity to the non-template 
strand relative to rightward Pxyl/tet* transcription; rightward-oriented arrows (depicted 
below) represent crRNAs with complementarity to the template strand. (B) 
Transformation of RN4220-derived strains with spacer 43T or 43B CRISPR-Cas 
plasmids in the presence or absence of ATc. Electrocompetent cells possessed either the 
forward ‘Target’ or ‘Reverse’ target vector insertions, and were transformed using the 
same miniprep for either CRISPR-Cas plasmid cloned in RN4220. Transformation 
efficiencies were calculated as the number of transformants per ng of miniprepped 
DNA used for electroporation (CFU / ng). Error bars, mean ± s.d. (n = 3, technical 
replicates).  
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to use the 43B/43T spacer pair (Figure 2-18A). This was done in part because, as Dr. 
Marraffini pointed out to me, it would be easier to explain that we’d taken a phage lytic 
gene target if its gene product was known to be a head protein, as opposed to a 
‘hypothetical’ protein. Furthermore, shortly after I designed my first type III spacer 
(16B), which was 34 bp in length, I realized that the majority of sequenced spacers our 
lab had identified in staphylococcal type III-A systems were actually either 35 or 36 bp, 
and began designing my spacers as such. Among these were the 43B and 43T spacers, 
which each had 36 bp. Therefore, I figured it would also be appropriate to utilize 
spacers exhibiting a more representative length, such as these. This time, the system 
was ATc-inducible; virtually no targeting was apparent in the absence of ATc for either 
orientation (Figure 2-18B). 
After hearing of these results, Dr. Bikard voiced some concern that addition of 
the ATc inducer might be simply unmasking a strand discrepancy that arises during 
DNA replication (e.g., leading vs. lagging strand discrepancies), since it was always the 
same DNA strand being targeted in my constructs relative to the chromosome’s origin 
of replication. I was not particularly concerned in this instance, because we had already 
observed type III targeting on both strands in multiple contexts. For one, my advisor 
originally found this while transforming with pC194-based plasmids in which he’d 
inserted the S. epidermidis RP62a nes spacer’s target region in both orientations 
(Marraffini and Sontheimer, 2008). Wenyan had essentially also shown this in pG0400 
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conjugation assays, when comparing the wild type nes spacer to his inverted (and 2 bp-
shifted) nes3 spacer as described above. Now, I was finding this as well in plaque assays 
with ɸNM1, using my 4B/4T spacer pair (Figure 2-2C). The Deng et. al. report (Deng et 
al., 2013) on PAM-independent targeting by a type III-B system in S. islandicus REY15A 
was also encouraging in this regard, and it was released online shortly after I obtained 
preliminary replicates with my second-generation chromosomal targeting vectors. 
Using plasmid-targeting transformation assays, this study essentially confirmed what I 
had found with my first-generation chromosomal targeting vectors: type III targeting 
was only licensed by crRNAs with complementarity to the non-template strand of a 
target sequence relative to a nearby promoter. This work also found that you could 
complement the non-targeting, template-strand-complementary scenario by 
introducing an oppositely oriented promoter downstream of the target, to ensure that 
the spacer’s crRNAs would once again bear complementarity to a non-template strand 
(in this case relative to the secondary promoter). Therefore, they too had demonstrated 
targeting on both strands of a DNA element. Presumably, these results would not have 
been observed if there was a strict replicative requirement for targeting of one particular 
strand but not the other. Based on these data, however, I could not exclude the 
possibility that a replicative strand discrepancy might be sufficient to license targeting 
on one strand in certain contexts, even if type III targeting were otherwise transcription-
dependent. To rule out such possibilities, I inverted the attP region (including putative 
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cis elements adjacent to the core motif (Lee and Buranen, 1989)) on my pKL55-iTET-
RC12-derived vectors such that they would integrate in the opposite orientation relative 
to their host’s chromosome. Using PCR, I confirmed that my inversions were successful; 
the vector-external primers must be swapped in order to amplify across an attL or attR 
junction with the same vector-internal primer adjacent to attP (Figure 2-19). Essentially 
the same results were observed in transformation assays when I tested these inverted 
Figure 2-19. Schematic diagram summarizing site-specific integration by pKL55-
iTET-RC12-derived vectors and their inverted attP variants.  
(A) As described for the original pCL55 vectors (Lee et al., 1991), site-specific 
integration of pKL55-iTET-RC12-derived vectors utilizes an attB attachment site in the 
S. aureus RN4220 chromosomal geh locus, along with an attP motif (derived from 
bacteriophage L54a) present on the plasmids. Primers ‘1’ (oGG50) and ‘3’ (oGG96) can 
amplify across the attL junction that results from recombination with the unmodified 
attP, while primers ‘2’ (oGG51) and 3 only amplify across the attR junction that results 
from integration of a vector with an inverted attP motif. Features of the diagram are 
scaled arbitrarily.  
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Figure 2-20. Testing of second-generation inducible targeting vectors integrated in 
the inverse orientation relative to the chromosomal origin of replication.  
(A) Schematics summarizing the orientation of spacer 43T or 43B crRNAs (orange and 
blue arrows) relative to a forward (left) or reversed (right) target sequence downstream 
of the Pxyl/tet* promoter in second-generation, inverted-attP integrative vectors. 
Leftward-oriented arrows (depicted above) represent crRNAs with complementarity to 
the template strand relative to leftward Pxyl/tet* transcription; rightward-oriented arrows 
(depicted below) represent crRNAs with complementarity to the non-template strand. 
(B) Transformation of RN4220-derived strains with spacer 43T or 43B CRISPR-Cas 
plasmids in the presence or absence of ATc. Electrocompetent cells possessed either the 
‘Inv-attP-Targetless’ vector insertion, the forward ‘Inv-attP-Target’ vector insertion, or 
the ‘Inv-attP-Reverse’ target vector insertion, and were transformed using the same 
miniprep for either CRISPR-Cas plasmid cloned in RN4220. Transformation efficiencies 
were calculated as the number of transformants per ng of miniprepped DNA used for 
electroporation (CFU / ng). Error bars, mean ± s.d. (n = 3, technical replicates). (C) High-
resolution growth curves of Inv-attP strains harboring the spacer 43T CRISPR-Cas 
plasmid. Each of the indicated strains was grown in the presence (solid lines) or absence 
(dashed lines) of ATc addition at the indicated time point (black arrow), and were 
originally isolated as CRISPR-Cas plasmid transformants plated in the absence of ATc.  
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attP variants with both forward and ‘reverse’ target insertions (Figure 2-20A), along 
with my inverted variant of the ‘targetless’ RC12 parent vector as a control (Figure 2-
20B). The result was reassuring. At least in this region of the chromosome, 
unidirectional transcription appears to be sufficient to drive strand discrepancies 
associated with type III-A targeting. I also tested these vectors with the spacer 43T 
CRISPR-Cas plasmid in high-resolution growth curves (Figure 2-20C), and found that 
severe growth reductions were only observed upon addition of ATc with the forward 
target insertion (where spacer 43T’s crRNAs are complementary to the target’s non-
template strand). Note that transformation efficiency data collected with the parental 
orientation was arbitrarily presented as ‘Inv-attP’ in the publication’s extended data 
section (Goldberg et al., 2014), because I had not collected high-resolution growth 
curves with the parental orientation, and we wanted to introduce transformation and 
growth curve data together in a primary figure. It was decided that showing data from 
two different sets of strains side by side could be potentially awkward or confusing, so 
the main figure data utilized the inverted attP constructs for which I’d collected both 
types of data, but it was simply presented as the default orientation rather than Inv-
attP. Note, also, that some growth reduction is apparent upon addition of ATc at this 
concentration (0.5 μg/ml), even for the targetless control strain (Figure 2-20C). This 
concentration was arbitrarily adopted from a modified pKOR (Bae and Schneewind, 
2006) protocol circulating in the lab, which uses the Pxyl/tet promoter for antisense secY 
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transcription. In different assays more recently, I’ve worked with lower ATc 
concentrations of 0.250 μg/ml and 0.125 μg/ml. Some general growth reduction is still 
observable at 0.250 μg/ml, although not at 0.125 μg/ml. This is consistent with the 
findings of a previous study on Pxyl/tet-based promoters in S. aureus, which reported that 
growth is not noticeably affected at ATc concentrations of 0.128 μg/ml, although strong 
induction could still be achieved here (Corrigan and Foster, 2009). Another study 
reported working with concentrations up to ~0.185 μg/ml (Helle et al., 2011). 
Concentrations in the range of 0.125-0.185 μg/ml are therefore probably ideal for the 
purpose of optimally inducing Pxyl/tet-based promoters in S. aureus with minimal toxicity. 
At this point, I had lingering concerns of my own, regarding the absence of a 
repeat downstream from my phage-targeting spacers. Perhaps this CRISPR architecture 
was producing unforeseen effects in phage assays—or worse, allowing for the 
conditional tolerance phenomenon altogether! I first became suspicious when I noticed 
that the pGG3 plasmid has a phenotype in the conjugation assay relative to either 
pWJ30β or my phage-targeting derivatives, which, unlike pGG3, all have a repeat 
downstream of the nes spacer. Although pGG3 comparably reduces conjugation 
efficiency when colonies are scored by eye, it allows for something which I could only 
describe as ‘pin-point puncta’ to form atop the background of counter-selected (‘dead’) 
cells. I was never able to re-isolate pin-point puncta from these background spots by re-
streaking; and, upon prolonged incubation, they never outgrew the background (and in 
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fact seemed to become part of the local lawn). In hindsight, the nature of these puncta 
might have been partially clarified with the use of a basic light microscope! In any case, 
before confirming that the downstream repeat was sufficient for alleviation of the pin-
point puncta phenotype, I had decided to clone a repeat downstream of the 32T*B 
spacer in my pGG14 plasmid (to produce the pGG22 plasmid). Testing of this 32T*B(-R) 
(pGG22) plasmid had initially allayed my concerns because the addition of the repeat 
did not produce a noticeable phenotype in ɸNM4 plaque assays (data not shown). 
However, I subsequently confirmed that the addition of a repeat downstream of the nes 
spacer in pGG3 (creating pGG25) was sufficient to eliminate the pin-point puncta 
phenotype. This confirmed that, at least in certain contexts, the absence of a 
downstream-flanking repeat could produce a phenotype. Hence, there was still cause 
for concern that the absence of a repeat downstream from my phage-targeting spacers 
could affect my results in other assays. For example, perhaps the ‘tolerance’ of 
chromosomal targets I was finding in various assays could be an unnatural by-product 
of this. Note that these CRISPR array architectures are not found in natural 
staphylococcal type III-A systems. I therefore compared transformation with the spacer 
32T*B and 32T*B(-R) CRISPR-Cas plasmids in lysogen transformation assays. Each 
plasmid produced similar numbers of TB4::ɸNM4 lysogen transformants, and also 
similar numbers of RN4220::ɸNM1 lysogen transformants (data not shown). This, 
finally, allayed my concern that the absence of a downstream repeat was not required 
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for tolerance in S. aureus per se. My colleague Wenyan would later encounter more 
striking phenotypes in some of his other assays if the targeting spacer lacked a 
downstream repeat, suggestive of partial loss-of-function (personal communication). 
Regarding the mechanism(s) of transcription-dependent targeting I was 
observing in my in vivo experiments, some additional concerns were raised by Dr. 
Bikard and other members of the lab at this time. Although direct evidence for target 
DNA cleavage by type III systems had yet to be obtained by any groups, cleavage of 
RNA targets had been demonstrated (Hale et al., 2012; Hale et al., 2009; Zhang et al., 
2012). On the one hand, regarding the possibility that our S. epidermidis RP62a system 
could also cleave (specific) target RNAs, I was fairly confident this would be insufficient 
to explain the in vivo results we’d observed thus far. For example, in the original work 
by Dr. Marraffini, knockdown of RNA at the nickase-derived target loci in pG0400 and 
pC194-based plasmids would not be expected to impair plasmid stability (Marraffini 
and Sontheimer, 2008). Likewise, knockdown of leftward lysogenic transcripts by the 2B 
or 4B spacers would not be expected to impair lytic infection by ɸNM1, and yet they 
licensed immunity in plaque assays (Figure 2-2C). I had now shown that transcription-
dependent targeting of engineered chromosomal insertions is also toxic, even though 
these entire insertions are non-essential for host growth (Figures 2-15, 2-18, & 2-20). On 
the other hand, some compelling hypotheses had meanwhile been raised about the role 
of the Csm6 and Csx1 proteins found in various type III systems, including the Csm6 of 
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our RP62a system. Based on homology to RNase domains found in previously 
predicted or confirmed toxin-antitoxin systems, the HEPN RNase domains found in 
Csm6/Csx1 proteins were proposed to offer a similar (potentially toxic) function 
(Anantharaman et al., 2013; Makarova et al., 2012). For example, toxin activities can be 
leveraged by abortive infection systems to prevent the spread of phages, by 
altruistically killing infected cells before their progeny phage are released (Labrie et al., 
2010). Therefore, we could not formally exclude the possibility that the type III-A 
targeting phenomena observed in the lab thus far had resulted from one or more toxins 
being activated by the presence of (transcribed) target DNA. Further adding to the 
complexity of the matter, Dr. Hatoum-Aslan (with help from Inbal Maniv and Dr. 
Samai) was finding that csm6 is required for immunity to pG0400 in conjugation assays 
with the wild type nes target, although it does not stably associate with the complex. 
These findings (Hatoum-Aslan et al., 2014; Hatoum-Aslan et al., 2013), still unpublished 
at the time, could alternatively be explained if Csm6 were contributing to plasmid 
(DNA) targeting in some way. Although Csm6 itself had not been shown or predicted 
to harbor DNase domains (to my knowledge), it was not inconceivable that it could be 
recruited by the type III complex to enable or augment DNA cleavage in a manner 
analogous to recruitment of Cas3 nucleases by type I systems (Westra et al., 2012). In an 
effort to address these concerns, I constructed a Δcsm6 knockout variant of my spacer 
43T CRISPR-Cas plasmid for testing in transformation assays with my second-
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generation inducible target vectors. Presumably, if transformation efficiency were still 
reduced in a transcription-dependent manner with this plasmid, I could rule out the 
possibility that Csm6/HEPN-mediated cellular suicide is strictly required for our in vivo 
targeting phenomena, and provide evidence in support of a model where the type III-A 
targeting complex is sufficient for DNA targeting (at least in certain contexts). Wenyan 
was just beginning his study on Csm6 around this time, and kindly pointed me to Dr. 
Marraffini’s primers for deleting csm6 from type III-A plasmids, such as pWJ30β and its 
derivatives. I tested the spacer 43T(Δcsm6) CRISPR-Cas plasmid with forward and 
reverse target insertions in both orientations relative to the chromosomal origin of 
replication, and found the same trends I’d observed with the wild type plasmid in 
transformation assays (Figure 2-21B). Inducible chromosomal targeting was also 
monitored in high-resolution growth curves with the ‘Inv-attP-Target’ strains, and 
again the toxicity licensed by the 43T(Δcsm6) plasmid was found to be comparable to 
that of wild type (Figure 2-21C). The recovery observed after ~6-8 hours with both wild 
type and Δcsm6 targeting plasmids was assumed at the time to result from escape 
mutants in the population. It’s also possible that the effects of ATc were simply wearing 
off around this time; other members of the lab have anecdotally reported that re-
supplementation is required to maintain active concentrations of ATc in liquid cultures. 
In hindsight, plating after different durations of ATc treatments to measure viable CFUs 
might have helped to determine whether type III-A chromosomal targeting is lethal in 
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Figure 2-21. Inducible chromosomal targeting using a Δcsm6 variant of the spacer 43T 
CRISPR-Cas plasmid.  
(A) Schematics summarizing the orientation of spacer 43T crRNAs (blue arrows) 
relative to forward or reversed target sequences downstream of the Pxyl/tet* promoter in 
second-generation unmodified-attP (left two schematics) and inverted-attP (right two 
schematics) integrative vectors. Leftward-oriented arrows (depicted above) represent 
crRNAs with complementarity to the template strand relative to leftward Pxyl/tet* 
transcription; rightward-oriented arrows (depicted below) represent crRNAs with 
complementarity to the non-template strand. (B) Transformation of RN4220-derived 
strains with the spacer 43T(Δcsm6) CRISPR-Cas plasmid in the presence or absence of 
ATc. Electrocompetent cells possessed either the ‘Targetless’ vector insertion, the 
forward ‘Target’ vector insertion, the ‘Reverse’ target vector insertion, the ‘Inv-attP-
Target’ vector insertion, or the ‘Inv-attP-Reverse’ target vector insertion, and were 
transformed using a single miniprep of the CRISPR-Cas plasmid cloned in RN4220. 
Transformation efficiencies were calculated as the number of transformants per ng of 
miniprepped DNA used for electroporation (CFU / ng). Dashed line represents the limit 
of detection under these assay conditions. Additional replicates were not performed. 
(C) High-resolution growth curves of ‘Inv-attP-Target’ strains harboring either the 
pGG3, spacer 43T, or spacer 43T(Δcsm6) CRISPR-Cas plasmid as indicated. Each of the 
indicated strains was grown in the presence (solid lines) or absence (dashed lines) of 
ATc addition at the indicated time point (black arrow), and were originally isolated as 
CRISPR-Cas plasmid transformants plated in the absence of ATc. Growth curves 
represent data from single biological replicates; additional replicates were not 
performed. 
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this assay. Nevertheless, these preliminary results did well to satisfy my curiosity, as 
well as the lab’s. A small plaque phenotype was also noted while testing this 
43T(Δcsm6) plasmid with ɸNM1, indicative of strongly impaired immunity. Ultimately, 
Wenyan would go on to show that Csm6 (and its HEPN domain’s RNase activity in 
particular) is required for robust immunity in this context because this particular target 
region is transcribed late during the ɸNM1 lytic cycle (Jiang et al., 2016). 
All of these findings were exciting and encouraging to me, but their general 
novelty was now somewhat compromised by a publication showing evidence in 
support of a transcription-dependent DNA targeting mechanism for an archaeal type III 
system (Deng et al., 2013). Accordingly, I made an effort to shift our study’s focus onto 
the more novel findings concerning temperate phages: namely, that transcription-
dependent immunity to lytic infection provides a mechanism for averting chromosomal 
targeting during lysogeny. The strategy was to distinguish type II systems and other 
transcription-independent CRISPR-Cas systems from type III systems, in that the 
former would provide indiscriminate immunity both to lytic and lysogenic infections 
by temperate phages, while the latter would provide immunity only under certain 
conditions (which were generally only met during lytic infections). Hence, I initially 
took to distinguishing the type III targeting mechanism in terms of its capacity for 
‘conditional targeting’ of temperate phages. It was later pointed out to me by Dr. 
Marraffini that the non-targeting scenario we observe during lysogeny—when spacers 
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match to lytic genes—could be considered a form of ‘tolerance’. Focusing on the type 
III-A system’s capacity for tolerance, in turn, allowed us to expand on the analogy 
between CRISPR-Cas systems and mammalian immune systems (Goldberg and 
Marraffini, 2015). I elaborate on this point in Chapter 4. However, considering that the 
type III system maintains its capacity for targeting during lytic infections, and that 
tolerance of prophages is not absolute (e.g., during prophage induction), we ultimately 
decided that the phenomenon could best be summarized as ‘conditional tolerance’. 
Experiments described in the next section helped us to convey this point more clearly in 
the publication (Goldberg et al., 2014). 
2.5 Transcription-dependent targeting by a type III-A CRISPR-Cas system allows
conditional tolerance of temperate phages 
In stark contrast to what was reported for E. coli with a type I CRISPR-Cas system 
targeting temperate phage λ (Edgar and Qimron, 2010), I was finding that S. aureus 
strains with various type III-A CRISPR-Cas plasmids could tolerate lysogenic infections 
by the same Newman temperate phages which are resisted during lytic infections. 
Moreover, this conditional tolerance phenomenon was found to be contingent upon 
immunity directed at lytic cycle genomic regions which are sufficiently repressed 
during lysogeny (Figures 2-11, 2-12, & 2-17). However, my core findings thus far had 
been gleaned from results with lysogenic transformants and egg yolk screen isolates. In 
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order to corroborate these findings, and also demonstrate more quantitatively that 
tolerance allows lysogeny to be established efficiently during infection, I adopted a 
lysogenization efficiency assay akin to what had been tested with the type I system 
(Edgar and Qimron, 2010). For sensitive hosts, lysogenization frequency can be 
calculated by using survival as a direct readout for lysogenization. For CRISPR-resistant 
hosts, the number of cells which survive infection is not necessarily correlated with 
lysogenization frequency, because CRISPR immunity can allow cells to survive 
infection even in cases where that infection was not lysogenic. To overcome this, the 
type I study utilized a recombinant λ phage carrying a tellurite resistance marker that is 
expressed from the prophage in lysogens. Thus, by virtue of the tellurite-resistance-
converting prophages they’ve acquired, lysogenized CFU can be quantified after brief 
infections (Edgar and Qimron, 2010). Accordingly, I endeavored to engineer a similar 
recombinant of ɸNM1. Unsure of where to insert a resistance marker, however, I asked 
Dr. John Chen of the Novick laboratory via e-mail. His reply was prompt and 
informative. He explained, among other things, that marker insertions tend to be 
functional on either side of the phage attachment site, and that erythromycin resistance 
would be preferable to kanamycin resistance for S. aureus. While it was too late for my 
pKL55-iTET vectors conferring kanamycin resistance, I heeded his advice regarding 
erythromycin resistance going forward. I designed a pKOR-based allelic exchange 
plasmid (Bae and Schneewind, 2006) for inserting an erythromycin resistance marker, 
108 
Figure 2-22. Conditional tolerance in RN4220 hosts infected with ɸNM1-ErmR.  
(A) Schematic diagram depicting a relevant genomic region of ɸNM1-ErmR that 
includes the ermC insertion (blue thick arrow) immediately downstream of int. ORFs 
were scaled by length in accordance with the ɸNM1 (NC_008583.1) or pE194 
(NC_005908.1) annotations. Grey bent arrows signify the presence of divergently 
oriented promoters in the ELCR of ɸNM1. (B) Plaquing efficiency of ɸNM1 and ɸNM1-
ErmR on lawns of RN4220 harboring the 32T or 32T* CRISPR-Cas plasmids, or the pGG3 
control plasmid (C). Error bars, mean ± s.d. (n = 3, technical replicates). (C) 
Lysogenization of RN4220 derivatives harboring CRISPR-Cas plasmids with the 
indicated targeting spacers, or the pGG3 control plasmid (C), quantified as the 
concentration (CFU / ml) of chloramphenicol- and erythromycin-resistant colonies 
obtained upon plating after brief infection with ɸNM1-ErmR. Prior to infection, cultures 
were plated in the presence of chloramphenicol alone to estimate the concentration 
(CFU / ml) of total recipients harboring CRISPR-Cas plasmids. Error bars, mean ± s.d. (n 
= 3, biological replicates). (D) ɸNM2-sensitivity assay for eight (1-8) randomly-selected 
clones isolated from ɸNM1-ErmR lysogenization experiments with the spacer 32T 
CRISPR-Cas plasmid. A ɸNM1-ErmR lysogen harboring the pGG3 plasmid was used as 
the sensitive control (C). After re-streak isolation, single colonies were streaked through 
the ɸNM2-seeded region from top to bottom. (E) PCR amplification of the CRISPR array 
(upper panel) and spacer 32T target region (lower panel) from the isolates tested in ‘D’. 
Size markers of 1 kb and 0.5 kb are indicated. All eight target region PCR products were 
sequenced by Sanger and no mutations were found (data not shown). (F) ɸNM2 
plaquing efficiency on soft agar lawns of an additional six randomly selected clones (9–
14) isolated from ɸNM1-ErmR lysogenization experiments with the spacer 32T CRISPR-
Cas plasmid. The ɸNM1-ErmR lysogen harboring the pGG3 control plasmid was also 
tested (–C/L), and plaquing efficiency with the non-lysogenic indicator strain harboring 
pGG3 is shown for comparison (–C). Error bars, mean ± s.d. (n = 3, technical replicates). 
(G) Plaque-forming potential of filtered overnight culture supernatants from a ɸNM1-
ErmR-lysogenic isolate harboring the spacer 32T CRISPR-Cas plasmid. PFU 
concentrations (PFU / ml) were measured by plating on soft agar lawns of RN4220 
harboring either the pGG3 control (C) or spacer 32T CRISPR plasmid. Dashed line 
represents the limit of detection under these assay conditions. Error bars, mean ± s.d. (n 
= 3, biological replicates). Pictures in ‘D’ and ‘E’ were derived from single experiments. 
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ermC, immediately downstream of ɸNM1’s integrase (Figure 2-22A). Recombination 
with the prophage allowed me to isolate a modified single lysogen, which in turn 
produced erythromycin-resistance-converting phage particles via spontaneous 
induction. Using this ɸNM1-ErmR phage, which seemed to behave no differently than 
ɸNM1 in plaque assays (Figure 2-22B), I confirmed that various type III-A CRISPR-Cas 
plasmids do not reduce lysogenization efficiency in RN4220 (Figure 2-22C). These 
included some of the same ‘conditionally tolerant’ plasmids that could efficiently 
transform pre-established RN4220::ɸNM1 lysogens (Figure 2-12C). In addition, I 
corroborated my results from the egg yolk screens by characterizing some ErmR isolates 
harboring the conditionally tolerant spacer 32T CRISPR-Cas plasmid (Figures 2-22D, 2-
22E, & 2-22F). For one of these isolates, I confirmed that the spontaneously induced 
PFU recovered from supernatants of overnight cultures were not spacer 32T escaper 
mutants (Figure 2-22G). Note that the number of PFUs derived from conditionally 
tolerant lysogens was again found to be reduced relative to that of non-targeting control 
lysogens. In turn, this was corroborated with wild type ɸNM1 by comparing the 
number of spontaneously induced PFUs derived from three lysogenic transformation 
isolates harboring either the spacer 32T, spacer 43T, or pGG3 (non-targeting) CRISPR-
Cas plasmids (Figure 2-23A). In order to visualize the effect of CRISPR-Cas targeting on 
prophage induction in conditionally tolerant lysogens, I monitored some of my strains 
in high-resolution growth curves following treatment with the DNA-damaging agent, 
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Mitomycin C (MMC). MMC treatments are known to be SOS-inducing for various 
bacteria, including S. aureus (Anderson et al., 2006). SOS-induction, in turn, can trigger 
Figure 2-23. Conditionally tolerant type III-A CRISPR-Cas systems limit prophage 
induction in lysogenic hosts.  
(A) Plaque-forming potential of filtered overnight culture supernatants from 
RN4220::ɸNM1 lysogens transformed with either the pGG3 (C), 32T, or 43T CRISPR-
Cas plasmids. PFU concentrations (PFU / ml) were measured by plating on soft agar 
lawns of RN4220 non-lysogens harboring the pGG3 control plasmid. Dotted line 
represents the limit of detection under these assay conditions. Error bars, mean ± s.d. (n 
= 3, biological replicates). (B) Growth of ɸNM1-ErmR lysogens harboring the pGG3 (red) 
or spacer 43T (blue) CRISPR-Cas plasmids as indicated, monitored at high-resolution in 
the presence (solid lines) or absence (dashed lines) of Mitomycin C added at the 
indicated time point (black arrow). An RN4220 non-lysogen harboring the 43T CRISPR-
Cas plasmid control plasmid was also tested (green). 
prophage induction by stimulating autocatalytic cleavage of lambdoid prophage CI-like 
repressors (Erill et al., 2007; Livny and Friedman, 2004). Whereas lysogenic cultures 
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with the non-targeting pGG3 plasmid lysed after MMC treatment, the conditionally 
tolerant lysogens with spacer 43T did not (Figure 2-23B). Whether or not this 
discrepancy reflects differences in viability was never rigorously determined, but my 
preliminary experiments with short (~45 min) MMC treatments of RN4220 and its 
derivatives in HIB media seemed to suggest that viability was diminished to a similar 
degree for both non-targeting and conditionally tolerant lysogens, even when using a 
subinhibitory concentration (0.5 μg/ml) of MMC such as this (Goerke et al., 2006). 
Therefore, while the conditionally tolerant lysogens were found to reach the same 
attenuance (D600 nm) readings as the non-lysogens harboring spacer 43T, this does not 
necessarily imply that they would display equivalent viabilities upon plating, because 
inviable cells that do not lyse may still contribute to attenuance measurements. 
Conditionally tolerant plasmids aside, the spacer 2B type III CRISPR-Cas plasmid was 
found to be ‘intolerant’ of lysogenization, in that it reduced the number of ErmR CFUs 
that result from infection (Figure 2-22C). Additional characterizations of the rare 
lysogenized and transformed clones isolated from spacer 2B experiments were 
presented to a skeptical reviewer during the first revision (Goldberg et al., 2014), and in 
all cases the isolates were shown to represent genetic escapers that had either 
inactivated their CRISPR-Cas system or lost their xis target region amplicon (data not 
shown). 
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Soon after, I demonstrated that (transcription-independent) targeting by type II 
CRISPR-Cas plasmids can likewise reduce lysogenization efficiency—in addition to 
preventing lytic infection by both ɸNM1 and ɸNM1γ6 (Figures 2-24A & B). Note that 
lytic infection by ɸNM1γ6 was prevented even when its bottom strand was targeted in 
a lysogeny gene (using spacer 4B-tII), presumably because type II targeting is largely 
indifferent to the reduced transcription in this region. Note also that the observed 
lysogenization efficiency was considerably higher for one of my type II CRISPR-Cas 
plasmids (harboring spacer 43B-tII), so I characterized a few ErmR isolates derived from 
those infections to confirm that they were in fact genetic escapers (Figure 2-24). A 
definitive explanation for the discrepancy between my two type II spacers in the 
lysogenization assay is still lacking, but some ideas were offered in response to a 
reviewer’s comments during the review process (although they were not explicitly 
discussed within the publication). Firstly, the discrepancy might result in part from 
differences in the frequency of target site mutation. Two escapers of the 43B-tII spacer 
were found to harbor identical large deletions within the prophage lytic region. These 
deletions (Figure 2-24H) appear to have utilized a 14 bp direct-repeat microhomology, 
suggesting that target site recombinogenicity is a contributing factor (e.g., via ‘hot-
spots’). Meanwhile, the location of the 4B-tII target within the cI-like repressor gene that 
is required for lysogenization, along with the proximity of this target to the ermC 
insertion, should reduce the likelihood of detecting mutations in this region when we 
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Figure 2-24. Transcription-independent targeting by a type II CRISPR-Cas system in 
S. aureus precludes detectable tolerance of DNA target elements. 
(A) Plaquing efficiency of ɸNM1 and ɸNM1γ6 on lawns of RN4220 harboring the 
indicated type II CRISPR-Cas plasmids. The pDB184 parent vector was used as the non-
targeting control. Error bars, mean ± s.d. (n = 3, technical replicates). (B) Lysogenization 
of RN4220 derivatives harboring the type II CRISPR-Cas plasmids tested in ‘A’, 
quantified as the concentration (CFU / ml) of chloramphenicol- and erythromycin-
resistant colonies obtained upon plating after brief infection with ɸNM1-ErmR. Prior to 
infection, cultures were plated in the presence of chloramphenicol alone to estimate the 
concentration (CFU / ml) of total recipients harboring CRISPR-Cas plasmids. Error bars, 
mean ± s.d. (n = 3, biological replicates). (C) ɸNM2-sensitivity assay for seven (1-7) 
randomly-selected clones isolated from ɸNM1-ErmR lysogenization experiments with 
the spacer 43B-tII CRISPR-Cas plasmid. For comparison, a resistant non-lysogen 
harboring the spacer 43B-tII plasmid and a sensitive lysogen harboring the pDB184 
plasmid were included as controls (+C and –C, respectively). After re-streak isolation, 
single colonies were streaked through the ɸNM2-seeded region from top to bottom. (D) 
ɸNM2 plaquing efficiency on soft agar lawns of an additional six randomly selected 
clones (8–13) isolated from ɸNM1-ErmR lysogenization experiments with the spacer 
43B-tII CRISPR-Cas plasmid, measured alongside a ɸNM1-ErmR lysogen harboring the 
pDB184 plasmid (–C/L). For comparison, plaquing efficiency of ɸNM2 on the non-
lysogenic indicator strain harboring pDB184 or the spacer 43B-tII targeting plasmid is 
also shown (–C and +C, respectively). (E) Agarose gel electrophoresis of plasmid DNA 
purified from isolates 8–13 from panel ‘D’, and the parental strain harboring the spacer 
43B-tII CRISPR-Cas plasmid (C). The symbols + or – indicate the presence or absence of 
treatment with the BamHI restriction enzyme, which produces two bands for the wild-
type spacer 43B-tII plasmid: 5367 bp and 3972 bp. Size markers correspond to 10 kb, 3 
kb and 0.5 kb bands of the 1 kb DNA ladder from NEB. (F) Colony PCR spanning the 
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type II CRISPR array for isolates 8–13. Spacer 43B-tII plasmid DNA was used as a 
template for the control (C). Size markers of 3 kb and 0.5 kb are indicated. (G) Colony 
PCR spanning the target region for isolates 8–13 and a ɸNM1-ErmR lysogen 
harboring the pDB184 control plasmid (C). Isolates 10 and 11 harbor 
identical deletions within the prophage that remove the target region (see 
below). Size markers of 3 kb and 0.5 kb are indicated. The presence of attL and 
attR prophage integration arms was also verified independently for each isolate 
using PCR (data not shown). (H) Location of the 16,985 bp deletion identified 
within the prophage of isolates 10 and 11 (shaded grey box). The location and 
orientation of the ermC insertion cassette is also shown (thick blue arrow). Deletion was 
mapped by primer walking. An ~9.1 kb product spanning the deletion was ultimately 
amplified using primers oGG6 and oGG241, and the deletion junction was sequenced 
by Sanger using oGG245. A perfect 14 bp direct repeat microhomology flanks the 
deletion. (I) Plaque forming potential of overnight culture supernatants from isolates 8, 
10 and 11. Supernatants were also plated with spacer 43B-tII targeting lawns, yielding 
no detectable PFUs. No PFUs were detected from the supernatants of isolates 10 and 11 
whatsoever, presumably resulting from their deletion of genes essential for prophage 
induction, including the ORF 43 head protein. Dotted line represents the limit of 
detection for this assay. Error bars, mean ± s.d. (n = 3, biological replicates). (J) 
Transformation of RN4220-derived strains with spacer 43B-tII or pDB184 CRISPR-Cas 
plasmids in the presence or absence of ATc. Electrocompetent cells possessed either the 
‘Inv-attP-Targetless’ vector insertion, the forward ‘Inv-attP-Target’ vector insertion, or 
the ‘Inv-attP-Reverse’ target vector insertion, and were transformed using the same 
miniprep for either CRISPR-Cas plasmid cloned in RN4220. Transformation efficiencies 
were calculated as the number of transformants per ng of miniprepped DNA used for 
electroporation (CFU / ng). Error bars, mean ± s.d. (n = 3, technical replicates). Pictures 
in ‘C’, ‘E’, ‘F’, and ‘G’ are derived from single experiments. 
116 
117 
select for ErmR CFU. In other words, the 4B-tII spacer might be more difficult to escape 
because it targets lysogenization functions that are required for integration of the ermC 
cassette associated with prophages. Furthermore, it has been shown that point 
mutations in the target which abrogate Cas9-mediated target cleavage do not 
necessarily abrogate Cas9-mediated binding altogether, and might therefore still allow 
repression via the dCas9-like mechanism (Bikard et al., 2013). In this scenario, 
knockdown of the cI-like repressor gene should also be selected against. However, these 
factors may be insufficient to explain the discrepancy, given that the dominant form of 
escape I observed with the 43B-tII spacer was due to CRISPR-Cas plasmid inactivation. 
On this note, it’s possible that the 43B-tII spacer promoted higher frequencies of 
plasmid rearrangement in the overnight cultures used for lysogenization, either due to 
the spacer sequence’s recombinogenicity itself, or due to stress associated with off-
target effects. In support of this latter idea, partial matching to the RN4220 chromosome 
appears to be greater for the 43B-tII spacer than for the 4B-tII spacer. To determine this, 
I took advantage of a script that Dr. Bikard had designed to look for partial matching 
adjacent to ‘NGG’ PAMs. When the parameters called for a minimum of 8 consecutive 
bp matched at the seed sequence adjacent to the PAM, no partial matches were found 
for the 4B-tII spacer, while eight were found for the 43B-tII spacer. Among these 43B-tII 
partial matches was a 15 bp match to an ORF encoding a putative pyrimidine 
nucleoside phosphorylase. In turn, partial matching might allow for occasional cleavage 
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of the chromosome, or dCas9-like repression of target gene(s) that are potentially 
essential for normal growth. The 43B-tII CRISPR-Cas plasmid was also used in 
transformation assays to target my second-generation chromosomal insertion vectors 
harboring the inverted attP motif. As expected, the 43B-tII transformation efficiency was 
reduced for both forward and reverse targets, regardless of the presence or absence of 
ATc (Figure 2-24J). 
Around this time, I also obtained the results from my second RNA-seq 
experiment. Dr. Bikard, again demonstrating his resourcefulness, provided me with a 
script for normalizing and plotting the reads. The results corroborated my previous 
results 15 minutes post-infection with ɸNM1, and expanded it to include additional 
time points. Perhaps as expected, strong rightward transcription of the early lytic genes 
immediately to the right of the ELCR was observed even at the early time points, 
whereas late genes further downstream were not strongly transcribed until later time 
points (Figure 2-25). Only moderate leftward transcription was observed to the left of 
the ELCR, but it remained essentially constant across time points. A moderate peak of 
rightward transcription across the xis ORF to the left of the ELCR was also discernible, 
and thereby confirmed our prediction that this region is bi-directionally transcribed 
during lytic infections. In a separate endpoint RT-PCR experiment (Figure 2-26), my 
results tested positive for bi-directional transcription across the target region of Dr. 
Marraffini’s original pC194-derived target plasmids harboring nes target insertions in 
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Figure 2-25. Visualization of ɸNM1 transcription profiles at various time points after 
infection (MOI 20).  
(A) RNA was harvested 6 minutes post-infection of a logarithmically growing culture of 
RN4220 cells harboring the non-targeting pGG3 plasmid. Rightward and leftward 
expression values are plotted as golden and purple lines, respectively, in reads per 
million (RPM). The position of relevant spacer targets are indicated with vertical solid 
lines. The dotted line with divergent arrowheads marks the position of the early lytic 
control region (ELCR) with divergently oriented PcI and Pcro promoters. To improve 
readability, curves were smoothened by plotting average reads per million values over 
a 500 bp sliding-window. (B) Same as in ‘A’, except RNA was harvested 15 minutes 
post-infection. (C) Same as in ‘A’, except RNA was harvested 30 minutes post-infection. 
To the left of the ELCR, rightward expression is comparable to leftward expression by 30 
minutes post-infection, consistent with the strand-independent targeting observed for 
this region. (D) Same as in ‘A’, except RNA was harvested 45 minutes post-infection.  
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either orientation (Marraffini and Sontheimer, 2008), which may also explain why he 
observed targeting in both cases. Importantly, my RNA-seq experiment indicated that 
Figure 2-26. Detection of transcription across target insertions for the pNes(wt-d) and 
pNes(wt-i) plasmids.  
(A) Reverse transcription was performed in both directions with DNase-treated total 
RNA from RN4220 cells harboring the indicated plasmids, using either forward or 
reverse primers for cDNA synthesis in two separate reactions for each target plasmid 
(Marraffini and Sontheimer, 2008). PCR was performed on cDNA products, or plasmid 
DNA templates for control (C) lanes. The symbols + or – indicate the presence or 
absence of reverse transcriptase enzyme in the reverse transcription reaction mixture 
used to template the PCR. Size markers of 500 bp and 100 bp are indicated. Picture is 
derived from a single experiment; reaction components were not tested in additional 
technical replicates. 
leftward transcription from the ELCR was reduced for the ɸNM1γ6 mutant relative to 
ɸNM1 at equivalent time points, while rightward transcription of ɸNM1γ6 was 
essentially unchanged (Figures 2-10D & 2-27). In particular, when I calculated the fold 
change for the sum of leftward expression values across the region bounded by the start 
of the phage genome and the ELCR, as well as for the sum of leftward expression values 
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Figure 2-27. Visualization of ɸNM1γ6 transcription profiles at two time points post- 
infection (MOI 20).  
(A) RNA was harvested 6 minutes post-infection of a logarithmically growing culture of 
RN4220 cells harboring the non-targeting pGG3 plasmid. Rightward and leftward 
expression values are plotted as golden and purple lines, respectively, in reads per 
million (RPM). The position of relevant spacer targets are indicated with vertical solid 
lines. The dotted line with divergent arrowheads marks the position of the early lytic 
control region (ELCR) with divergently oriented PcI and Pcro promoters. To improve 
readability, curves were smoothened by plotting average reads per million values over 
a 500 bp sliding-window. (B) Same as in ‘A’, except RNA was harvested 15 minutes 
post-infection.  
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across the entire phage genome, I found approximately 32-fold and 4-fold reductions, 
respectively, for ɸNM1γ6 at the 15 minute time point (suggesting a net 8-fold reduction 
in leftward expression across this region). 
During the initial review process, some concern was raised by an anonymous 
reviewer regarding our evidence for in vivo DNA targeting. Our efficiency of plaquing 
and chromosomal targeting results were difficult to explain without invoking a DNA 
targeting argument, but the evidence was still arguably indirect. Similar to Dr. Bikard’s 
initial concerns regarding Csm6, the reviewer seemed to be concerned that a toxic 
activity associated with targeting—perhaps of RNA alone—could explain our results. 
Toxicity associated with specific targeting of RNA by the complex in vivo still seemed 
highly unlikely. However, the reviewer may have been privy to knowledge about 
Csm6, or at least the hypotheses surrounding its non-specific, toxin-like RNase function 
(Anantharaman et al., 2013; Makarova et al., 2012). Given the mounting evidence in our 
lab that csm6 was not strictly required for targeting in these assays, we were not 
particularly concerned (but to be fair, no mention of Csm6 or its mutagenesis was 
included in the manuscript). Nevertheless, we provided some experiments that helped 
to address the reviewer’s concern. In particular, I provided high-resolution growth 
curves of strains harboring different CRISPR-Cas plasmids, following infection with 
ɸNM1 at MOI ~10 or MOI ~100. Growth was largely unperturbed at MOI ~10 for all the 
spacers tested, relative to uninfected cultures (Figure 2-28A). This suggested that cells 
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were not strictly arresting upon infection (i.e., that the immunity observed in plaque 
assays was not due to an abortive-infection-like mechanism), because presumably all or 
most of the cells are injected at MOI ~10. In other words, infected cells appeared to be 
clearing the phage, or at least surviving infection. At higher MOIs (~100), growth was 
more noticeably perturbed (Figure 2-28B). This was assumed to reflect the CRISPR-Cas 
Figure 2-28. Infection with ɸNM1 in liquid culture. 
(A) Growth of RN4220 hosts harboring various CRISPR-Cas plasmids (as indicated) 
was monitored at high-resolution following infection with ɸNM1 (MOI ~10) at time 
zero (solid lines). Growth of the uninfected RN4220/pGG3 host is also shown for 
comparison (dashed clay-red lines). (B) Same as in ‘A’, except cultures were infected 
with ɸNM1 at MOI ~100.  
system being overwhelmed with an unnaturally high amount of phage. Furthermore, 
spacers targeting late-transcribed genes seemed to perform even more poorly. This 
could conceivably still be explained in terms of a transcription-dependent DNA 
targeting model, if these discrepancies were assumed to result from differences in the 
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onset of DNA targeting. In other words, delays in DNA targeting for late-transcribed 
targets might simply give the phage a head start, and generally overwhelm the CRISPR-
Cas system more readily. Wenyan and Dr. Samai (with help from others in the lab) 
would later go on to show that the robustness of type III-A immunity at normal MOIs (< 
~10) is also due in part to the contributions of its Csm3 and Csm6 RNase activities (Jiang 
et al., 2016; Samai et al., 2015). However, prior to establishing a function for Csm6 in 
phage defense, Wenyan had also been working to engineer an inducible system for 
targeting (and perhaps curing) of plasmids with the nes protospacer, such as pG0400. 
His initial attempts utilized Lac-inducible promoters for expression of the type III-A 
system, either in its entirety or in parts. Despite these efforts, the systems were 
generally still leaky, and targeting would occur in the absence of induction. 
Furthermore, curing of pG0400 could not be achieved using wild type CRISPR-Cas 
systems. Once I had demonstrated that the modified ATc-inducible promoter 
architecture based off pRAB12 (Figure 2-16) allowed sufficient tightness to prevent 
severe chromosomal targeting by our constitutively-expressed type III-A systems 
(Figures 2-18 & 2-20), and thereby allowed for conditional targeting of DNA elements 
by such CRISPR-Cas systems, it became clear that this type of setup might offer a 
solution in plasmid-targeting assays. Wenyan’s new approach was therefore to use this 
modified ATc-inducible architecture and clone the nes protospacer downstream 
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Figure 2-29. Inducible curing of a target plasmid.  
(A) Schematic representation of the plasmid components used in this plasmid-curing 
experiment. The pGG3 CRISPR-Cas plasmid harbors a single spacer (‘1’) matching to 
the nes target sequence inserted downstream of the Pxyl/tet*-inducible promoter in 
pWJ153. The size of each plasmid is indicated below in kilobase pairs (kbp). Also 
depicted on pWJ153 is the ermC cassette conferring resistance to erythromycin, as well 
as the tetR gene encoding the inducible promoter’s repressor. (B) Agarose gel 
electrophoresis of linearized plasmid DNA purified both from 0.250 μg/ml ATc-treated 
(+ATc) and untreated (–ATc) cultures at the indicated time points. Size markers of 10 
kb, 5 kb and 4 kb are indicated. Picture is representative of a single technical replicate. 
(C) Concentration (CFU / ml) of colonies recovered upon plating of the cultures 
analyzed in ‘B’ at each time point. Cultures were plated with selection for either CmR 
CFUs (green) or CmR+ErmR CFUs (blue) as indicated. Targeting of the pWJ153 plasmid 
via induction with ATc (filled circles) is accompanied by a severe drop in ErmR CFUs 
relative to untreated cultures (open circles). Error bars, mean ± s.d. (n = 3, technical 
replicates). 
127 
128 
of its Pxyl/tet* promoter onto a pE194-based plasmid, creating pWJ153. This proved 
fruitful; the target plasmid was indeed stable in the absence of ATc, and could be cured 
by pGG3 upon induction (Figure 2-29). Although this was only demonstrated for one 
target orientation, it provided a final confirmation of in vivo DNA targeting by a type 
III-A system in S. aureus. Whereas growth was essentially halted upon induction in my 
chromosomal targeting assays (Figure 2-20), Wenyan found that growth could continue 
during plasmid targeting, and thereby allow cells to lose their target plasmid’s DNA 
(Figure 2-29B) and its associated resistance (Figure 2-29C) over time. Growth was not 
completely unperturbed, however; increases in the number of CmR CFUs were delayed 
upon ATc treatment. This is probably due, at least in part, to the generalized toxicity 
associated with ATc at this concentration (0.250 μg/ml). However, the possibility that 
this was also the result of side effects or toxicity associated with targeting should not be 
ruled out, in light of recent evidence concerning the potential for collateral RNA 
degradation by HEPN-containing Cas nucleases (Shmakov et al., 2017). I elaborate on 
this point in Chapter 3. 
2.6 Proposed implications of transcription-dependent targeting and conditional 
tolerance by type III-A CRISPR-Cas systems 
The work described in Chapter 2 illustrates how transcription-dependent targeting by a 
type III-A CRISPR-Cas system offers a mechanism for conditional tolerance of genetic 
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elements in S. aureus hosts. In particular, my experiments with temperate phages 
indicated that conditional tolerance engenders several consequences for the type III-A 
systems that target temperate phages, as well as their host population(s). For one, 
tolerance helps ensure the genetic stability of these CRISPR-Cas systems during 
temperate phage infection, given that pressure to integrate prophages in the presence of 
intolerant spacers was found to select for genetic CRISPR-Cas inactivation (Figures 2-4, 
2-12, & 2-24)—similar to what has been reported in the context of plasmid uptake 
(Fischer et al., 2012; Gudbergsdottir et al., 2011; Jiang et al., 2013b). In other words, 
conditionally tolerant spacers ensure that type III-A systems can provide CRISPR-Cas 
immunity to lytic infections without compromising their own stability in the event of 
lysogenization. An important consequence of this is that lysogenized lineages can 
maintain type III-A immunity to lytic infection by heteroimmune phages if the 
heteroimmune phages also contain a matching target for the conditionally tolerant 
spacer (Figures 2-11 & 2-22). This implies, moreover, that type III-A immunity operates 
via transcription-dependent targeting of transcribed elements in cis (because lysogenic 
cells survive infection by the heteroimmune phage despite the presence of their 
prophage with a matching target). I corroborated this in two assays. Firstly, I monitored 
growth of ɸNM1γ6-infected strains harboring my second-generation, inverted attP 
integrative vectors at high-resolution in the absence of ATc. Growth was essentially 
unperturbed relative to uninfected cultures for the strains that harbored the spacer 43T 
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Figure 2-30. Type III-A immunity to a transcribed target element does not result in 
detectable targeting of repressed DNA target elements in trans.  
(A) Growth of the indicated ‘Inv-attP’ chromosomal insertion strains from Figure 2-20 
harboring either spacer 43T or pGG3 CRISPR plasmids, monitored at high-resolution in 
the absence (dotted lines) or presence (solid lines) of ɸNM1γ6 addition at an MOI of 
~10. Black arrow denotes the time of phage addition; no ATc was used in this assay. The 
presence of a chromosomal target for spacer 43T has no discernable effect on culture 
growth during spacer 43T-mediated immunity to ɸNM1γ6 (compare green and blue 
solid lines). The strain harboring the pGG3 plasmid serves as a sensitive control (clay-
red lines). (B) Schematic representation of the plasmid components used in the plasmid-
curing experiment of panel ‘C’. The pGG8 CRISPR-Cas plasmid harbors a spacer in 
position 2 that matches to the nes-γB target sequence inserted downstream of the Pxyl/tet*-
inducible promoter of pWJ153γ. In pG0mut, the nes-γB target is thought to be lacking 
antisense transcription, because it is not targeted by pGG8 in conjugation assays. 
Induction of the target in pWJ153γ produces the same RNA that would result from 
antisense transcription of the nes-γB target in pG0mut. Also depicted on pWJ153 is the 
ermC cassette conferring resistance to erythromycin, as well as the tetR gene encoding 
the inducible promoter’s repressor. The pG0mut plasmid confers resistance to 
mupirocin. (C) Concentration (CFU / ml) of colonies recovered upon plating of cultures 
either treated (filled circles) or untreated (open circles) with ATc at 0.125 μg/ml. 
Cultures were plated with selection for either CmR CFUs (green), CmR+ErmR CFUs 
(blue), or CmR+MupR CFUs (purple) as indicated. Relative to untreated cultures (open 
circles), targeting of the pWJ153γ plasmid via induction with ATc (filled circles) is 
accompanied by a severe drop in the number of CmR+ErmR CFUs, but not CmR+MupR 
CFUs. After plating of untreated cultures at time zero, only the 2-hour and 6-hour time 
points were plated. Additional replicates were not performed under these assay 
conditions. 
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CRISPR-Cas plasmid, regardless of whether they bore a matching target in the 
chromosome as well (Figure 2-30A). In another assay, I attempted to detect loss of 
mupirocin resistance associated with pG0mut while curing a modified version of 
pWJ153 (pWJ153γ) with a target for the nes-γB spacer (Figure 2-30B). In pWJ153γ, the 
nes target of pWJ153 was replaced with the nes-γB sequence which is not normally 
targeted by pGG8 in pG0mut (Figure 2-14). Again, immunity appeared to be 
specifically directed at the transcribed target element upon induction of antisense 
transcription (in cis), because I still did not detect targeting of pG0mut by the nes-γB 
spacer in trans while curing the pWJ153γ plasmid (Figure 2-30C). 
If confirmed for other type III systems, the capacity for conditional tolerance 
might be particularly vital to the stability of type III systems in general, since type III 
targeting in archaea has been shown to provide immunity despite up to 15 spacer-target 
mismatches (Manica et al., 2013). Evidence for type III immunity occurring within 
staphylococcal hosts despite the presence of spacer-target mismatches was provided in 
this work (Figures 2-8, 2-11, & 2-22), and also in three subsequent works (Cao et al., 
2016; Jiang et al., 2016; Maniv et al., 2016). Therefore, without the potential for phages to 
readily evade targeting via point mutation that is seen for type I and type II systems 
(Deveau et al., 2008; Semenova et al., 2011), transcription-dependent type III-A targeting 
offers an alternative route to lysogenization that need not provide selection for mutants. 
In addition, the ability of the type III-A system to provide immunity in the presence of 
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spacer-target mismatches appears to result in more stringent selection against phage 
mutants during lytic infections. For example, ɸNM1 escapers were not observed with 
our spacer 43T type III CRISPR-Cas plasmid (Figure 2-2), while they were observed 
with the 43B-tII type II CRISPR-Cas plasmid (Figure 2-24)—despite the fact that its 3’-
most 12 bp (and ‘AGG’ PAM) are contained within the 36 bp of the type III target. 
However, with other type III spacers where the target sequences were apparently non-
essential for lytic infection, escapers were observed. For three such spacers, preliminary 
characterization (section 2.2) indicated that target site deletions are the dominant route 
of escape in these cases (Figures 2-7 & 2-13). Where microhomologies (< 20 bp) could be 
identified flanking the deletions, I speculate that deletion may have occurred through a 
recA-independent pathway (Bzymek and Lovett, 2001; Chayot et al., 2010), since the 
minimum homology for efficient recA-dependent recombination is thought to be closer 
to ~30 bp (Martinsohn et al., 2008; Shen and Huang, 1986). It’s also possible that our 
lambdoid Newman phages encode lambda red-like homologs that can facilitate these 
deletions (Datta et al., 2008). For example, the Newman phage annotations include 
ORFs encoding SSB-like proteins which might provide a recombinase function. 
However, the efficiency of red-mediated recombination was also shown to drop 
drastically for homologies shorter than ~30 bp (Yu et al., 2000). Whether the activity of 
Cas nucleases during immunity stimulates one or more of these pathways remains to be 
determined. On this note, the type of CRISPR-Cas system used for targeting could 
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potentially influence the sequence or frequency of deletions that arise, even when the 
same site is targeted (e.g., if different Cas nuclease lesions produce different substrates 
that favor deletion via one pathway over another). Evidently, certain type III spacers 
can also be escaped by mutants that reduce transcription of their target sequences 
during lytic infection (Figure 2-10). However, this was presumably enabled by the fact 
that those spacers were engineered to target lysogenization genes. Targeting of lytic 
genes should not be readily escaped in this manner, since reduced transcription of lytic 
genes would simultaneously compromise phage viability. 
Although a few spacers targeting putative or confirmed lysogenization genes did 
not provide tolerance (Figures 2-6, 2-12, & 2-22), it is important to note that these genes 
only constitute a small portion of the phage genome. Hence, spacers targeting these 
regions should be acquired less frequently, even if spacer acquisition occurs randomly 
without an additional mechanism for distinguishing tolerant from intolerant spacers 
during acquisition. Interestingly, our survey of sequenced staphylococcal type III 
spacers showed that naturally acquired spacers with known target sequences produced 
crRNAs complementary to the non-template strand of predicted ORFs in nine out of ten 
cases (Figure 2-31). This bias suggests negative selection on non-functional spacers 
targeting template strands. Alternatively, type III systems may utilize an unknown 
mechanism to discriminate template and non-template strands during spacer 
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Figure 2-31. Survey of unique spacers associated with staphylococcal type III-A 
systems possessing known targets with five or fewer mismatches.  
(A) Spacer-containing organisms and target elements are listed in the left column; the 
sequence of each spacer and its complementary target are provided in the middle 
column. Right column indicates whether the target strand is a template or non-template 
strand, inferred from annotated open reading frames. In cases where additional target 
elements were identifiable for a given spacer, a target element with the most available 
matches was chosen arbitrarily. 
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acquisition. Moreover, the temperate-phage-targeting spacers that we identified were 
found to match to lytic regions. A recent study corroborated our in silico findings, and 
expanded the analysis to include sequences from six additional S. aureus isolates with 
type III-A systems which were previously unavailable (Cao et al., 2016). 
Finally, conditional tolerance by type III-A systems ensures that a host 
population can efficiently sample phenotypes that result from prophage integration 
(i.e., lysogenic conversion phenotypes)—and again whilst maintaining immunity to 
lytic infection. However, prophage induction was found to be disrupted by type III-A 
targeting in lysogenized lineages that maintain conditional tolerance (Figure 2-23). 
Therefore, it is worth noting here that lysogenic conversion phenotypes which depend 
on processes which occur via prophage induction, including rapid lysis of induced cells, 
might also be curbed by conditional tolerance in lysogenized lineages. As discussed in 
section 1.4.2, the ability of a helper prophage to mobilize a resident SaPI via prophage 
induction could be considered a lysogenic conversion phenotype. In Chapter 3, I 
present my preliminary evidence indicating that this too can be disrupted in lysogens 
where the helper prophage is targeted by a type III-A CRISPR-Cas system. 
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2.7  Tables associated with Chapter 2 
Table 2-1. Spacers tested in Chapter 2. 
Spacer(a) Sequence (5’-3’)(b) Coordinates(c) 
Gene 
product(d) 
Plasmid 
Name 
2Told TTTTTAATTTAAGTTCTTGTTCATCGTCATAAATA 1317-1351 Excisionase pGG34 
2T AATTTTTAATTTAAGTTCTTGTTCATCGTCATAAA 1319-1353 Excisionase pGG52 
2B TATTTATGACGATGAACAAGAACTTAAATTAAAAA 1317-1351 Excisionase pGG9 
4T AATTTCGAGGAAGTTGCAATTGATAATGAAAAATT 2706-2740 Repressor pGG31 
4B AATTTTTCATTATCAATTGCAACTTCCTCGAAATT 2706-2740 Repressor pGG30 
4B-tII GAAATTTCCAGCAGAAACTTTACCGAAATA 2735-2764 Repressor pGG51 
16T CATTTTGTTTCTGTTCATGCCTCTGCCGACTGCT 8527-8560 Hyp. protein pGG19 
16B AGCAGTCGGCAGAGGCATGAACAGAAACAAAATG 8527-8560 Hyp. protein pGG4 
16B-tII AGACCTGGCACATTATGAAGCAGTCGGCAG 8509-8538 Hyp. protein pGG33 
17T TAATAAGTTTTATGCTCCTCAGTTTTTAAATCACTT 9045-9080 Hyp. protein pGG60 
17B AAGTGATTTAAAAACTGAGGAGCATAAAACTTATTA 9045-9080 Hyp. protein pGG59 
19T TTTTTAAAAATTCTTTGGTTACCATGCATCTCGCT 11293-11327 Replication pGG53 
19B AGCGAGATGCATGGTAACCAAAGAATTTTTAAAAA 11293-11327 Replication pGG10 
32T TTAAATCTTTGATTGCTCTTAGCTCTAGTTATGTAT 15352-15387 Hyp. protein pGG12 
32T*A GTAAACCTTTGATTGCTCTTAGCTCGAGTTATGTGC 15352-15387 Hyp. protein pGG13 
32B ATACATAACTAGAGCTAAGAGCAATCAAAGATTTAA 15352-15387 Hyp. protein pGG36 
43T ATTCGTCATCTTCAAGTAATGCCTCTAAATCAATAA 22411-22446 Head protein pGG41 
43B TTATTGATTTAGAGGCATTACTTGAAGATGACGAAT 22411-22446 Head protein pGG40 
43B-tII ACTTCACACAAGATAACATTATTGATTTAG 22393-22422 Head protein pGG37-full 
56T GCATGCACCTTGCCTGAATGTTTTAAAAATTCATT 34512-34546 Hyp. protein pGG54 
56B AATGAATTTTTAAAACATTCAGGCAAGGTGCATGC 34512-34546 Hyp. protein pGG11 
61T-1 ATGTCACCTAAGTCAACACCATCATTTTTTATTCT 39013-39047 Tail fiber pGG17 
61B-1 CTTAGGTGACATTGGCTGTCGATTTTACACTGAAG 39036-39070 Tail fiber pGG15 
61T-2 TTATGATTTTTTGGAGCATATAAATCATTTAGTGT 39949-39983 Tail fiber pGG18 
61B-2 CAGAAAGTGTATTGCAACAGATTGGCTCAAAAGTT 39884-39918 Tail fiber pGG16 
nes-γB ATAAATATGTATAAGGAAAATGAAAGACTATATGA 9232-9266 Nickase pGG8 
nes-γT TCATATAGTCTTTCATTTTCCTTATACATATTTAT 9232-9266 Nickase pGG24 
nes(-R) ACGTATGCCGAAGTATATAAATCATCAGTACAAAG 8174-8208 Nickase pGG25 
32T*B GTAAACCTTTGATTACTCTTAGCTTTAGTTATGTGT 15256-15291 Hyp. protein pGG14 
32T*B(-R) GTAAACCTTTGATTACTCTTAGCTTTAGTTATGTGT 15256-15291 Hyp. protein pGG22
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sequence with a ‘NGG’ PAM motif flanking the target’s 3’ end, required for 
Cas9-mediated immunity (Deveau et al., 2008; Jiang et al., 2013a). 
(c) Numbers reflect the coordinates of target regions for each spacer in the ɸNM1 
(NC_008583.1), pGO1 (NC_012547.1), or ɸNM4 (NC_028864.1) genomes. 
(d) Predicted gene product of the nearest ORF for each target, according to the NCBI 
annotations for ɸNM1, pGO1, or ɸNM4. 
(a) Numbers refer to the nearest ORF designation for the closest ɸNM1 target match, 
where applicable; crRNA complementarity to the ‘Top’ or ‘Bottom’ strand is 
denoted with a ‘T’ or ‘B’. Type II spacers are specified with a ‘-tII’ suffix.  
(b) Type III spacers were chosen to avoid homology between the 5’ crRNA tag and 
the target flanking sequences, which was shown to prevent immunity in S. 
epidermidis (Marraffini and Sontheimer, 2010b). Type II spacers match the nearest 
Table 2-1. Spacers tested in Chapter 2 (continued). 
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Table 2-2. Oligos used in Chapter 2. 
Name Sequence Primary Purpose 
oGG6 TACCCTAGTTAACGTCTCTTG Specific identification of ɸNM1 
oGG7 GATATCAACTTGTAGTGCATCG Specific identification of ɸNM1 
oGG8 TTGTAGCAAATCAAGAATTGACAG Specific identification of ɸNM2 
oGG9 CTAATTCATCTTGATTAGACATCTC Specific identification of ɸNM2 
oGG10 GCTGACTTACAAGAAGGTGGAC Specific identification of ɸNM4 
oGG11 GTTGTAATTGGATTAAATTCAGTC Specific identification of ɸNM4 
A10 CTTTGTACTGATGATTTATATACTTCGGCATACG Construction of pGG3 control/parent vector 
L55 TAAATCTAACAACACTCTAA Construction of pGG3 control/parent vector 
L6 AAAGGTACCAAATTTAATGCTATTTTCCTTCGC Type III CRISPR array verification 
L50 AAAAGATCTAATAATGTATTTACGCTGGGGC Type III CRISPR array verification 
oGG12 GTTCTCGTCCCCTTTTCTTCGGGGTGGGTATCGATCCTTTGTACTGATGATTTATATACTTC Common primer for spacer cloning via PCR 
oGG13 AGCAGTCGGCAGAGGCATGAACAGAAACAAAATGTAAATCTAACAACACTCTAAAAAATTG Construction of pGG4 
oGG18 ATAAATATGTATAAGGAAAATGAAAGACTATATGATAAATCTAACAACACTCTAAAAAATTG Construction of pGG8 
oGG19 TATTTATGACGATGAACAAGAACTTAAATTAAAAATAAATCTAACAACACTCTAAAAAATTG Construction of pGG9 
oGG20 AGCGAGATGCATGGTAACCAAAGAATTTTTAAAAATAAATCTAACAACACTCTAAAAAATTG Construction of pGG10 
oGG21 AATGAATTTTTAAAACATTCAGGCAAGGTGCATGCTAAATCTAACAACACTCTAAAAAATTG Construction of pGG11 
oGG22 TTAAATCTTTGATTGCTCTTAGCTCTAGTTATGTATTAAATCTAACAACACTCTAAAAAATTG Construction of pGG12 
oGG23 GTAAACCTTTGATTGCTCTTAGCTCGAGTTATGTGCTAAATCTAACAACACTCTAAAAAATTG Construction of pGG13 
oGG24 GTAAACCTTTGATTACTCTTAGCTTTAGTTATGTGTTAAATCTAACAACACTCTAAAAAATTG Construction of pGG14 
oGG46 CTTAGGTGACATTGGCTGTCGATTTTACACTGAAGTAAATCTAACAACACTCTAAAAAATTG Construction of pGG15 
oGG47 CAGAAAGTGTATTGCAACAGATTGGCTCAAAAGTTTAAATCTAACAACACTCTAAAAAATTG Construction of pGG16 
oGG48 ATGTCACCTAAGTCAACACCATCATTTTTTATTCTTAAATCTAACAACACTCTAAAAAATTG Construction of pGG17 
oGG49 TTATGATTTTTTGGAGCATATAAATCATTTAGTGTTAAATCTAACAACACTCTAAAAAATTG Construction of pGG18 
oGG56 CATTTTGTTTCTGTTCATGCCTCTGCCGACTGCTTAAATCTAACAACACTCTAAAAAATTG Construction of pGG19 
oGG72 TCATATAGTCTTTCATTTTCCTTATACATATTTATTAAATCTAACAACACTCTAAAAAATTG Construction of pGG24 
oGG84 AATTTTTCATTATCAATTGCAACTTCCTCGAAATTTAAATCTAACAACACTCTAAAAAATTG Construction of pGG30 
oGG85 AATTTCGAGGAAGTTGCAATTGATAATGAAAAATTTAAATCTAACAACACTCTAAAAAATTG Construction of pGG31 
oGG91 TTTTTAATTTAAGTTCTTGTTCATCGTCATAAATATAAATCTAACAACACTCTAAAAAATTG Construction of pGG34 
oGG101 ATACATAACTAGAGCTAAGAGCAATCAAAGATTTAATAAATCTAACAACACTCTAAAAAATTG Construction of pGG36 
oGG115 ATTCGTCATCTTCAAGTAATGCCTCTAAATCAATAATAAATCTAACAACACTCTAAAAAATTG Construction of pGG41 
oGG121 TGAGACCAGTCTCGGAAGCTCAAAGGTCTCTTAAATCTAACAACACTCTAAAAAATTG Construction of pGG3-BsaI 
oGG122 GAACTTATTGATTTAGAGGCATTACTTGAAGATGACGAAT Construction of pGG40 
oGG123 TTTAATTCGTCATCTTCAAGTAATGCCTCTAAATCAATAA Construction of pGG40 
oGG175 GAACAATTTTTAATTTAAGTTCTTGTTCATCGTCATAAA Construction of pGG52 
oGG176 TTTATTTATGACGATGAACAAGAACTTAAATTAAAAATT Construction of pGG52 
oGG177 GAACTTTTTAAAAATTCTTTGGTTACCATGCATCTCGCT Construction of pGG53 
oGG178 TTTAAGCGAGATGCATGGTAACCAAAGAATTTTTAAAAA Construction of pGG53 
oGG179 GAACGCATGCACCTTGCCTGAATGTTTTAAAAATTCATT Construction of pGG54 
oGG180 TTTAAATGAATTTTTAAAACATTCAGGCAAGGTGCATGC Construction of pGG54 
oGG225 GAACAAGTGATTTAAAAACTGAGGAGCATAAAACTTATTA Construction of pGG59 
oGG226 TTTATAATAAGTTTTATGCTCCTCAGTTTTTAAATCACTT Construction of pGG59 
oGG227 GAACTAATAAGTTTTATGCTCCTCAGTTTTTAAATCACTT Construction of pGG60 
oGG228 TTTAAAGTGATTTAAAAACTGAGGAGCATAAAACTTATTA Construction of pGG60 
oGG58 GAAGAAAAGGGGACGAGAACTAAATCTAACAACACTCTAAAAAATTG Construction of pGG22/pGG25 
oGG61 GGGGTGGGTATCGATCACACATAACTAAAGCTAAGAGTAATC Construction of pGG22 
oGG74 GGGGTGGGTATCGATCCTTTGTACTGATGATTTATATACTTC Construction of pGG25 
L342 AAAGGGCCCAAATAATATTTTCATTATAGCACCTC Construction of pGG41Δcsm6 
L343 AAACGGCCGGAAAAAAATAAGGAATTTAAAGAGC Construction of pGG41Δcsm6 
W18 TATTCTGAAAAGGTCAATCAAGG pGG41Δcsm6 ligation junction verification 
W122 AGGTGTTTGTATATTAAGACGTAC pGG41Δcsm6 ligation junction verification 
L362 AAACTCGTGGATTCTGTGATTTGGATCCTTCC Construction of pWJ40 
W278 AAAAAGATCTTATGACTGTTATGTGGTTATCG Construction of pWJ40 
W270 AAAAAGATCTTGCATAATTCACGCTGACCTC Construction of pWJ40 
W282 AAAACACGAGCGTTTGTTGAACTAATGGGTGC Construction of pWJ40 
oGG82 AACATTGCCGATGATAACTTGAG Construction of pGG32 
oGG83 GTTTTGGGACCATTCAAAACAGCATAGCTCTAAAACCTCGTAG Construction of pGG32 
oGG86 TGAAGCAGTCGGCAGAACATTGCCGATGATAACTTGAGAAAG Construction of pGG33s 
oGG87 TAATGTGCCAGGTCTGTTTTGGGACCATTCAAAACAGCATAG Construction of pGG33s 
oGG89 TTTGAATGGTCCCAAAACAACATTGCCGATGATAACTTGAGAAAG Construction of pGG33 
oGG90 ACAGCATAGCTCTAAAACCTGCCGACTGCTTCATAATGTGC Construction of pGG33 
B220 AAAAAGCGCAAGAAGAAATCAACCAGCGCACTCGTAGACTATTTTTGTCTAAA Construction of pDB184 
B334 ACACTGAGACTTGTTGAGTTCAAACGAAAATTGGATAAAGTGGG Construction of pDB184 
L448 ATTATTTCTTAATAACTAAAAATATGG Construction of pDB184 
B333 CTTTATCCAATTTTCGTTTGAACTCAACAAGTCTCAGTGTGCTG Construction of pDB184 
oGG148 AAACACTTCACACAAGATAACATTATTGATTTAGG Construction of pGG37-full 
oGG149 AAAACCTAAATCAATAATGTTATCTTGTGTGAAGT Construction of pGG37-full 
oGG166 AAACGAAATTTCCAGCAGAAACTTTACCGAAATAG Construction of pGG51 
oGG167 AAAACTATTTCGGTAAAGTTTCTGCTGGAAATTTC Construction of pGG51 
oGG191 GAAGCTTTAGCTTTGCAGTGG ɸNM1(-Erm) attL junction verification 
W277 CTGTAATAGACATCGTTCGCAG ɸNM1(-Erm)  attL junction verification 
oGG206 GCTACATTAATTATAGGGAATCTTAC ɸNM1(-Erm)  attR junction verification 
W276 TCCTAACAGAAATTGCGTTAAAG ɸNM1(-Erm)  attR junction verification 
L8 TTTTATACAATACTATTTATAAGTGC RT-PCR 
L86 CATATAGTTTTATGCCTAAAAACC RT-PCR 
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L87 ATATATTTATTTGGCTCATATTTGC RT-PCR 
L484 AAACTCGAGCGCGCAAGCTGGGGATCCG Construction of pKL55-iTET-B 
L485 AAACTCGAGTAGGTACTAAAACAATTCATCCAG Construction of pKL55-iTET-B 
L482 AAACTCGAGCTGAGAGTGCACCATATGCGG Construction of pKL55-iTET-B 
L483 AAACTCGAGCTTAATAGCTCACGCTATGCCG Construction of pKL55-iTET-B 
oGG108 TAATTCCTCCTTTTTGTTGACATTATATCATTGATAGAGTTATTTG Construction of pKL55-iTET-RC12 
oGG109 ACTCTATCAATGATATAATGTCAACAAAAAGGAGGAATTAATGATG Construction of pKL55-iTET-RC12 
oGG110 TGACACTCTATCATTGATAGAGCATAATTAAAATAAGCTTGATATC Construction of pKL55-iTET-RC12 
oGG111 AAGCTTATTTTAATTATGCTCTATCAATGATAGAGTGTCAATATTT Construction of pKL55-iTET-RC12 
oGG112 TTGATAGAGTGATATCGAATTCGGAGGCATATC Construction of pKL55-iTET-RC12 
oGG113 TGATAGAGAGCTTATTTTAATTATGCTCTATC Construction of pKL55-iTET-RC12 
oGG124 GATCTCAAGATAACATTATTGATTTAGAGGCATTACTTGAAGATGACGAATTAGAAGCAAACCGC ‘Forward’ target insertion
oGG125 GGTTTGCTTCTAATTCGTCATCTTCAAGTAATGCCTCTAAATCAATAATGTTATCTTGA ‘Forward’ target insertion
oGG126 GATCTTTTGCTTCTAATTCGTCATCTTCAAGTAATGCCTCTAAATCAATAATGTTATCTTGCCGC ‘Reverse’ target insertion
oGG127 GGCAAGATAACATTATTGATTTAGAGGCATTACTTGAAGATGACGAATTAGAAGCAAAA ‘Reverse’ target insertion 
oGG64 TCTTATTCAAGACAACACTTACAC Verification of inducible target insertions 
oGG88 ATCTAACATCTCAATGGCTAAGG Verification of inducible target insertions 
oGG102 CCACATACCTATATCTGCCCTTTTTCTGCCCTTTTTTATTTTTAAAG attP inversion 
oGG103 GTGTACTAAAAGGTAATCGATACGGTTATATTTATTCCC attP inversion 
oGG104 GGCAGAAAAAGGGCAGATATAGGTATGTGGTTTTGTATTGG attP inversion 
oGG105 TATAACCGTATCGATTACCTTTTAGTACACAAGTTTTTC attP inversion 
oGG50 GTTAATGTTACGAATGATGAACC ɸNM4 and pKL55-iTET attL junction 
oGG51 TTGGCAAGTTCTGCACCTTTAC ɸNM4 and pKL55-iTET attR junction 
oGG96 AAGATGCAACAATGGGAACCAAG ɸNM4 and pKL55-iTET attL/R junctions 
oGG25 CTAAATGTGATATAATAAAATAAAAAG Spacer 2B (xis) target verification 
oGG26 ATAAAGACACCGATTCAACTATG Spacer 2B (xis) target verification 
oGG38 AAGATAAAGAATTTGCTCAAGACG Spacer 32T target verification  
oGG39 TTCATCAGCTGACATTAACTCAC Spacer 32T target verification (ɸNM1/ɸNM2) 
oGG40 ACCATTAAAACTCGTCATTCTTTC Spacer 32T target verification (ɸNM4) 
oGG52 GGTGCTAGCTTCGTAAGAAAGG Spacer 61T-1 target verification 
oGG53 CAGCTTACAACGAACATAACCAG Spacer 61T-1 target verification 
oGG233 GCAAGAGAGTTAAAAGGTATACG Spacer 43B-tII target amplification 
oGG234 CTGTATATCCTTGTATCAACTATC Spacer 43B-tII target amplification 
W176 CCTATCTGACAATTCCTGAATAG Type II CRISPR array amplification 
W234 GCTTATTAACGATTCATTATAACC Partial sequence verification of pWJ153(γ) 
W235 TCATAAAGTCTAACACACTAGAC Partial sequence verification of pWJ153(γ) 
oGG229 TCCTTATACATATTTATAGGTGTTACATGTTCATATTTATCAGAGCTCGTG Construction of pWJ153γ 
oGG230 AAATGAAAGACTATATGATTTAAAACAAGATCTCCTAGGTCATTTGATATGC Construction of pWJ153γ 
oGG241 CGTTTCGGTACTTATTTCAACAC 43B-tII target deletion escaper mapping 
oGG245 GTTAATTCTATGTCCATTTGTAACC Deletion junction sequencing 
oGG181 GGGGACAAGTTTGTACAAAAAAGCAGGCTATTCGAAATTGTACCTGTTTCATCTC ɸNM1-Erm construction 
oGG182 CGAAAAAAGAGTGTCTTGTGATGGTATCATATCGGTATCAAATAAC ɸNM1-Erm construction 
oGG183 TGATACCGATATGATACCATCACAAGACACTCTTTTTTCGCACC ɸNM1-Erm construction 
oGG184 CTATGAACATATTTGATTAACGTATATAGATTTCATAAAGTCTAAC ɸNM1-Erm construction 
oGG185 CTTTATGAAATCTATATACGTTAATCAAATATGTTCATAGCTTGATG ɸNM1-Erm construction 
oGG186 GGGGACCACTTTGTACAAGAAAGCTGGGTCATTAGATATAAAGATGTATACGG ɸNM1-Erm construction 
L29 TACGACTCACTATAGGGG ɸNM1-Erm sequencing 
oGG192 TCTACTTAATCTGATAAGTGAGC ɸNM1-Erm sequencing 
L325 AAACCCGGGACGCAAACCGCCTCTCCCC ɸNM1-Erm sequencing 
Table 2-2. Oligos used in Chapter 2 (continued). 
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2.8  Materials and methods used in Chapter 2 
Bacterial strains and growth conditions. 
Cultivation of S. aureus RN4220 (ref. (Nair et al., 2011)), TB4 (ref. (Bae et al., 2006)) and 
derivative strains was done in TSB media (BD) at 37 °C, except when phage infections 
were performed, or when otherwise noted (see below). Whenever applicable, media 
were supplemented with chloramphenicol at 10 μg ml-1 to ensure CRISPR plasmid 
maintenance. Selection for MupR strains possessing pG0400 or pG0mut was carried out 
with mupirocin at 5 μg ml-1. RN4220 strains harboring pCL55-derived insertion vectors 
were grown similarly, but kanamycin was provided at 25 μg ml-1 except during re-
culture for competent cell preparation. E. coli DH5a was grown in LB Broth (BD) 
supplemented with kanamycin at 25–50 μg ml-1 to maintain pCL55-derived plasmids. 
Selection for ɸNM1-ErmR lysogens with resistance to erythromycin (10 μg ml-1) was 
only applied during the lysogenization protocol as described below, and, where 
applicable, during the subsequent ɸNM2 sensitivity assays. Soft agar lawns were 
composed of 50% HIB-agar (BD) supplemented with 5 mM CaCl2 (and chloramphenicol 
at 10 μg ml-1 where applicable) and 100 μl of an overnight culture, and poured over 
similarly supplemented 100% HIB-agar plates. High-titer phage lysates were harvested 
from infected soft agar lawns that were sufficiently lysed via overnight growth at 37 °C. 
Within 72 hours of storage at 4 °C, soft agar was hydrated with 600 μl fresh HIB, 
scraped and decanted into a 50 ml conical-bottom Falcon tube, supplemented with an 
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additional 600 μl fresh HIB, and then centrifuged at 4303g for 8-10 min. Filtered 
supernatants containing the phage particles were stored in autoclaved 1.5 ml tubes 
(Eppendorf) at 4 °C. 
Estimation of phage lysate titers. 
Serial dilutions were prepared in triplicate and plated on soft agar lawns of RN4220 
(technical replicates). Plates were incubated at 37 °C for 16–24 h after drying at room 
temperature (25 °C). 
DNA preparation and cloning. 
Plasmid DNA was purified from 2 to 6 ml of E. coli DH5a or S. aureus RN4220 overnight 
cultures. For preparation from S. aureus cultures, cells were pelleted, re-suspended in 
100 μl TSM buffer (50 mM Tris-HCl pH7.5, 10 mM MgCl2, 0.5 M sucrose) then treated 
with 5 μl lysostaphin (2 mg ml-1) at 37 °C for 1.5 h before treatment with plasmid 
miniprep reagents from Qiagen. Purification used Qiagen or EconoSpin columns. 
Restriction enzymes were obtained from New England Biolabs (NEB). 
Cloning in S. aureus used RN4220 electrocompetent cells unless otherwise stated. 
For most type III CRISPR plasmids, scarless addition of repeat-spacer units to the pGG3 
parent vector was accomplished by ‘round-the-horn PCR (ref. (Moore and Prevelige, 
2002)) followed by blunt ligation, using common primer oGG12 and spacer-specific 
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oligonucleotides listed in Table 2-2. The pGG3 vector was itself constructed by ‘round-
the horn PCR using primers L55 and A10 to remove extraneous repeat-spacer elements 
from the pWJ30β CRISPR array. Construction of pWJ30β was described previously: 
“pcrispr” (Hatoum-Aslan et al., 2013). To construct pGG22, the pGG14 plasmid was 
used as a template for ‘round-the-horn PCR using oligos oGG58 and oGG61. The 
pGG25 plasmid was constructed similarly, except that the oGG74 primer was used with 
oGG58, and the pGG3 plasmid was used as a template. For construction of the 
remaining type III CRISPR-Cas plasmids, a modified parent vector (pGG3-BsaI) was 
created by introducing a placeholder spacer harboring two BsaI restriction sites, to 
facilitate scarless cloning of spacers by replacement with annealed oligonucleotide pairs 
possessing BsaI-compatible overhangs. Type III-A CRISPR arrays were amplified with 
primers L50/L6 and sequenced by Sanger using either forward or reverse primers. The 
pGG41Δcsm6 plasmid was obtained via intramolecular ligation of doubly digested PCR 
products amplified from pGG41 by ‘round the horn PCR with the primer pair 
L342/L343. PspOMI/EagI restriction enzymes were used for digestion, and clones were 
verified using primers W18/W122 to PCR-amplify and Sanger sequence the ligation 
junction. The BsaI cloning method was also used to construct type II CRISPR plasmids 
from the pDB184 parent vector, a modified version of pWJ40 with only the single 
placeholder spacer. Type II CRISPR arrays were amplified with primers L448 and 
W176, and sequenced by Sanger using L448. After the cloning of each spacer, plasmid 
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sizes were verified by restriction digest with BssSI for type III plasmids or BtgI for type 
II plasmids. The pC194-derived pWJ40 vector contains the full S. pyogenes SF370 type II 
CRISPR-Cas system and was constructed by amplifying S. pneumoniae LAM226 
genomic DNA with oligonucleotides L362/W278 and pC194 (ref. (Horinouchi and 
Weisblum, 1982a)) with oligonucleotides W270/W282, followed by digestion of the PCR 
products with BglII and BssSI and a subsequent ligation. pDB184 was created via 
Gibson assembly (Gibson et al., 2009) of two PCR fragments: a pWJ40 backbone 
amplified using primers B220/B334, and a CRISPR array amplified from pCas9 (ref. 
(Jiang et al., 2013a)) using primers L448/B333. 
For construction of pCL55-iTET-derived inducible target vectors, cloning used 
chemically competent DH5a cells. Briefly, the chloramphenicol resistance cassette was 
first replaced with a kanamycin resistance cassette amplified from S. pneumoniae 
LAM202-3 using primers L484/L485. This was accomplished by ‘round-the-horn PCR 
on the pCL55-iTET parent vector using primers L482/L483, followed by blunt ligation 
with the PCR-amplified resistance cassette to create the new pKL55-iTET(-B) parent 
vector (first-generation). Directionality of the insertion was verified afterwards with an 
analytical restriction digest using BtgI. Modification of the Pxyl/tet and PtetR promoters in 
accordance with pRAB12 (ref. (Helle et al., 2011)) architecture was achieved via three 
steps. First, two consecutive overlap PCR steps were used to introduce point mutations 
with oligonucleotide pairs oGG108/oGG109 and oGG110/oGG111, creating the pKL55-
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iTET-R and pKL55-iTET-RC intermediates, respectively. The third step involved 
‘round-the-horn PCR using oligonucleotides oGG112 and oGG113, followed by blunt 
ligation, to introduce the downstream operator sequence. The resulting pKL55-iTET-
RC12 parent vector (second-generation) harboring the Pxyl/tet* modifications was used for 
downstream manipulations. For forward and reverse target insertions, annealed 
oligonucleotide pairs (oGG124/oGG125 and oGG126/oGG127, respectively) with 
appropriate overhangs were ligated into the multiple cloning site after digesting the 
vector with BglII and SacII restriction enzymes. Target insertions were verified by PCR 
amplification and Sanger sequencing using the primers oGG64 andoGG88. Inversion of 
the attP motif for both forward and reverse target vectors, and for the targetless (pKL55-
iTET-RC12) parent vector, was achieved by Gibson assembly of two PCR fragments, 
using oligonucleotides oGG102/oGG103 for the attP motif and oGG104/oGG105 for the 
backbones. Directional integration into the RN4220 chromosome was verified by 
amplification of either the attL or attR junctions using primer pairs oGG50/oGG96 and 
oGG51/oGG96, respectively. The pWJ153-inducible target vector is a pKL55-iTET-RC12- 
and pE194- (ref. (Horinouchi and Weisblum, 1982b)) derived plasmid constructed via 
multiple steps of either ‘round-the-horn PCR followed by blunt ligation or Gibson 
assembly. A region that contains the Pxyl/tet* inducible promoter components and the nes 
target was sequenced by Sanger using forward (W234) and reverse (W235) primers that 
flank the region. The expected sequence of pWJ153, including this Sanger-verified 
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region, was included as a supplementary sequence in the published work (Goldberg et 
al., 2014). The pWJ153γ plasmid is a derivative of pWJ153 that was constructed by 
replacing the nes protospacer with the nes-γB target via ‘round-the-horn PCR followed 
by blunt ligation using primers oGG229 and oGG230. Clones were checked by PCR-
amplifying the ligation junction using the W234/W235 primers, and Sanger sequencing 
with W234. 
Construction of the ɸNM1-ErmR lysogen was achieved via pKOR allelic exchange 
(Bae and Schneewind, 2006). Homology arms (~1 kb) were amplified from the 
chromosome of S. aureus RN4220::ɸNM1 using primer pairs oGG181/oGG182 and 
oGG185/oGG186, while the ~1.25 kb ermC resistance cassette was amplified from a 
pE194 plasmid preparation using primers oGG183 and oGG184. An ~3.25 kb fragment 
was assembled by SOEing PCR (Horton, 1993) using external primers oGG181 and 
oGG186 with clonase (QuikChange) attB adapters that allowed directional integration 
into the pKOR vector (Bae et al., 2006). Sequence integrity of the ~3.25 kb insertion was 
verified by Sanger using primers L29, oGG191, oGG192, W277 and L325. 
 
Preparation of electrocompetent S. aureus cells. 
S. aureus RN4220, TB4, or derivative strains were grown overnight in TSB medium, 
diluted 1:100 in fresh medium without antibiotics, then allowed to grow to an 
attenuance (D600 nm) reading of 0.8–1.0 for RN4220 or 0.7–0.9 for TB4. Measurements 
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were taken using a NanoDrop 2000c Spectrophotometer (Thermo Scientific) and 
disposable polystyrene cuvettes. After re-culture, cells were pelleted at 4 °C, and two or 
three washes were performed using chilled, sterile dH2O or 10% glycerol. Cells were 
ultimately re-suspended in 1/100th volume of chilled, sterile 10% glyercol and 50 ml 
aliquots were distributed for storage at –80 °C. 
 
Conjugation assays.  
Conjugation assays were carried out by the filter mating method essentially as 
described previously (Marraffini and Sontheimer, 2008), except that TSB and TSA 
media were used throughout, overnight cultures were mixed directly in 5 ml fresh 
broth at approximately 1:1 attenuances (D600 nm), and growth was carried out at 30 °C for 
approximately 24 hours following the serial dilution and plating step. Recipients and 
transconjugants were quantified as the number of CmR CFUs or CmR+MupR CFUs, 
respectively, scored by eye. Conjugation efficiencies were subsequently calculated as 
the ratio of transconjugants to recipients.  
 
Efficiency of plaquing assays.  
High-titer lysates (~1011 PFU ml-1) of either ɸNM1, ɸNM1γ6 or ɸNM2 were serially 
diluted in triplicate and applied to RN4220 or TB4 soft agar lawns harboring different 
CRISPR-Cas plasmids, including pGG3 or pDB184 non-targeting control lawns infected 
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in parallel (technical replicates). Plates were incubated at 37 °C for 18 h. After 
incubation, plates were monitored at bench top for up to 24 h to facilitate quantification 
of plaque-forming units. Efficiency ratios were calculated as the number of plaques 
formed on a lawn of interest divided by the number of plaques formed on the non-
targeting control lawn infected in parallel. 
Isolation of type III CRISPR-escape mutant phages. 
Soft agar lawns of TB4 harboring a CRISPR-Cas plasmid of interest were infected with 
high-titer lysates (~1011 PFU ml-1) of ɸNM1, ɸNM2, or ɸNM4 either by spotting on the 
lawn or mixing with cells prior to pouring. Plaques that escape targeting were picked, 
resuspended in a small volume of HIB broth, and subjected to at least one additional 
round of counter-selection on lawns with the same CRISPR-Cas plasmid. Subsequent 
propagation on non-targeting lawns initially used TB4 lawns harboring the pGG3 
plasmid. High-titer phage lysates were ultimately harvested from sufficiently lysed soft 
agar lawns, as described in the “Bacterial strains and growth conditions” section above. 
Quantification of erythromycin-resistant lysogens. 
Overnight cultures of RN4220 with respective CRISPR-Cas plasmids were inoculated in 
triplicate from single colonies in HIB medium supplemented with chloramphenicol 
(biological replicates). After chilling at 4 °C, 1:10 dilutions were prepared in 1 ml fresh 
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HIB supplemented with chloramphenicol and 5mM CaCl2. Diluted cultures were 
infected with ɸNM1-ErmR at ~MOI 10 and incubated on ice for 30 min. After incubation 
on ice, cultures were transferred to a 37 °C incubator for 30 min with shaking. Serial 
dilutions from each culture were then applied to HIB-agar plates supplemented with 
chloramphenicol, erythromycin and 5 mM CaCl2 for quantification of lysogenic colony-
forming units. In selected cases, type III-A CRISPR locus and target sequence integrity 
was verified by colony PCR after re-streaking single colonies using primer pairs L6/L50 
(CRISPR array) and oGG25/oGG26 (ORF 2) or oGG38/oGG39 (ORF 32). Where 
applicable, Sanger sequencing of PCR products was also performed using these 
primers. When verifying type II lysogenization isolates, the spacer 43B-tII target 
region was amplified using primers oGG233 and oGG234, and the type II CRISPR 
array was amplified using L448 and W176. The presence of integrated ɸNM1 or 
ɸNM1-ErmR prophages was confirmed by colony PCR using primer pairs oGG191/ 
W277 and oGG206/W276 to amplify the attL and attR junctions, respectively. To 
estimate the total number of recipient cells, serial dilutions of untreated overnight 
cultures were plated on TSB- or HIB-agar supplemented with chloramphenicol. 
Streak-test (phage-sensitivity) assays. 
High-titer phage lysates (~1011 PFU ml-1) were applied to the surface of a pre-dried HIB-
agar plate supplemented with 5 mM CaCl2 and appropriate antibiotics, then allowed to 
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dry for an additional ~30 min at room temperature (25 °C). Single colonies isolated from 
egg yolk screens, CRISPR-Cas plasmid transformations, or ɸNM1-ErmR lysogeny 
experiments were streaked through the phage-seeded region using a sterile plastic loop, 
then incubated for ~12-16 h at 37 °C. 
Quantification of PFU in lysogenic culture supernatants or other lysates. 
Overnight cultures of either RN4220::ɸNM1-ErmR or RN4220::ɸNM1 lysogens 
harboring targeting or non-targeting CRISPR-Cas plasmids were inoculated in 
triplicate from single colonies in HIB media supplemented with chloramphenicol 
(biological replicates). After overnight growth, cells were transferred to 4 °C then 
pelleted by centrifugation at 4696g for 5 min. Supernatants were filtered, and 100 μl 
from each lysate was mixed with 100 μl of either an indicator strain or targeting 
strain overnight culture for plating by the soft agar method. After drying at room 
temperature (25 °C), plates were incubated for 18 h at 37 °C. When quantifying plaque-
forming potential (PFU / ml) from high-titer lysates of ɸNM1, ɸNM2, or ɸNM4 raised 
on lawns of TB4 harboring the pGG3 plasmid, 5 ul of diluted or undiluted lysate was 
spotted and dripped on an uninfected lawn of interest after drying at room temperature 
(25 °C), and then incubated for 18 h at 37 °C. 
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Screens for lipase-negative ɸNM4 lysogens. 
An overnight culture of S. aureus TB4 harboring the spacer 32T or spacer 61T-1 CRISPR-
Cas plasmid was re-cultured to log phase growth in HIB medium supplemented with 5 
mM CaCl2. Re-cultures were treated with ɸNM4 at ~MOI 50 after measurement of 
attenuance (D600 nm) to approximate cell densities. After incubation with phage for 1 h, 
cells were plated on TSA supplemented with 5% egg yolk emulsion. After ~24 h 
incubation at 37 °C, approximately 1,000 colonies were inspected for lipase secretion. 
Lipase-negative candidates were re-streaked to single colonies for PCR analysis and 
functional testing. 
Phage DNA isolation and deep sequencing. 
Samples of high-titer phage lysates (~1011 PFU ml-1) were treated with DNase and RNase 
to a final volume of 150 μl for 1 h at 37 °C. Samples were treated with EDTA (pH 8.0) to 
a final concentration of 20mM, followed by treatment with SDS to a final concentration 
of 0.5% and 2 μl proteinase K. Samples were incubated for 1 h at 65 °C, then subjected 
to a PCR purification protocol (Qiagen). Paired-end library preparation was performed 
on purified phage DNA using a Nextera Tagmentation protocol (Illumina), and samples 
were pooled for multiplexed sequencing on a MiSeq (Illumina). De novo assembly 
of phage genomes used ABySS (Simpson et al., 2009). 
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RNA preparation for reverse transcription PCR and RNA sequencing. 
For reverse transcription PCR (RT-PCR), overnight cultures were diluted 1:20 in 25 ml 
fresh media and grown for 2.5 h at 37 °C with shaking. After re-culture, cells were 
pelleted and washed twice in 1 ml ice cold TSM buffer, then treated with 3 μl 
lysostaphin (2 mg ml-1) for 20 min at 37 °C in 500 μl TSM buffer. Treated cells were 
pelleted then re-suspended in 750 μl cold TRIzol Reagent (Life Technologies) after 
discarding the supernatant. The following chloroform extraction and precipitation 
was performed according to the manufacturer’s protocol. After resuspension in dH2O, 
samples were treated with Qiagen DNase I for 45 min at 30 °C, then re-purified using 
RNeasy Cleanup columns (Qiagen). In some cases, it was necessary to repeat this 
step a second time to ensure the complete removal of DNA. After cleanup, all samples 
were again treated with DNase I (Sigma-Aldrich) for 30–45min at 30 °C, before 
use in the reverse transcription reaction. 
For RNA sequencing, overnight cultures were diluted 1:100 in fresh HIB 
supplemented with chloramphenicol and 500 μM CaCl2, and grown for 1.5 h 
(approximately mid-log phase) at 37 °C with shaking. Cultures were removed, infected 
at MOI ~20 then split into 10 ml portions for an additional 6, 15, 30 or 45 min of growth. 
Immediately following incubation, samples were mixed with 10 ml of a 1:1 
acetone/ethanol solution and transferred to –80 °C. The ɸNM1 lysogen was grown 
similarly, except without antibiotics, and harvested immediately after the 1.5 h re-
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culture at 37 °C. After at least one overnight at –80 °C, samples were thawed on ice and 
pelleted by centrifugation at 4696g for 10 min. After two washes of 1 ml TE buffer, cells 
were re-suspended in 1 ml RLT buffer (Qiagen) supplemented with BME, and 
transferred to 2-ml tubes pre-loaded with ~0.5–1 cm3 of 0.1 mm glass beads (BioSpec). 
Samples were processed in a Mini-Beadbeater instrument (BioSpec) three times for 10 s 
at 4,200 oscillations per minute, with 40 s of chilling on ice between runs. After 
beadbeating, samples were spun down for 2 min at 16,100g in a refrigerated 
microcentrifuge. Supernatant (750 μl) was transferred to a clean tube for mixing with 
500 μl of 100% ethanol, and the following RNeasy purification was done according to 
the manufacturer’s protocol (Qiagen). After elution, samples were treated with either 
Qiagen or Sigma-Aldrich DNase I for 30–45 min at 30 °C, then re-purified using 
RNeasy cleanup columns. In some cases, it was necessary to repeat this step a second 
time to ensure the complete removal of DNA. rRNA-depleted samples were 
subsequently generated using the RiboZero Magnetic Kit for bacteria (Epicentre), 
according to the manufacturer’s protocol. 
 
RNA preparation for reverse transcription PCR and RNA sequencing. 
Reverse transcription used M-Mulv Reverse Transcriptase (NEB), with DNA-free total 
RNA isolated from RN4220 cultures harboring either the pNes(wt-d) or pNes(wt-i) 
plasmids as templates for cDNA synthesis. For pNes(wt-d), reverse transcription used 
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either the L8 or L86 primers in two separate 30 ml reactions, alongside mock reactions 
(–RT enzyme). For pNes(wt-i), the same was done using primers L8 or L87. After 
incubation, 1 μl of each reaction was used as a template for PCR, with respective primer 
pairs for each sample. 
Phage transcriptome analysis and visualization. 
Reads were aligned to reference genomes using Bowtie and sorted using Samtools. 
Using a custom script, sorted reads were accessed via Pysam, normalized as reads per 
million values, and plotted in log scale as the average over consecutive windows of 500 
base pairs using matplotlib tools for IPython. 
Transformation assays. 
S. aureus RN4220 plasmid preparations were dialyzed on 0.025 μm nitrocellulose filters 
(Millipore) then quantified using a NanoDrop 2000c Spectrophotometer (Thermo 
Scientific). Aliquots (50 μl) of electrocompetent cells were transformed in triplicate with 
80 ng dialyzed miniprep DNA per transformation (or as otherwise noted in figure 
legends) using a Gene Pulser Xcell (BioRad) with the following parameters: 2900 V, 25 
μF, 100 Ω, 2 mm (technical replicates). After electroporation, cells were immediately re-
suspended in TSB to a final volume of 200 μl and recovered at 30 °C for 2 h with 
shaking. Serial dilutions were then prepared for plating with appropriate antibiotics. 
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For targeting of iTET insertion vectors, additional plating in the presence of ATc at a 
final concentration of 0.5 μg ml-1 was performed in parallel using the same dilutions. 
Plates were incubated at 37 °C for 18–24 h. 
Plate reader high-resolution growth curves. 
For ATc induction experiments, overnight cultures were launched from single colonies 
in triplicate (or as otherwise noted in the figure legend) and diluted 1:200 in TSB broth 
(biological replicates). After 1 h of growth, ATc was added at a final concentration of 0.5 
μg ml-1 where applicable. Measurements were taken every 5 min. For mitomycin C 
induction experiments, overnight cultures were launched from single colonies in 
duplicate and diluted 1:100 in HIB broth (biological replicates). After 1.5 h of growth, 
mitomycin C was added at a final concentration of 0.5 μg ml-1 where applicable. 
Measurements were taken every 10 min. For ɸNM1 infections, overnight cultures were 
launched from single colonies in triplicate and diluted 1:100 in HIB broth supplemented 
with CaCl2 5 mM (biological replicates). After 1 h 25 min of growth, attenuance (D600 nm) 
was measured for three representative cultures to estimate MOI. Aliquots were then 
loaded into 96-well plates along with ɸNM1 at the appropriate MOI (10 or 100), where 
applicable. Measurements were taken every 5 min. For ɸNM1γ6 infections, overnight 
cultures were launched from single colonies in triplicate and diluted 1:200 in HIB 
supplemented with CaCl2 5 mM (biological replicates). An average attenuance (D600 nm) 
156 
measurement was taken after 1 h of growth, and ɸNM1γ6 was added at an MOI of 10 
on the basis of this value, where applicable. Measurements were taken every 5 min. 
Plasmid-curing assays. 
RN4220 strains harboring the CRISPR-Cas plasmid (pGG3 or pGG8) and the target 
plasmid (pWJ153 or pWJ153γ) were cultured in TSB supplemented with 
chloramphenicol (10 μg ml-1) to an attenuance (D600 nm) of 0.45. Strains harboring the 
pGG8 and pWJ153γ combination also harbored the pG0mut plasmid as a bystander 
plasmid to assay for targeting in trans. After splitting the cultures in two, transcription 
across the target was induced for one of the cultures via the addition of ATc to a final 
concentration of 0.250 μg ml-1 or 0.125 μg ml-1 as noted in the figure legends. Where 
applicable, aliquots of cells from each culture were harvested before (0) and after (1, 2, 
3, 4, 5 and 6 h) the time of induction for miniprepping of plasmids. In parallel, serial 
dilutions of both cultures were prepared in triplicate for each time point and plated on 
TSA plates supplemented with chloramphenicol and erythromycin or chloramphenicol 
alone, for quantification of antibiotic-resistant CFU (technical replicates). In experiments 
with pG0mut, serial dilutions for each time point were also plated on TSA plates 
supplemented with chloramphenicol and mupirocin. After miniprepping, plasmids 
were linearized with the common single cutter BamHI and subjected to agarose gel 
electrophoresis. 
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CHAPTER 3: INVESTIGATION OF PHENOTYPIC CONSEQUENCES
ASSOCIATED WITH MAINTENANCE OF CONDITIONAL TOLERANCE IN
LYSOGENIZED S. AUREUS LINEAGES 
The work described in Chapter 2 established key insights into the targeting mechanism 
of a type III-A CRISPR-Cas system, and thereby provided a foothold for understanding 
the biology of these systems in the context of temperate phage infections. Prior to that 
work, it was unclear whether stable co-existences between active CRISPR-Cas systems 
and their temperate phage targets could occur, because CRISPR-Cas targeting was 
shown to resist lysogenic infections by phage lambda (Edgar and Qimron, 2010). This 
finding, however, made use of a particular transcription-independent type I-E CRISPR-
Cas system in E. coli. While I observed similar results with a transcription-independent 
(type II-A) CRISPR-Cas system in S. aureus, the type III-A system I tested, in contrast, 
was found to prevent temperate phage propagation when targets are transcribed 
during lytic infection or prophage induction, and tolerate prophages in cases where 
targets are sufficiently repressed in the chromosome (Goldberg et al., 2014). Thus, this 
work provided the first demonstration that a temperate phage which was otherwise 
targeted by a CRISPR-Cas system could be acquired via lysogeny without mutating its 
target, and even in the absence of CRISPR-Cas inactivation via inhibition (Bondy-
Denomy et al., 2013) or mutation. Unlike inactivation of transcription-independent 
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CRISPR-Cas systems by temperate-phage-encoded targeting inhibitors (Bondy-Denomy 
et al., 2013; Pawluk et al., 2014), conditional tolerance via transcription-dependent 
targeting ensures that the host can maintain type III-A resistance to subsequent lytic 
infections by heteroimmune phages that bear a matching target. Another consequence 
of transcription-dependent targeting is that tolerance breaks down during prophage 
induction, when the lytic cycle reinitiates and target sequences are transcribed. 
However, additional consequences for the lysogenic hosts that maintain conditional 
tolerance have not been described. 
In preliminary attempts to determine the effect of prophage induction on 
RN4220::ɸNM1 lysogens harboring the spacer 43T CRISPR-Cas plasmid, I found no 
evidence that these conditionally tolerant lysogens survived better than non-targeting 
lysogens following treatment with MMC, even at a sub-inhibitory concentration of 0.5 
μg/ml (data not shown). Therefore, an a priori reason to suspect that conditional 
tolerance could provide a direct advantage to lysogenized lineages was, in my view, 
still lacking. In fact, the scarcity of type III-A systems observed among staphylococcal 
isolates seemed to argue the opposite: that these systems might be too detrimental—or 
at least insufficiently advantageous—to be maintained in those populations. 
Furthermore, given that conditional tolerance contributes to the genetic stability of the 
type III-A CRISPR-Cas system itself, it could be viewed as a paradigm of genetic 
‘selfishness’ (Doolittle and Sapienza, 1980; Orgel and Crick, 1980) first and foremost—
159 
and perhaps should be. The stabilizing effects of conditional tolerance, for example, 
might be sufficient to explain why this phenomenon has also evolved as an emergent 
property of other phage defense mechanisms, such as SaPI interference (Ram et al., 
2014) and abortive infection (Depardieu et al., 2016). Viewing conditional tolerance in a 
selfish light makes it easier to envision a scenario where negative side-effects associated 
with its maintenance over the long term could provide pressure to abandon the phage-
defense system responsible—despite the short-term stabilizing effects it can afford. For 
example, considering that type III-A targeting was found to occur during prophage 
induction (which, can occur spontaneously even in growing populations), it seemed 
plausible to me that maintenance of conditionally tolerant type III-A systems in 
lysogenized lineages could be accompanied by unforeseen phenotypic consequences. 
The work described in Chapter 3 was designed to investigate this possibility. An 
understanding of such phenotypes, in turn, could offer valuable insight into factors that 
influence the stability and distribution of type III-A systems among natural, 
lysogenization-prone populations of S. aureus (Aanensen et al., 2016; Cao et al., 2016; 
Goerke et al., 2009). 
In an effort to emulate natural systems more closely, I once again began using the 
Newman phages’ native host background, TB4, as a model host for investigating the 
biology of type III-A temperate phage targeting in clinically-relevant strains of S. aureus. 
Various mutations had been identified previously (Nair et al., 2011) in the genome of S. 
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aureus RN4220, including mutations in DNA repair and housekeeping genes, which 
could potentially have an impact during CRISPR-Cas targeting (although not 
necessarily). Moreover, I resolved to exclusively work with wild type CRISPR array 
architectures where spacers are flanked by repeats on both sides. To facilitate the 
cloning of such CRISPR-Cas systems, I constructed a new set of BsaI-based parent 
vectors. The pGG-BsaI-R parent vector was constructed by adding a repeat downstream 
of the BsaI placeholder spacer in pGG-BsaI (Samai et al., 2015), and is suitable for 
constructing single-spacer arrays with the ‘R-S-R’ architecture. However, after a slew of 
inefficient cloning attempts with this vector, I endeavored to improve the cloning 
efficiency by eliminating a base pair from the 3’ end of the BsaI placeholder spacer to 
produce different downstream overhangs upon restriction digest. Aside from this 
change, the resulting pGG78 plasmid is otherwise identical to pGG-BsaI-R. The pGG79 
parent vector, also constructed at this time, is a variant of pGG78 with the nes spacer 
still present in position 1, and was derived from pGG3-BsaI (Figure 3-1). Whether or not 
the placeholder spacer modification was effective in improving the cloning efficiency 
was not rigorously determined, and remains unclear to me. In any event, I began using 
the pGG79 vector for downstream manipulations, because I decided that it might still 
on occasion be useful to assay whether the backbone is functional via the nes spacer in 
position 1 (independently of the variable spacers I introduce at position 2). Such 
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functional testing became even easier after my colleague, Dr. Varble, engineered a 
variant of ɸNM4γ4 with the 32T spacer’s target replaced by the nes protospacer. Indeed, 
Figure 3-1. Generation of a modified BsaI parent vector for cloning of type III-A 
CRISPR-Cas plasmids with wild type CRISPR architecture. 
(A) Schematic representations of the pGG3-BsaI (left) and pGG79 (right) type III-A 
CRISPR-Cas plasmids. pGG3-BsaI harbors the type III-A system from S. epidermidis 
RP62a, including its conserved leader sequence (‘L’, dark grey box), but with a modified 
CRISPR array containing only two spacers. The wild type nes spacer is located at 
position 1, while its 30 bp placeholder spacer (green) containing BsaI restriction sites to 
facilitate oligo cloning is located at position 2. To construct pGG79, an additional 
CRISPR repeat was added downstream of the BsaI placeholder spacer in pGG3-BsaI 
(middle). pC194 backbones include a chloramphenicol acetyltransferase (cat) gene 
conferring resistance to chloramphenicol, which is also depicted alongside cas genes in 
the plasmid diagrams. 
CRISPR-Cas-mediated resistance to this phage, which we called ɸNM4γ4α2, could be 
assayed with a simple streak-test if needed. 
Now that I was testing various lysogenic derivatives of TB4, it became more 
efficient to introduce plasmids via generalized transduction rather than transformation. 
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Transformation required that I would have to prepare different batches of competent 
cells for each strain, and then transform them with each (miniprepped) plasmid. 
Transduction only required that a single transducing lysate was prepared per plasmid, 
which could then be used to deliver the plasmid to each strain directly during log-phase 
growth. One potential obstacle here is that preparation of the transducing lysate 
requires efficient lysis of the CRISPR-Cas plasmid’s host by a phage; i.e., the phage 
should not harbor a target for the CRISPR-Cas system. However, I now had various 
clear-plaque phages at my disposal, so I could readily transduce each CRISPR-Cas 
plasmid by simply lysing its host with a suitable phage that lacks a target. In addition, I 
had at my disposal a tetM-marked SaPI—SaPI1tst::tetM (Lindsay et al., 1998) —which 
our lab had received from the Novick group. This SaPI confers resistance to tetracycline 
upon delivery and integration into a suitable host chromosome, and its transfer can 
therefore be readily monitored using standard transduction protocols. In the first 
section of this chapter, I describe some experiments illustrating how the mobilization of 
this SaPI in lysogenic hosts can be impeded by type III-A targeting of its helper phage(s) 
during prophage induction. 
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3.1 Conditionally tolerant type III-A CRISPR-Cas systems that target helper 
prophages can impede SaPI mobilization in lysogenic hosts 
The SaPI1(tst::tetM) element can be mobilized by various helper phages, including 80α 
and ɸNM1 (Dearborn and Dokland, 2012; Lindsay et al., 1998). SaPI1 induction by 80α 
requires the Sri antirepressor protein (Tormo-Mas et al., 2010), and induction by ɸNM1 
is thought to be licensed by its homolog in ɸNM1 (Dearborn and Dokland, 2012). The 
ORF encoding this sri homolog is missing from the original ɸNM1 annotation 
(NC_008583.1), but is located roughly between ORFs 19 and 20. To facilitate lysogen 
strain construction, I used an ErmR-marked derivative of ɸNM1 (ɸNM1-ErmR2) as my 
helper phage of interest (such that I could readily select for lysogens on the basis of 
erythromycin resistance). The ɸNM1-ErmR2 phage (Figure 3-2A) is a derivative of 
ɸNM1-ErmR (Goldberg et al., 2014) that I constructed in an effort to improve plating 
efficiency during lysogenization assays. Its ermC insertion was trimmed upstream of the 
5’ UTR and contains the tyc-1 allele SNP that was shown to improve constitutive 
expression of this cassette in B. subtilis (Gryczan et al., 1980). After lysogenizing TB4 (or 
derivatives of TB4 harboring CRISPR-Cas plasmids), the SaPI1tst::tetM element was 
introduced into lysogens via transduction. I first confirmed that the presence of the SaPI 
alone did not appreciably alter lysis profiles mediated by ɸNM1-ErmR2 during MMC-
stimulated prophage induction: as expected, lysis was still observed (Figure 3-2B). For 
comparison, I tested TB4 derivatives lysogenized with ɸ11, which is not a helper phage 
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Figure 3-2. Effects of helper phage targeting in conditionally tolerant, SaPI-
containing lysogens. 
(A) Schematic representation of the ɸNM1-ErmR2 prophage genome, with ORFs (thick 
arrows) scaled by length in accordance with the ɸNM1 annotation (NC_008583.1). The 
ermC(tyc-1) insertion (blue) is located immediately downstream of the ɸNM1 integrase. 
The sri antirepressor ORF (green) is located between ORFs 19 and 20 in the original 
ɸNM1 annotation. Precise locations of the target sites for the gp16 and gp43ori spacers 
tested in this chapter are also shown above their respective color-coded ORFs. 
Divergently oriented grey bent arrows signify the presence of PcI and Pcro promoters in 
the ELCR. (B) Quantification of PFU concentrations (PFU / ml) in filtered supernatants 
from overnight cultures of TB4::ɸNM1-ErmR2 lysogens with the indicated CRISPR-Cas 
plasmid, grown in TSB supplemented with chloramphenicol for 14 hours. Lysogens 
with the control CRISPR-Cas plasmid are either lacking (C/S-) or harboring (C/S+) the 
SaPI1tst::tetM element. Horizontal bars emphasize the measurement from a single 
experiment, plotted as a black dot in each column. Dashed line represents the limit of 
detection under these assay conditions. (C) High-resolution growth curves of 
TB4::ɸNM1-ErmR2 or TB4::ɸ11 lysogens either lacking or possessing the SaPI1 element 
as indicated, with MMC added at the indicated time point (black arrow). Solid lines 
represent attenuance (D600 nm) measurements from single biological replicates in the 
presence of MMC; for comparison, attenuance measurements from the same biological 
replicate grown in the absence of MMC is plotted for two strains (dashed lines). (D) 
Quantification of STU and PFU concentrations (STU /ml or PFU / ml) in filtered 
supernatants from subcultures of TB4::ɸNM1-ErmR2 lysogens harboring the SaPI and a 
CRISPR-Cas plasmid as indicated, four hours post-treatment with MMC at 2.0 μg/ml. 
After 95 minutes of growth and immediately prior to treatment, subculture attenuances 
(D600 nm) were normalized to ~0.5. The pGG115 plasmid was used as the non-targeting 
control (C) in this assay. Additional biological replicates were not performed. (E) Same 
as in ‘C’, except with TB4::ɸNM1-ErmR2 lysogens that harbor both the SaPI and a 
CRISPR-Cas plasmid as indicated, and all three untreated curves were plotted. The 
pGG115 plasmid was also used as the non-targeting control (C) in this assay. (F) 
Schematic diagram summarizing the multiplex PCR reaction that allows for a coarse-
grained assessment of integrated and excised SaPI1 genome relative abundances. The 
attC and attS junctions are only present when the SaPI is excised by a helper phage. 
Primers ‘1’ through ‘4’ correspond to oGG338 through oGG341. Features are scaled 
arbitrarily. (G) Multiplexed PCR amplification with the oGG338-oGG341 primer set and 
one of 6 colony lysate templates. Templates 1 through 4 were from TB4::ɸNM1-ErmR2 
lysogens harboring the pGG79, gp16, gp16(csm6*), or gp43ori CRISPR-Cas plasmids (in 
that order). Templates 5 and 6, respectively, were from TB4::ɸNM1 and TB4::ɸ11 
lysogens lacking CRISPR-Cas plasmids. All lysogens harbored the SaPI. Size markers of 
1 kb and 0.5 kb are indicated, along with the expected banding position for the intact 
attC, attR, attL, and attS junction amplicons. Additional technical replicates were not 
performed on these templates, but similar banding patterns were observed for the gp16 
and gp43ori strains in a separate biological replicate (not shown). 
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for SaPI1tst::tetM (Lindsay et al., 1998). Meanwhile, the presence of the SaPI was 
sufficient to reduce spontaneously induced PFU from ɸNM1-ErmR2 lysogens harboring 
a non-targeting CRISPR-Cas plasmid (Figure 3-2C), presumably as a result of SaPI-
mediated interference. For comparison, spontaneous induction was measured under the 
same assay conditions for TB4::ɸNM1-ErmR2 lysogens lacking the SaPI but harboring 
conditionally tolerant type III-A CRISPR-Cas plasmids with either the gp16 or gp43ori 
spacers. The gp43ori spacer harbors the same 36 bp sequence as the 43T spacer published 
previously (Goldberg et al., 2014), and is identical to the 35 bp variant published as 
‘gp43’ (Jiang et al., 2016) aside from the one bp at its 3’ end. For the next experiments, I 
introduced the gp16 or gp43ori CRISPR-Cas plasmids into TB4::ɸNM1-ErmR2 lysogens 
harboring the SaPI. The presence of these conditionally tolerant type III-A systems 
prevented lysis when prophage induction was stimulated with MMC (Figure 3-2D). To 
demonstrate that type III-A targeting during prophage induction could impede SaPI 
transfer, I next measured the number of SaPI transfer units (STUs) in supernatants of 
lysogenic cultures after a four-hour treatment with MMC. For comparison, PFU were 
also measured. By interfering with lysis during prophage induction, type III-A plasmids 
are expected to prevent release of STU and PFU altogether. Indeed, the concentration of 
STUs and PFUs in culture supernatants were both reduced appreciably for strains 
harboring conditionally tolerant type III-A plasmids, four hours post-induction (Figure 
3-2E). To determine whether intracellular mobilization of the SaPI was also reduced by 
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either of these spacers, I designed a multiplex PCR reaction for amplifying across 
excised and integrated SaPI attachment junctions (Figure 3-2F). The presence of an attS 
and/or attC amplicon indicates that the SaPI genome is excised (and possibly already 
replicated or packaged). Meanwhile, only the attL and attR junctions can be amplified if 
the SaPI is stably integrated. PCR was performed on single colony lysates to probe the 
effects of helper prophage targeting during spontaneous induction. Whereas excised 
SaPIs were detectable in TB4::ɸNM1-ErmR2 lysogens harboring the non-targeting parent 
vector, this was not the case for lysogens harboring the gp16 CRISPR-Cas plasmid 
(compare to control amplification from TB4::ɸ11 lysogens harboring a non-helper 
prophage, Figure 3-2G). Interestingly, excised SaPIs were still detectable with the gp43ori 
CRISPR-Cas plasmid. In fact, the attC amplicon appeared to be slightly enriched relative 
to non-targeting lysogens (Figure 3-2G). I speculate that this enrichment results from 
the accumulation of replicated SaPI genomes in cells which cannot lyse via prophage 
induction, due to targeting by the gp43ori spacer. Previously published work (Jiang et al., 
2016) from my colleagues showed that immunity licensed by the gp43 spacer allows for 
intracellular accumulation of phage DNA because its target is transcribed late during 
the lytic cycle, when replication is already under way. In contrast, phage DNA 
accumulation was not observed when an early-transcribed ORF (gp14) was targeted, 
presumably because the phage could be cleared before replication (Jiang et al., 2016). 
Given that the sri antirepressor ORF falls within an early transcribed region upstream of 
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gp43ori, it could presumably be expressed before targeting by gp43ori occurs. Similarly, 
the effect on intracellular SaPI mobilization observed with the gp16 spacer—which also 
targets an early transcribed ORF—might be explained by the location of the gp16 target 
upstream of the sri ORF (Figure 3-2A). In other words, type III-A targeting at the gp16 
ORF during prophage induction might prevent intracellular SaPI mobilization by 
interfering with expression of the downstream sri ORF. I also tested a variant of the 
gp16 CRISPR-Cas plasmid with catalytic site mutations in csm6 that abolish its HEPN 
domain’s non-specific RNase activity (Jiang et al., 2016), in order to rule out the 
possibility that the effects observed with gp16 were due to this activity operating on 
phage, SaPI, or host transcripts at other loci during targeting. As expected for a spacer 
matching to an early-transcribed region of ɸNM1, the RNase activity of Csm6 appeared 
to be dispensable for targeting effects (Figures 3-2C, D, E, & G). Whether or not the 
gp43ori spacer allows intracellular accumulation of intact SaPI particles was not assessed, 
and it’s possible that targeting of the head protein disrupts intracellular packaging in 
addition to preventing completion of the lytic cycle. Extraction of intracellular particles 
via mechanical or chemical lysis could help to clarify these points. Interactions between 
a phage-encoded type I-F CRISPR-Cas system and an ~18-kb element, resembling a 
SaPI-like phage-inducible chromosomal island (PICI), were previously described in 
Vibrio cholerae (Seed et al., 2013).  In that work, however, the CRISPR-Cas system 
directly targeted the PICI-like element, and therefore did not interfere with completion 
169 
of the helper phage’s lytic cycle. Type III-A systems that directly target SaPIs might be 
similarly expected to allow a helper phage to complete its lytic cycle, by neutralizing the 
SaPI, but it is unclear if such systems could evolve naturally. 
The results described above indicate that targeting of helper prophages by 
conditionally tolerant type III-A CRISPR-Cas systems can impede the transfer of SaPI 
particles from lysogens via prophage induction. Similar outcomes would be expected 
during lytic infections by heteroimmune helper phages bearing a target for the type III-
A system, although this was not tested. By preventing the transfer of genes carried 
directly on the SaPI genome, and perhaps also by limiting the transfer of host genes via 
island-mediated (or by extension, phage-mediated) generalized transduction (Chen et 
al., 2015b), phage targeting by type III-A systems could be detrimental in natural 
populations of S. aureus that thrive off such forms of HGT. In turn, the loss of type III-A 
CRISPR-Cas systems from S. aureus genomes might help to ensure that such 
populations remain adaptive in rapidly changing environments, and/or that they can 
readily resist Muller’s ratchet mechanism (Muller, 1932, 1964) over the long term. 
However, the possibility that maintenance of conditionally tolerant type III-A systems 
in lysogenic populations could impact host fitness more directly has not been ruled out. 
In the remainder of this chapter, I provide evidence that conditionally tolerant type III-
A systems can impose constitutive fitness costs on lysogenic hosts which lack SaPIs 
altogether. 
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3.2 Detection of incomplete prophage tolerance by type III-A CRISPR-Cas 
systems in lysogenic hosts 
In Chapter 2, the CRISPR-Cas system of S. epidermidis RP62a was re-engineered to 
contain spacers targeting the temperate phages of S. aureus Newman, and introduced 
into heterologous RN4220 (Nair et al., 2011) or TB4 hosts (Bae et al., 2006) on pC194-
based plasmids (Horinouchi and Weisblum, 1982a). The spacers were all introduced 
into the CRISPR loci of my original parent vectors (pGG3 or pGG3-BsaI), and many of 
them were found to license conditional tolerance. However, a small-colony phenotype 
was clearly apparent when the spacer 2T CRISPR-Cas plasmid was introduced into 
RN4220::ɸNM1 lysogens. As explained in section 2.4, this was assumed to result from 
slightly elevated rightward transcription across the prophage’s xis target ORF, relative 
to other target regions (Figure 2-17). In other words, this result seemed to suggest that 
leaky prophage transcription could license an incomplete tolerance phenotype. Once I 
began working with pGG79-derived CRISPR-Cas plasmids, and also primarily TB4 
lysogens, it became clear that this incomplete tolerance phenotype was more common 
than previously expected. For example, a small-colony phenotype was clearly apparent 
when the pGG79-derived gp32* CRISPR-Cas plasmid was introduced into TB4::ɸNM1 
lysogens (Figure 3-3A). A colony size reduction, albeit less pronounced, was also 
observed with the mismatched gp32 variant of this spacer. Hypothesizing that these 
phenotypes reflect a general growth rate reduction relative to non-targeting lysogens, I 
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Figure 3-3. Maintenance of conditionally tolerant type III-A CRISPR-Cas systems in 
lysogenic hosts can incur fitness costs. 
(A) Colony size comparison of TetR-marked TB4::ɸNM1 single lysogens harboring 
CRISPR-Cas plasmids containing either non-targeting spacers alone (C), the perfectly 
matched gp32 spacer (gp32*), or the originally identified gp32 spacer with 5 mismatches 
(gp32). Picture is representative of a biological replicate for each strain plated in the 
presence of chloramphenicol to select for the CRISPR-Cas plasmids. (B) Pairwise 
competition experiments with the gp32* spacer that licenses conditional tolerance of 
ɸNM1. An ErmR-marked control lysogen harboring the parent vector with non-
targeting spacers was competed against the TetR-marked conditionally tolerant lysogen. 
Relative frequencies (y-axis) are plotted against the number of transfers (x-axis), with 
one transfer per day. Individual values from each biological replicate are depicted in 
black as a triangle, circle, or rhombus. Solid lines represent the average change in 
relative frequency across the three replicates, and share color coding with the target 
ORF indicated in Figure 3-4A. (C) Same as in ‘B’, except that the TetR-marked 
conditionally tolerant lysogen used for competitions harbored the gp32 (partially 
mismatched) spacer. (D) Schematic summary of pairwise competition assays used in 
this work to assess the relative fitness of antibiotic resistance-marked TB4 lysogens. 
Lysogens harboring CRISPR-Cas plasmids with either non-targeting or targeting 
spacers were mixed ~1:1 and passaged daily, with selective plating at each interval to 
calculate relative abundances as the ratio of TetR CFUs over total (TetR + ErmR) CFUs. 
Chloramphenicol was also maintained in all media and plates to ensure selection for 
CRISPR-Cas plasmids. Falcon tube graphic adapted from an online source: 
https://clipartfest.com/download/c8aa2089bcf055d864c0317e14ff369ded0b3d10 
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sought to quantify them more precisely in terms of a fitness cost. This was 
accomplished by marking the TB4::ɸNM1 lysogens with small plasmids (Horinouchi 
and Weisblum, 1982b; Khan and Novick, 1983) conferring resistance to either 
tetracycline (Tet) or erythromycin (Erm), and measuring their relative abundances over 
time in pair-wise competition co-cultures (Figure 3-3D). As anticipated, the relative 
abundance of lysogens with the perfectly matching gp32* spacer declined more rapidly 
than lysogens with the mismatched spacer, when competed against control lysogens 
containing the parent vector with non-targeting spacers (Figures 3-3B & C). Fitness 
costs were quantified in terms of a selection coefficient, s, based on instruction from 
Robert Heler on how to calculate these values for a set of competition data points, using 
formulas in Microsoft Excel. Table 3-1 lists the calculated values for all competition 
experiments performed in this work. To probe the generality of spacer-dependent 
fitness costs, I tested four additional spacers with perfect identity to sequences within 
gp5, gp8, gp16, and gp43 of ɸNM1 (Figure 3-4A), and assayed them for relative fitness 
using the same setup. In three cases, a decline in relative abundance was clearly 
apparent (Figures 3-4B, C, & D), whereas no change in relative abundance was found in 
control co-cultures where competing lysogens harbored the same non-targeting parent 
vector (Figure 3-4E). 
Previous studies have demonstrated that chromosomal targeting by CRISPR-Cas 
systems in bacteria is severely detrimental to growth and potentially lethal 
174 
Figure 3-4. Incomplete prophage tolerance by type III-A systems can be licensed by 
prophage-internal promoter activity.  
(A) Schematic representation of the integrated ɸNM1 prophage genome, with ORFs 
(thick arrows) scaled by length according to the annotation (NC_008583.1). The gp5, gp8, 
gp16, gp32, and gp43 ORFs are colored to denote inclusion of a target sequence for one 
or more spacers tested in this work. Grey bent arrow indicates the position of ɸNM1’s 
early lytic promoter (Pcro). LLCR denotes the location of an intergenic region in ɸNM1 
with homology to regulatory sequences reported to control late gene expression for 
related phages (Ferrer et al., 2011; Quiles-Puchalt et al., 2013). (B) Pairwise competition 
experiments for testing the perfectly matching gp5 spacer in marked single lysogens of 
TB4::ɸNM1, performed as described in Figure 3-3. (C) Same as in ‘B’, except the 
perfectly matching gp16 spacer was tested. (D) Same as in ‘B’, except the perfectly 
matching gp43 spacer was tested. (E) Control co-culture competition experiment; same 
as in ‘B’, except that both ErmR- and TetR-marked TB4::ɸNM1 lysogens harbored the 
non-targeting pGG79 parent vector. (F) Sequences of the Pcro promoter in wild type 
ɸNM1 or its inactive variant in ɸNM1Pcro-, with point mutations (red lettering) in the -10 
element. The location of Pcro, along with the approximate position of its transcriptional 
start site (+1), was inferred from RNA-sequencing analysis of ɸNM1 during lytic 
infections (Goldberg et al., 2014). This designation is further supported by research on 
S. aureus temperate phages with related lambdoid regulatory architecture (Ganguly et 
al., 2009; Iandolo et al., 2002; Quiles-Puchalt et al., 2013). (G) Pairwise competition 
experiments for testing the perfectly matching gp5 spacer in marked single lysogens of 
TB4::ɸNM1Pcro-, performed as described in Figure 3-3. Individual values from each 
biological replicate are depicted in grey with black outlines as a triangle, circle, or 
rhombus. (H) Same as in ‘G’, except the perfectly matching gp16 spacer was tested. (I) 
Same as in ‘G’, except the perfectly matching gp43 spacer was tested. 
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(Jiang et al., 2013b; Vercoe et al., 2013), even in cases where prophage loci are targeted 
(Cady et al., 2012; Edgar and Qimron, 2010; Goldberg et al., 2014). In light of these 
findings, I hypothesized further that the spacer-dependent fitness costs result from 
growth defects associated with incomplete prophage tolerance, licensed by leaky 
transcription across targets from one or more promoter within the prophage. To explore 
this possibility, I introduced inactivating mutations into the early lytic promoter 
upstream of ɸNM1’s cro-like regulator, encoded by gp5 (Figure 3-4F). Mutation of this 
promoter (ɸNM1Pcro-) virtually abolished the fitness cost associated with the gp5 spacer 
(Figure 3-4G). Interestingly, the cost associated with the gp16 spacer was only partially 
reduced (Figure 3-4H), suggesting that downstream promoters might license different 
growth defects in the absence of a dominant promoter upstream. In support of this 
notion, I observed a clear discrepancy in the magnitude of the costs associated with the 
gp5 or gp16 spacers compared to that of the gp43 spacer in wild type lysogens (Figures 
3-4B, C, & D), despite their similar capacities to disrupt phage lytic propagation via 
spontaneous or MMC-stimulated prophage induction (Figures 3-5A & B). The gp43 
target, unlike the gp5 and gp16 targets, is located within a gene cluster that is 
transcribed late during the lytic cycle of ɸNM1 (Goldberg et al., 2014). In staphylococcal 
phages with related genomic architecture, this cluster lies downstream of a regulatory 
region that was shown to contain a conserved transcriptional terminator (Ferrer et al., 
2011), and I identified such a region (LLCR) in ɸNM1 between gp36 and gp37 (Figure 3- 
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Figure 3-5. Prophage inducibility is not a prerequisite for incomplete tolerance by 
type III-A systems. 
(A) Quantification of PFU concentrations (PFU / ml) in filtered supernatants from 
overnight cultures of TetR-marked TB4::ɸNM1 single lysogens harboring CRISPR-Cas 
plasmids with one of several targeting spacers, or the control parent vector with non-
targeting spacers (C). Horizontal bars indicate the mean value of three biological 
replicates, plotted as black dots in each column. TetR-marked lysogens harboring the 
control parent vector and mutant prophages ɸNM1Pcro- or ɸNM1ind- were also tested, and 
plaques were only detected in one of the replicates for ɸNM1ind-. Dotted line represents 
the limit of detection under these assay conditions. (B) High-resolution growth curves 
of TetR-marked TB4::ɸNM1 single lysogens harboring the CRISPR-Cas plasmids tested 
in panel ‘A’. Solid lines represent the average attenuance (D600 nm) measured from three 
biological replicates with MMC added at the indicated time point (black arrow), and are 
colored to match the target ORFs highlighted in Figure 3-4A or black for the control 
parent vector. A dotted line is used for the gp32 (mismatched) spacer, but note that 
individual dots do not correspond to measurements taken every 10 minutes. For 
comparison, average attenuance measured from three biological replicates in the 
absence of MMC is plotted for two strains (dashed lines). (C) Same as in ‘B’, except 
using TetR-marked TB4::ɸNM1Pcro- lysogens with select CRISPR-Cas plasmids. (D) Same 
as in ‘B’, except using TetR-marked TB4::ɸNM1ind- lysogens with select CRISPR-Cas 
plasmids; a TetR-marked TB4 non-lysogen harboring the pGG79 parent vector was also 
tested (grey lines). (E) Schematic diagram illustrating different outcomes expected for 
the wild type ɸNM1 prophage (left) or the ɸNM1ind- prophage mutant (right) in 
response to a canonical SOS-inducing signal. Monomers of CI-like repressor are 
depicted as black bar bells, with green spots for the ɸNM1ind- mutant indicating the 
presence of a S124A substitution in the C-terminal serine protease domain. When intact 
repressors are present, only leaky transcription originates from the regulated promoter 
(dashed grey bent arrows). Under inducing conditions, autoproteolysis of wild type 
repressor is stimulated by the presence of activated RecA (RecA*) and allows 
transcription required for the lytic cycle (solid black bent arrow), while ɸNM1ind- mutant 
repressor remains intact and continues to allow only leaky transcription. (F) Pairwise 
competition experiments for testing the perfectly matching gp16 spacer in marked single 
lysogens of TB4::ɸNM1ind-, performed as described in Figure 3-3. (G) Same as in ‘F’, 
except the perfectly matching gp43 spacer was tested. 
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4A). Conceivably, the magnitude of the gp43 spacer’s fitness cost is determined by one 
or more late promoters that are insulated from upstream transcription during the non-
inducing conditions of lysogeny, perhaps in part due to this regulatory region. In order 
to better assess the plausibility of this surmise, I used an online promoter prediction 
tool to identify putative promoters upstream of my targets (Table 3-2). Candidates were 
selected from among the initial hits by cross-referencing with the position of relative 
transcriptional peaks identified along the traces of non-averaged plots from a stranded 
RNA-seq dataset collected previously (Goldberg et al., 2014). Particularly when 
considering the relative peaks observed 6 minutes post-infection with ɸNM1 (Figure 3-
6A), it is apparent that there are multiple regions that display a dip in coverage 
followed by a peak, which could thus indicate the presence of a promoter. However, 
although this stranded RNA-seq dataset distinguished between the directionality of 
transcription, it did not distinguish transcriptional start sites from processed or cleaved 
RNA ends (which could also manifest as a local dip in coverage). Additional analyses 
would therefore be required to confirm the presence of bona-fide promoters at these 
sites. Note that the magnitudes of rightward transcription observed in the 
RN4220::ɸNM1 lysogen dataset (Figure 3-6B) should be interpreted with caution, 
because rightward transcription may be derived from a subset of the cells in the 
population undergoing spontaneous prophage induction, in addition to the stably 
lysogenic cells. Note, also, that both of these expression profiles were measured with 
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Figure 3-6. Location of ɸNM1 promoter candidates inferred from promoter 
predictions and stranded RNA-seq profiles.  
(A) Schematic representation of the ɸNM1 genome as presented in Figure 3-4A, aligned 
with ɸNM1’s rightward transcription profile (solid green line), obtained six minutes 
after infection of sensitive RN4220/pGG3 cells. Values are plotted in reads per million 
(RPM), but were not averaged over a 500 bp sliding-window as displayed previously 
(Goldberg et al., 2014). Vertical dashed lines below grey bent arrows represent the 
position of candidate promoters as indicated. Their sequences are listed in Table 3-2. 
(B) Same as in ‘A’, except that data was collected from a logarithmically growing 
RN4220::ɸNM1 lysogen. 
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the RN4220 host background. Nevertheless, I speculate that leaky transcription from at 
least some of these candidates—in addition to Pcro—could license incomplete prophage 
tolerance and a concomitant fitness reduction for the lysogen. Consistent with this 
notion, the ɸNM1Pcro- mutation had no discernible effect on the cost associated with the 
gp43 spacer (Figure 3-4I). Furthermore, this mutation was found to completely abolish 
the lysogen’s capacity for detectable prophage induction in two assays (Figures 3-5A & 
C). This suggests that the costs I’ve observed do not require transcription derived from 
lytic propagation. In further support of this idea, fitness costs associated with the gp32* 
spacer in the ɸNM1Pcro- background were comparable to that observed in the wild type 
background prior to day 3, and in fact somewhat elevated (Table 3-1). However, a 
fitness equilibrium plateau was not reached at this point when Pcro was mutated in the 
ɸNM1Pcro- background (Figure 3-7). Evidently, the pronounced curing of the wild type 
ɸNM1 prophage detectable by day 3 with the gp32* spacer (data not shown) requires 
that the prophage’s lytic capabilities are intact, although the fitness costs per se do not. 
In fact, by eliminating the target sequence, prophage curing apparently has the effect of 
rapidly extinguishing the fitness cost associated with maintenance of this CRISPR-Cas 
system. Meanwhile, prophage curing was not observed with the gp5, gp16, and gp43 
spacers in wild type ɸNM1 lysogens, or the gp32* spacer in ɸNM1Pcro- lysogens, where 
genetic escape via CRISPR-Cas plasmid inactivation was instead apparent by day 6  
(data not shown). The reason for this discrepancy between the gp32* spacer and the 
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Figure 3-7. An intact ɸNM1 prophage is required for high-frequency genetic escape 
of gp32*-dependent fitness costs observed in TB4::ɸNM1 lysogens. 
(A) Pairwise competition experiments for testing the perfectly matching gp32* spacer in 
marked single lysogens of TB4::ɸNM1, performed as described in Figure 3-3. (B) Same 
as in ‘B’, except that the perfectly matching gp32* spacer was tested in marked single 
lysogens of TB4::ɸNM1Pcro-, and individual values from each biological replicate are 
depicted in grey with black outlines as a triangle, circle, or rhombus. 
other perfectly matching spacers in wild type lysogens is still unclear to me. I speculate, 
however, that the unique position of its target within the prophage genome, and the 
dispensability of the gp32 ORF (based on homology to ɸNM2 and ɸNM4; see Chapter 2) 
for lytic infections, might be responsible. In temperate phages of Pseudomonas 
aeruginosa, accessory genes have been identified at an analogous region upstream of 
late-transcribed phage structural genes (Bondy-Denomy et al., 2013; Pawluk et al., 
2014), and they are thought carry their own promoters (Pawluk et al., 2014). It is 
possible that this region in ɸNM1 also encodes accessory genes with their own 
promoters, and that the regulation of these promoters is relatively uncoordinated with 
184 
the phage’s other promoters. In turn, such unregulated transcription might allow for 
bursts of targeting at opportune times during prophage induction, and targeting of this 
region would not necessarily disrupt the early lytic functions required for curing 
(because they are located upstream). It is also interesting to note that the fitness plateau 
was reached within a mixed population where non-targeting (ErmR-marked) lysogens 
release normal levels of infective phage particles. CRISPR-Cas immunity to lytic 
infection licensed by the gp32* spacer therefore appears to be sufficient to maintain the 
fitness of TetR-marked non-lysogens alongside control lysogens, at least under the 
growth conditions tested. 
In order to further demonstrate that these spacer-dependent fitness costs arise 
independently of prophage induction, I disrupted ɸNM1’s SOS-inducibility without 
altering its promoters by introducing a serine to alanine missense mutation in the 
catalytic domain of its cI-like repressor (Figures 3-5D & E). The CI-like repressors of 
lambdoid phages possess a serine protease activity that is required for prophage 
induction via RecA*-stimulated autoproteolysis and de-repression (Erill et al., 2007; 
Livny and Friedman, 2004; Mo et al., 2014). Spontaneous prophage induction was 
almost undetectable for this ɸNM1ind- mutant as well (Figure 3-5A). A previous report 
with phage lambda showed that when the primary recA-dependent pathway of 
prophage induction is prevented, rare spontaneously induced plaques can be found 
with compensatory mutations in either cI or its operator region that destabilize the 
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repression circuit (Little and Michalowski, 2010). I therefore used PCR and Sanger 
sequencing to check this region in the five plaques I detected, and confirmed that the 
plaques were indeed created by mutants of ɸNM1ind- that harbor additional SNPs 
(Figure 3-8). I next tested the marked TB4::ɸNM1ind- lysogens in pairwise competition 
assays. For reasons unclear, I was not able to isolate stable transductants of 
TB4::ɸNM1ind- harboring the gp5 CRISPR-Cas plasmid. I speculate that, in the absence of 
RecA*-stimulated repressor cleavage, the stability of the repression circuit in ɸNM1ind- 
may be more prone to fluctuations that increase transcription of its gp5 (cro-like) ORF. 
In lambda, CI represses its own promoter at higher concentrations in a negative 
feedback loop (Ptashne, 2011). Therefore, if CI-like repressors accumulate to high 
concentrations more readily in the ɸNM1ind- background, they may in turn repress their 
own promoter more frequently than in wild type (and thus allow for more frequent 
bursts of gp5 transcription). Notwithstanding, when the gp16 and gp43 spacers were 
tested with this prophage mutant in competition assays, no reduction in their fitness 
costs was observed (Figures 3-5F & G). Taken together, these results demonstrate that 
conditionally tolerant type III-A systems can impose spacer-dependent fitness costs 
even if their target prophages are not inducible, and thus suggest that the costs arise 
from transcription of prophage targets within otherwise stably lysogenic cells. 
Supporting this view, I did not find the relative fitness of conditionally tolerant 
lysogens at steady state to be correlated with their ability to survive brief MMC 
186 
Figure 3-8. Characterization of five ɸNM1ind- spontaneous induction escapers. 
(A) Schematic diagram depicting a relevant genomic region of the ɸNM1ind- prophage 
delimited by gp3 and gp7, according to the ɸNM1 annotation (Accession: NC_008583.1). 
Green vertical line denotes location of the engineered missense mutation in ɸNM1ind- 
that causes a SerineAlanine substitution at residue 124 of its CI-like repressor gene 
product. Dashed line denotes the location of Sanger-sequenced PCR products (1355 bp) 
amplified from the five spontaneously induced PFUs using primers oGG31 and oGG33. 
Grey bent arrow indicates the position of the inferred Pcro transcriptional start site. (B) 
Sequence of the Pcro promoter region in ɸNM1ind-/op*. Whereas the putative Pcro -35 and -10 
elements (underlined) are intact, a point mutation (red lettering) was found within a 
putative operator binding site that partially overlaps these elements (dashed blue box). 
This point mutation appears to diminish the palindromy of this sequence (consult Table 
3-2 for the wild type sequence), and was found in 2/5 plaques. (C) Sequence of the first 
18 codons in the mutant cI-like repressor gene of ɸNM1ind-/cI*. The TC missense 
mutation (red lettering) within codon 17 is expected to produce a SerineProline 
substitution. This mutation was found in 3/5 plaques. 
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treatments at a subinhibitory concentration (Figure 3-9A). For example, although fitness 
costs were undetectable with conditionally tolerant lysogens harboring the gp8 spacer 
(Figure 3-9B), they survived MMC treatment worse than conditionally tolerant lysogens 
with the gp43 spacer for which a fitness cost was observed (Figure 3-4D). Given that 
completion of the lytic cycle is not required for a decline in viability associated with 
lambdoid prophage induction (Livny and Friedman, 2004), and that CRISPR-Cas 
targeting of induced prophages could potentially occur prior to excision from the 
Figure 3-9. Survival of conditionally tolerant lysogens following MMC-stimulated 
prophage induction is not a predictor of relative fitness in untreated cultures.  
(A) Percent survival of TetR-marked TB4::ɸNM1 lysogens harboring the indicated 
conditionally tolerant CRISPR-Cas plasmid or the pGG79 parent vector (C/L+), 
following a 45-minute treatment with MMC at a subinhibitory concentration (0.5 
μg/ml). Survival of a TetR-marked TB4 non-lysogen harboring the pGG79 parent vector 
is also shown (C/L-). (B) Pairwise competition experiments for testing the perfectly 
matching gp8 spacer in marked single lysogens of TB4::ɸNM1, performed as described 
in Figure 3-3. 
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chromosome, it is expected that prophage induction might still have a lethal outcome 
even when targeting spacers are present. 
3.3 Contributions of type III-A targeting nucleases 
Having demonstrated that lysogenic hosts which maintain type III-A systems can incur 
spacer-dependent fitness costs, I sought to clarify whether this phenomenon reflects 
CRISPR-Cas targeting. To this end, I tested my gp16 spacer with mutations in Cas 
nuclease active sites previously implicated in targeting by the S. epidermidis type III-A 
system (Figure 3-10A). Mutation of Csm3 (D32A) was previously shown to abolish the 
targeting complex’s capacity for specific cleavage of complementary RNAs, while 
mutation of Cas10’s palm polymerase domain (D586A,D587A) was shown to abolish 
the complex’s capacity for transcription-dependent cleavage of DNA on the non-
template strand (Samai et al., 2015). Furthermore, mutations in the HEPN domain of 
Csm6 (R364A,H369A) were shown to abolish its RNase activity and eliminate its 
contributions to phage defense (Jiang et al., 2016). I first assessed the targeting capacity 
of mutant CRISPR-Cas plasmids during prophage induction. When csm3, csm6, or both 
RNases were mutated, spontaneous release of plaque forming units (PFUs) from 
overnight cultures was reduced to a similar degree as wild type, with individual 
replicates exhibiting as much as 3.2- to 4-log reductions relative to the average 
measured for lysogens harboring the non-targeting parent vector (Figure 3-10B). In 
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Figure 3-10. Effect of targeting nuclease active site mutations on conditional tolerance 
and spacer-dependent fitness costs associated with type III-A systems. 
(A) Schematic diagram summarizing the arrangement of CRISPR-Cas loci used 
throughout the work, with position 2 of the CRISPR array occupied by the gp16 spacer 
(purple rectangle) in this example. The naturally occurring nes spacer (white rectangle) 
from S. epidermidis RP62a is maintained at position 1 in all cases. ORFs encoding Cas 
nucleases implicated in targeting are highlighted in blue with green outline (cas10), red 
(csm3), or yellow (csm6), and the positions of their active site mutations are labeled to 
scale within each ORF. Other features of the diagram are not drawn to scale. (B) 
Quantification of PFU concentrations (PFU / ml) in filtered supernatants from overnight 
cultures of TetR-marked TB4::ɸNM1 single lysogens harboring mutant or wild type 
CRISPR-Cas plasmids with the gp16 spacer, or the wild type pGG79 parent vector with 
non-targeting spacers (C). Horizontal bars indicate the mean value of three biological 
replicates, plotted as black dots in each column. (C) High-resolution growth curves of 
TetR-marked TB4::ɸNM1 single lysogens harboring the mutant or wild type CRISPR-
Cas plasmids tested in panel ‘B’. Solid lines represent the average attenuance (D600 nm) 
measured from three biological replicates with MMC added at the indicated time point 
(black arrow), and are colored to match the cas gene ORFs highlighted in panel ‘A’ for 
each mutant, or otherwise green for the cas10HD mutant, blue for the cas10DD palm 
domain mutant, orange for the csm3*/csm6* double mutant plasmid, purple for the wild 
type gp16 plasmid, or black for the non-targeting pGG79 plasmid. For comparison, 
average attenuance measured from three biological replicates in the absence of MMC is 
plotted for two strains (dashed lines). (D) Pairwise competition experiments with 
marked TB4::ɸNM1 single lysogens, performed as described in Figure 3-3, except that 
the targeting strain harbored the gp16(csm3*) mutant CRISPR-Cas plasmid. (E) Same as 
in ‘D’, except with the gp16(cas10HD) mutant plasmid. (F) Same as in ‘D’, except with the 
gp16(cas10DD) palm domain mutant plasmid. (G) Same as in ‘D’, except with the 
gp16(csm6*) mutant plasmid. (H) Same as in ‘D’, except with the gp16(csm3*/csm6*) 
double mutant plasmid. 
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contrast, spontaneously induced PFU were never reduced more than ~1.3 logs among 
replicates with the cas10DD mutant, indicating that its targeting is partially impaired. 
Similar results were obtained in high-resolution growth curves following treatment 
with MMC, where partial lysis could be detected with the cas10DD mutant, but not with 
either or both of the RNAses mutated (Figure 3-10C). These results corroborate 
previous findings which demonstrated that both the Csm3 and Csm6 RNAse activities 
are dispensable for immunity during the lytic cycle when the target falls within an 
early-transcribed region of the phage genome such as this (Jiang et al., 2016). 
Recent reports on type III systems from other groups have shown that the HD 
domain of Cas10 proteins is required for RNA-activated cleavage of ssDNA in vitro 
(Elmore et al., 2016; Estrella et al., 2016; Han et al., 2017; Kazlauskiene et al., 2016; Park 
et al., 2017), although a requirement for cleavage of the non-template DNA strand in a 
transcription-coupled assay has yet to be demonstrated. Moreover, while mutation of 
the HD domain was not found to abolish anti-plasmid immunity by the type III-A 
system of S. epidermidis RP62a in a pG0400 conjugation assay (Hatoum-Aslan et al., 
2014), the effect of this mutation on type III-A targeting in lysogens has not been 
explored. I first tested the cas10HD mutant in prophage induction assays. Interestingly, 
while this mutant still appeared to be largely capable of preventing lysis in high-
resolution growth curves following MMC-stimulated prophage induction, almost no 
reduction in spontaneously released PFUs was observed in this background. The reason 
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for this discrepancy is currently unclear, but I speculate that the HD domain’s DNase 
activity might be required to prevent phage DNA from being packaged efficiently, and 
yet not per se required to prevent completion of the lytic cycle. Additional insight could 
perhaps be obtained by quantifying the number of PFUs released (or produced 
intracellularly) at different time points after induction with MMC in this mutant 
background. For example, it’s possible that a residual targeting activity—potentially 
derived from one or both of the type III-A system’s RNases—could be delaying lysis 
without degrading phage DNA or sufficiently preventing its packaging. I further 
speculate that the residual targeting observed in high-resolution growth curves reflects 
the same activity or activities that allow for immunity to pG0400 conjugation via the 
native nes spacer in this background (Hatoum-Aslan et al., 2014), because the immunity 
to pG0400 licensed by this spacer was, incidentally, found to depend on csm6 (Hatoum-
Aslan et al., 2014). Testing of double or triple mutants with the HD domain and one or 
both RNase functions mutated would likely clarify this point. 
I next measured the relative fitness of lysogens harboring mutant CRISPR-Cas 
plasmids. The fitness cost associated with the gp16 spacer was not reduced by the csm3* 
mutation (Figure 3-10D), and perhaps only slightly reduced by the cas10HD mutation 
(Figure 3-10E). Meanwhile, the fitness cost appeared to be completely abolished by the 
cas10DD palm domain mutation (Figure 3-10F). Interestingly, both the csm6* and 
csm3*/csm6* mutants also displayed a strongly reduced fitness cost (Figures 3-10G & 
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H). This finding implies that the RNase activity of Csm6 can contribute to growth 
defects associated with chromosomal targeting, although the mechanism for this 
remains to be elucidated. An important caveat of these nuclease mutant data is that 
isogenic plasmid backbones were not used when measuring relative fitness in the 
competition experiments; as such, the observed reduction in gp16-associated fitness 
costs could in fact reflect reduced general toxicity associated with expression of the 
intact nucleases, rather than reduced targeting at prophage loci. To rule this out, mutant 
CRISPR-Cas plasmids with the gp16 spacer should be tested against their respective 
non-targeting mutant parent vectors. Notwithstanding, my results suggest that costs 
associated with incomplete prophage tolerance by type III-A systems may depend on 
the activity of at least one Cas nuclease implicated in transcription-dependent targeting. 
3.4 Consequences of conditionally tolerant type III-A systems in polylysogens 
Clinical isolates of S. aureus are seldom found to possess CRISPR-Cas systems (Cao et 
al., 2016), and in many cases are polylysogens harboring more than one prophage 
(Aanensen et al., 2016; Goerke et al., 2009). The clinical isolate S. aureus Newman, for 
example, does not harbor an endogenous CRISPR-Cas system but harbors four 
heteroimmune lambdoid prophages (Bae et al., 2006). However, among the 
staphylococcal type III-A CRISPR-Cas systems which have been identified so far, some 
spacers have been found to match conserved temperate phage lytic genes, at least 
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partially (Cao et al., 2016; Goldberg et al., 2014). These observations prompted us to 
investigate the consequences of maintaining type III-A systems in a polylysogenic 
scenario where more than one prophage can be targeted. This was accomplished using 
ɸNM1 and ɸNM4, which integrate into distinct chromosomal loci but share regions of 
sequence homology, including a perfectly conserved target for the gp16 spacer (Figure 
3-11A). Provided that each target sequence falls within lytic gene clusters which are 
sufficiently repressed during lysogeny, I anticipated that polylysogeny would be 
tolerated even in the presence of perfectly matching spacers. To confirm this, 
TB4::ɸNM4 lysogens harboring CRISPR-Cas plasmids with spacers matching to ɸNM1’s 
gp5, gp16, or gp43 targets were infected with an erythromycin resistance-conferring 
derivative of ɸNM1 (ɸNM1-ErmR2) that allows quantification of newly formed lysogens. 
Lysogens with singly (gp5, gp43) and doubly (gp16) targeting spacers tolerated 
secondary lysogenization by ɸNM1-ErmR2 at a comparable frequency as control 
lysogens harboring a fully mismatched (35 mm) spacer (Figure 3-11B), while plaque 
formation on the same hosts was reduced only in the presence of targeting spacers 
(Figure 3-11C). However, differences in colony size phenotype were clearly discernible 
among the resulting double lysogens (Figure 3-11D). Relative to double lysogens with 
the control spacer, double lysogens with the gp5 or gp43 spacers which do not target 
ɸNM4 had a less severe colony size reduction than lysogens with the gp16 spacer 
targeting both prophages. This trend was likewise observed with unmarked 
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Figure 3-11. Type III-A systems which target multiple temperate phages can impose 
greater fitness costs in polylysogenic hosts. 
(A) Schematic representation of the integrated ɸNM1 (NC_008583.1) and ɸNM4 
(NC_028864.1) prophage genomes. ORFs (thick arrows) were scaled in accordance with 
their annotated lengths. Colored ORFs denote the presence of a target sequence for one 
or more spacer tested in section 3.4. ɸNM1’s gp16 ORF includes a target that is found 
with 100% conservation in gp17 of ɸNM4, as indicated by color-matched ORFs (purple). 
(B) Secondary lysogenization of TB4::ɸNM4 with ɸNM1-ErmR2 in the presence of the 35 
mm, gp5, gp16, or gp43 CRISPR-Cas plasmids as indicated. The ‘35 mm’ spacer is a fully 
mismatched variant of the gp16 spacer that serves as a non-targeting control. 
Lysogenization was quantified as the concentration (CFU / ml) of CmR+ErmR CFUs in 
each culture following treatment with ɸNM1-ErmR2. For comparison, total recipients 
were quantified as the concentration (CFU / ml) of CmR CFUs in each untreated culture. 
Error bars, mean ± s.d. (n = 3, biological replicates).  (C) Plaquing efficiency of ɸNM1-
ErmR2 on TB4::ɸNM4 lysogens harboring the different CRISPR-Cas plasmids tested in 
panel ‘B’, as indicated by the labels. Dotted line represents the limit of detection under 
these assay conditions. Error bars, mean ± s.d. (n = 3, technical replicates). (D) Colony 
size comparison of TB4::ɸNM4+ɸNM1-ErmR2 double lysogens harboring the different 
CRISPR-Cas plasmids tested in panel ‘B’, as indicated by the labels above. Picture is 
representative of a biological replicate for each strain plated in the presence of 
chloramphenicol to maintain CRISPR-Cas plasmids. (E) Batch competition experiment 
with unmarked TB4::ɸNM1+ɸNM4 double lysogens harboring the different CRISPR-
Cas plasmids tested in panel ‘B’. As outlined in the methods, deep sequencing was used 
to determine targeting spacer frequencies relative to the 35 mm non-targeting spacer 
within the sample (y-axis), and plotted against the number of transfers (x-axis, one 
transfer per day). Dashed lines illustrate the change in relative frequency across time 
points, and are color-coded for their targets according to the schematic in panel ‘A’. 
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TB4::ɸNM4+ɸNM1 double lysogens when the same CRISPR-Cas plasmids were 
introduced via transduction (data not shown). To determine whether these phenotypes 
reflect discrepancies in relative fitness, I performed pairwise competition assays with 
marked double lysogens harboring either the gp5 spacer, the gp16 spacer, or the gp43ori 
spacer. A control co-culture experiment where differentially marked double lysogens 
both harbored the same pGG79 parent vector was also performed. Surprisingly, the 
TetR-marked double lysogens had an apparent advantage even in control co-cultures 
(data not shown). Furthermore, although the double lysogens with the gp16 spacer 
indeed declined the most rapidly at the outset, all of the fitness costs were offset, and 
the relative abundance of TetR-marked lineages would even increase by the end of the 
six-day experiment in cases where sufficient genetic inactivation of the conditionally 
tolerant CRISPR-Cas plasmid had presumably occurred (data not shown). I speculate 
that the pE194 plasmid is less stable in this doubly lysogenic background, perhaps due 
to synergistic or additive effects of harboring both prophages. For example, harboring 
both prophages might provide additional opportunities for leaky expression of 
prophage terminase proteins that could license off-target cleavage of plasmids. In this 
scenario, specific loss of the pE194 plasmid rather than pT181 could be explained by 
intrinsic terminase sequence preferences (Chen et al., 2015b). Note, however, that 
neither of these prophages were sufficient to license this effect on their own (Figures 3-
4E & 3-12A). In order to circumvent this technical constraint, and also to assess the 
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relative fitness of multiple strains in a less cumbersome manner, I mixed unmarked 
double lysogens harboring each of the four spacers (35 mm, gp5, gp16, or gp43) into a 
single batch and competed them in liquid culture for three days. After each day, and 
also at time ‘zero’ before the first transfer, spacer abundances were measured by deep 
sequencing, and the frequency of each targeting spacer was calculated relative to the 35 
mm spacer’s frequency in the sample. Deep sequencing in a single MiSeq run was 
performed on small PCR amplicons spanning the spacer of interest, alongside two 
additional series of three-day batch competitions described later in this chapter. This 
was enabled by independently barcoding each of the 12 PCR samples, with advice on 
barcode design provided by Dr. Modell. Spacer quantification was subsequently 
performed with a sequence-matching Python script that I designed to tally reads 
containing each of the expected sequences with 100% identity (including their expected 
barcode sequences). Troubleshooting of the script was carried out with mini files 
containing a subset of the reads (to reduce processing times). I generated these mini 
files using another Python script, provided by Phil Nussenzweig and Dr. Varble, which 
pulls out a user-specified range of reads. During the troubleshooting process, I also 
generated modified scripts for sampling and tallying aberrant reads (including barcode 
cross-contaminants that were likely generated during the library preparation steps), 
which allowed me to confirm that these reads contributed negligibly to my primary 
tallies. Ultimately, a representative dataset was manually compiled and plotted using 
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Microsoft Excel. My analysis indicates that the dual-targeting gp16 spacer declined 
more rapidly than the spacers targeting only ɸNM1 (Figure 3-11E), and its rate of 
decline was more than double that observed in pairwise competitions with either of the 
marked TB4::ɸNM1 or TB4::ɸNM4 single lysogens (Figures 3-4C & 3-12B). Importantly, 
this was not observed for double lysogens where only ɸNM1 was targeted with the gp5 
or gp43 spacers (Figure 3-11E), which declined at rates similar to those observed in their 
Figure 3-12. Fitness costs associated with conditional tolerance in marked TB4::ɸNM4 
single lysogens harboring the gp16 CRISPR-Cas plasmid.  
(A) Pairwise competition experiments for measuring the relative fitness of differentially 
marked TB4::ɸNM4 lysogens each harboring the non-targeting pGG79 plasmid, 
performed as described in Figure 3-3. (B) Same as in ‘B’, except that the perfectly 
matching gp16 spacer was tested, and the solid line shares color coding with the ɸNM4 
target ORF indicated in Figure 3-11A. (C) High-resolution growth curves of TetR-
marked TB4::ɸNM4 single lysogens harboring either the gp16 or non-targeting pGG79 
CRISPR-Cas plasmid. Solid lines represent the average attenuance (D600 nm) measured 
from three biological replicates with MMC added at the indicated time point (black 
arrow), and are colored to match the target ORFs highlighted in Figure 3-11A, or black 
for the non-targeting vector. For comparison, average attenuance measured from three 
biological replicates in the absence of MMC is plotted for two strains (dashed lines). 
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respective pairwise competitions using marked TB4::ɸNM1 single lysogens (Figures 3-
4B & D and Table 3-1). Thus, in spite of their capacity for conditional tolerance, type 
III-A CRISPR-Cas systems can become a greater fitness liability if they target multiple 
temperate phages. It should be pointed out, however, that these broadly targeting 
systems are expected to confer superior short-term advantages when guarding against 
lytic infection by heteroimmune phages. 
The results described above confirmed the expectation that conditional tolerance 
can operate independently on heteroimmune temperate phages during infection. 
However, the effects of targeting in double lysogens, for example during prophage 
induction, were not explored. To investigate this, I first measured the number of PFUs 
released from unmarked doubly lysogenic cultures four hours post-induction with 
MMC, and plated supernatants on lawns of TB4::ɸNM1, TB4::ɸNM4, and TB4, in order 
to determine the relative proportion of ɸNM1 and ɸNM4 particles out of the total. For 
comparison, PFUs were also measured under these assay conditions from unmarked 
single lysogens of TB4::ɸNM1 and TB4::ɸNM4 harboring the non-targeting (35 mm) 
CRISPR-Cas plasmid. When double lysogens harboring this non-targeting plasmid are 
induced, ɸNM1 makes up the majority of the phage particles recovered (Figure 3-13A). 
Such asymmetries have also been observed during induction of E. coli double lysogens 
harboring heteroimmune lambdoid prophages, and are likely the result of intracellular 
competition (Refardt, 2011). For reasons unclear, ɸNM1 PFUs were specifically depleted 
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Figure 3-13. Conditionally tolerant type III-A systems can display prophage targeting 
specificity within double lysogens undergoing induction.  
(A) Quantification of PFU concentrations (PFU / ml) in filtered supernatants from 
subcultures of unmarked TB4::ɸNM1+ɸNM4 double lysogens harboring one of the 
CRISPR-Cas plasmids tested in Figure 3-11, four hours post-treatment with MMC at 2.0 
μg/ml. For comparison, single lysogens of TB4::ɸNM1 and TB4::ɸNM4 harboring the 35 
mm CRISPR-Cas plasmid were also tested under these assay conditions. All lysates 
were spotted on TB4 lawns to measure total PFU, as well as TB4::ɸNM1 and TB4::ɸNM4 
lawns to measure the fraction of ɸNM4- and ɸNM1-derived PFUs, respectively. Dashed 
line represents the limit of detection under these assay conditions. Error bars, mean ± 
s.d. (n = 3, biological replicates). (B) High-resolution growth curves of unmarked 
TB4::ɸNM1+ɸNM4 double lysogens harboring the gp5, gp16, gp43ori, or 35 mm CRISPR-
Cas plasmids. Solid lines represent the average attenuance (D600 nm) measured from three 
biological replicates with MMC added at the indicated time point (black arrow), and are 
colored to match the target ORFs highlighted in Figure 3-11A, or black for the non-
targeting vector. For comparison, average attenuance measured from three biological 
replicates in the absence of MMC is plotted for two strains (dashed lines). (C) Same as 
in ‘B’, except that the gp5(csm6*), gp16(csm6*), and gp43ori(csm6*) mutant CRISPR-Cas 
plasmids were tested. For comparison, data from experiments with the 35 mm wild 
type CRISPR-Cas plasmid are also plotted. 
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from the total by approximately one order of magnitude even when both prophages 
were targeted with the gp16 spacer. Potentially, ɸNM4 simply fairs better during 
induction under the gp16 targeting conditions, but neither prophage was particularly 
proliferative; PFU measurements were approaching my limit of detection in these 
experiments. Nevertheless, a much more pronounced effect was observed when only 
ɸNM1 was targeted with either the gp5 or gp43 spacers: ɸNM1 PFUs were specifically 
depleted from the total by about 3 orders of magnitude in each case. The absolute 
number of PFUs released during induction was lower with the gp43 spacer than with 
the gp5 spacer. This was initially puzzling, but high-resolution monitoring of these 
cultures during induction provided some additional insight. Whereas the dual-
targeting gp16 spacer prevented lysis, the gp5 and gp43ori spacers did not (Figure 3-
13B)—presumably because ɸNM4 is allowed to complete its lytic cycle when it is not 
targeted. However, lysis profiles were more noticeably perturbed by the gp43ori spacer 
than by the gp5 spacer. The effect was similarly observed in a triplicate experiment with 
unmarked double lysogens harboring the gp43 CRISPR-Cas plasmid (data not shown). 
This perturbation—suggestive of a simple delay in ɸNM4-mediated lysis—might 
explain why I recovered fewer particles overall with the gp43 spacer, four hours post-
induction. Assessing the number of particles released at a later time point could help to 
clarify this point. Nevertheless, given that ɸNM1 was specifically depleted to the same 
extent by the gp5 spacer without a concomitant strong reduction in total PFUs, the lysis 
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perturbation I observed with gp43ori likely reflects a non-specific effect encountered 
during targeting. Given, also, mounting evidence which suggests that the HEPN RNase 
domain of type VI effector nucleases—and perhaps other Cas nucleases—can license 
off-target effects (Jiang et al., 2016; Shmakov et al., 2017), I tested whether an intact 
HEPN domain active site in Csm6 was required for the lysis perturbations in this assay. 
Whereas the gp16 spacer still prevented lysis even in the csm6-mutant background 
(csm6*), lysis profiles in double lysogens with the gp5(csm6*) and gp43ori(csm6*) CRISPR-
Cas plasmids were essentially indistinguishable from double lysogens with the non-
targeting plasmid (Figure 3-13C). Taken together, these results demonstrate that 
conditionally tolerant type III-A systems can display prophage targeting specificity 
within double lysogens. However, the RNase activity of Csm6 can apparently license 
off-target effects during induction, and potentially perturb lysis by another prophage 
that is not targeted. Additional insight into the specificity of the type III-A targeting 
complex during induction could be provided by measuring PFUs derived from csm6*-
mutant cultures. For example, it would be interesting to see if the remaining nuclease 
activities associated with Cas10 and Csm3 are sufficient to license a specific reduction in 
ɸNM1-derived PFUs. 
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3.5 Effects of spacer-target mismatches in single and double lysogens 
The above results confirmed that type III-A systems which target multiple temperate 
phages are not a barrier to polylysogenization per se, even if they possess perfectly 
matching spacers. However, natural examples of prophage targets and type III-A 
systems with perfectly matching spacers co-existing within staphylococcal isolates have 
yet to be reported. Having found that the mismatched gp32 spacer in single lysogens is 
associated with a lower fitness cost than its perfectly matched gp32* variant but is still 
capable of targeting during the lytic cycle (Figures 3-3 & 3-5), I wondered if spacer-
target mismatches could likewise help to stabilize conditionally tolerant systems in 
polylysogenic populations. To investigate this, I constructed a series of mismatched 
spacers based around the gp16 spacer, which targets an identical sequence found in 
both ɸNM1 and ɸNM4. It was previously shown that mismatches most readily abrogate 
type III targeting when they’re distributed at both the 5’ and 3’ ends of the spacer (Cao 
et al., 2016; Manica et al., 2013). Accordingly, I introduced increasing numbers of 
mutations at both ends of the gp16 spacer in an effort to sample a range of targeting 
potentials with a minimal number of mismatches (Figure 3-14A). The resulting CRISPR-
Cas plasmids were then transduced into unmarked TB4::ɸNM4+ɸNM1 double lysogens, 
as well as unmarked TB4::ɸNM1 single lysogens for comparison. First, I examined the 
targeting potential of each spacer in single and double lysogens during MMC-
stimulated prophage induction. In both cases, PFU induction was reduced to a similar 
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Figure 3-14. Effects of spacer-target mismatches in single and double lysogens 
harboring type III-A CRISPR-Cas systems with dual-targeting potential.  
(A) Sequence summary of the gp16 spacer and its mismatched variants. Black lettering 
indicates sequences found in the parental gp16 spacer; red lettering indicates mutated 
base pairs. A subset of transversion mutations were used to avoid introducing G:U 
pairing when complementarity between the crRNA and transcribed target RNA is 
considered. (B) Quantification of PFU concentrations (PFU / ml) in filtered supernatants 
from subcultures of single (TB4::ɸNM1) or double (TB4::ɸNM1+ɸNM4) lysogens 
harboring the spacers depicted in panel ‘A’, four hours post-treatment with MMC at 1.0 
μg/ml. Error bars, mean ± s.d. (n = 3, biological replicates). (C) Batch competition 
experiment with unmarked TB4::ɸNM1 single lysogens harboring CRISPR-Cas 
plasmids with the perfectly matched gp16 spacer or one of several mismatched 
derivatives shown in panel ‘A’. As outlined in the methods, deep sequencing was used 
to determine targeting spacer frequencies relative to the 35 mm spacer within the 
sample (y-axis), and plotted against the number of transfers (x-axis, one transfer per 
day). Dashed lines illustrate the change in relative frequency across time points, and are 
color-coded according to the labeled inset. (D) Same as in panel ‘C’, except that 
unmarked TB4::ɸNM1+ɸNM4 double lysogens were used in the experiment. 
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degree by spacers with 6 or fewer mismatches, while targeting was undetectable with 8 
or more mismatches (Figure 3-14B). I next tested each group of single or double 
lysogens in batch competition experiments lasting three days. Again, spacer 
abundances were measured by deep sequencing at each time point, and the frequency 
of each spacer was calculated relative to the 35 mm spacer’s frequency in the sample. 
My analysis indicates that the spacers with 4 and 6 mismatches declined less rapidly 
than the spacers with 0 or 2 mismatches within their respective populations (Figures 3-
14C & D). Meanwhile, no decline was discernible for the spacers with 8 or more 
mismatches in either population, consistent with the complete lack of detectable 
targeting by these spacers in the prophage induction assay. Furthermore, I observed a 
similar rate of decline for the perfectly matching gp16 spacer across experiments with 
marked and unmarked single lysogens (Figures 3-4C & 3-14C), which served to 
validate my usage of the method in assessing relative fitness. I also found that the costs 
associated with dual-targeting spacers possessing either 4 or 6 mismatches (Figure 3-
14D) were comparable to that of the perfectly matched gp5 spacer targeting only ɸNM1 
in double lysogens (Figure 3-11E). Thus, mismatches which alleviate fitness costs may 
help to ensure that spacers targeting multiple prophages are not always more 
burdensome to their polylysogenic hosts than singly targeting spacers. Moreover, this 
feature of type III-A systems might improve the long-term stability of spacers that 
guard against lytic infection by a range of heteroimmune phages with partially 
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divergent target sequences, given that the 4 and 6 mismatches did not abrogate 
targeting outright. 
3.6 Discussion points and additional proposed experiments 
I report here that S. aureus lysogens which maintain type III-A CRISPR-Cas systems can 
incur constitutive fitness costs, despite the genetic stability generally afforded by 
conditional tolerance. The costs depend on the presence of certain prophage-targeting 
spacers, and likely result from incomplete prophage tolerance by the system’s 
transcription-dependent targeting machinery. Several lines of evidence support this 
interpretation. 
Previously, transcription-dependent chromosomal targeting by the type III-A 
system of S. epidermidis RP62a was found to cause severe growth defects (Goldberg et 
al., 2014; Jiang et al., 2016), and similar effects have been observed with other types of 
CRISPR-Cas systems (Edgar and Qimron, 2010; Jiang et al., 2013b; Vercoe et al., 2013). 
At least in part, this appears to result from toxicity associated with frequent nicking or 
cleavage of the host’s chromosomal DNA. Minor growth defects, in line with the fitness 
costs described in this work, might instead be expected if type III-A chromosomal 
targeting were infrequent; e.g., licensed by transcription in a sufficiently small 
subpopulation of cells. When lambdoid lysogens are cultured under standard growth 
conditions, transcription from lytic promoters can occur in a subpopulation of cells 
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undergoing the lytic cycle via spontaneous prophage induction (Nanda et al., 2015). For 
SOS-inducible lambdoid phages, the frequency of spontaneous prophage induction in 
the population depends almost entirely on the host’s SOS responsiveness (Fuchs et al., 
1999; Little and Michalowski, 2010; Nanda et al., 2015), and this is presumably 
unaltered by the presence or absence of conditionally tolerant spacers. Given that 
prophage induction leads to lysis in the absence of targeting spacers, the fitness of 
conditionally tolerant lysogens would not necessarily be impaired relative to non-
targeting lysogens if spontaneous prophage induction events were strictly required for 
toxicity. Indeed, even when ɸNM1’s capacity for detectable spontaneous prophage 
induction was nearly completely eliminated by mutations in its cI-like repressor 
(Figures 3-5A & 3-8), fitness costs were not alleviated (Figures 3-5F & G). This suggests 
that the fitness costs might depend instead on leaky transcription of prophage targets 
occurring within stably lysogenic cells (Figure 3-5E); in other words, targeting occurring 
in a subpopulation of cells that is not undergoing spontaneous prophage induction. 
Consistent with a requirement for transcription at prophage target loci, costs associated 
with the gp5 spacer were virtually undetectable when the Pcro promoter immediately 
upstream of its target was inactivated (Figure 3-4G). Meanwhile, mutation of Pcro did 
not eliminate fitness costs associated with spacers that target other prophage loci 
(Figures 3-4H & I), despite preventing detectable prophage induction (Figures 3-5A & 
C). 
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The potential for prophage lytic loci to be de-repressed independently of 
spontaneous prophage induction is not unprecedented for lambdoid temperate phages, 
and was previously demonstrated using a genetic reporter system (Livny and 
Friedman, 2004). In this study, furthermore, the authors detected slight de-repression 
above background even when prophages carried a non-inducible cI allele similar to that 
of my ɸNM1ind- mutant. Conceivably, leaky transcription arising in this manner may 
license the fitness costs I’ve detected. This model could also account for the 
discrepancies I observed with spacers matching to different regions of the ɸNM1 
prophage in single lysogens (Figure 3-4). For example, different promoters in each 
region might produce distinct patterns of leaky transcription within stably lysogenic 
cells, even if upregulation of the promoters is normally coordinated by extrinsic 
factors—such as the host’s SOS response—within cells undergoing prophage induction. 
Moreover, this model could explain why a combined effect of having both ɸNM1 and 
ɸNM4 was observed in double lysogens with the dual-targeting gp16 spacer (Figure 3-
11E), even though induction of heteroimmune prophages can be coordinated in 
polylysogens by the SOS response (Refardt, 2011). In this scenario, if instances of leaky 
transcription in each prophage are poorly correlated within cells that are not 
undergoing induction, the combined effect of having both targets might be essentially 
additive at the population level. The cost observed with the gp16 spacer in double 
lysogens was indeed comparable to the sum of that observed with single lysogens of 
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ɸNM1 and ɸNM4 alone (Figures 3-4C & 3-12B). Regarding the potential for 
uncorrelated leaky expression from distinct chromosomal loci in bacteria, there is 
precedent here as well. It was previously demonstrated that cell-cell variability becomes 
elevated under transcriptionally repressed conditions, even when expression from two 
loci with identical promoters and identical repressors is compared (Elowitz et al., 2002). 
Similar single-cell approaches could be used to clarify whether expression of each 
prophage is occasionally uncoupled from one another, and from the host’s SOS 
response. The combined effect I observed could also be synergistic, at least in part, 
particularly if transcription were found to occur simultaneously at both loci in certain 
cells. Cells which are targeted at both loci within a sufficiently small timeframe might 
experience more severe toxicity. In this scenario, however, it is assumed that a subset of 
the target’s transcription events do not produce lethal outcomes; otherwise, if a single 
transcription event at the target site were always sufficient to license lethality, it is 
difficult to imagine how synergy would arise. Testing the effects of CRISPR arrays with 
more than one prophage-targeting spacer could perhaps help to clarify whether or not 
this is the case. I’m proposing, for example, to construct a conditionally tolerant 
TB4::ɸNM1 single lysogen with a CRISPR array that has two spacers targeting nearby 
sequences within the gp16 ORF. If transcriptional surveillance by the type III-A system 
were saturating with a single spacer, we might find that the presence of the 
downstream spacer incurs no additional fitness cost. Such a result would imply that all 
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of the target’s transcription events lead to lethal outcomes. Expanded CRISPR arrays 
could also be used to investigate the effects of targeting at different loci within the same 
prophage. For example, if transcription of the gp5 and gp43 loci were poorly 
coordinated within single cells of TB4::ɸNM1, we might expect a CRISPR array 
possessing both the gp5 and gp43 spacers to license more severe fitness costs (again, 
perhaps essentially equal the sum of the gp5- and gp43-associated fitness costs alone). 
It is still unclear to me why the fitness cost associated with the gp16 spacer was 
reduced in the ɸNM1Pcro- background (Figure 3-4). One interpretation follows that a 
weaker downstream promoter which is coordinately transcribed with Pcro in wild type 
ɸNM1 could license these residual fitness costs in the absence of Pcro (e.g., if 
transcription from Pcro is effectively ‘dominant’ to transcription from this downstream 
promoter, and yet not strictly required for it). Based on my RNA-seq and promoter-
prediction analyses (Figure 3-6 and Table 3-2), one such downstream promoter might 
be located within the annotated gp9 ORF. In this scenario, leaky transcriptional read-
through of gp16 from Pcro would explain the higher fitness cost observed in the wild 
type ɸNM1 background, and potentially also explain why the gp5 and gp16 fitness costs 
were so similar in magnitude. Arguing against this, however, a spacer which targets the 
intervening gp8 ORF was not associated with a detectable fitness cost (Figures 3-4A & 
3-9B). An alternative interpretation follows that leaky transcription from Pcro terminates 
before gp8 in the lysogenic populations, but gives rise to one or more immediate early 
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gene products which can partially enhance transcription from a downstream promoter, 
such as the putative promoter in gp9. In this scenario, leaky transcription from Pcro and 
the downstream promoter is not necessarily well-coordinated, and the similarity 
between the fitness costs observed with the gp5 and gp16 spacers in wild type ΦNM1 
lysogens is simply fortuitous. Again, testing of a CRISPR-Cas plasmid with multiple 
ΦNM1-targeting spacers (e.g., targeting both gp5 and gp16), could potentially prove 
insightful, and help to distinguish between these interpretations. 
Additional evidence pointing to transcription-dependent chromosomal targeting 
as the source of the fitness costs was provided by experiments with mutant type III-A 
Cas nucleases. Ablation of csm3’s RNase activity did not reduce fitness costs (Figure 3-
10D). Given its role in specific cleavage of target RNAs by type III systems, this was 
perhaps expected (Tamulaitis et al., 2017); knockdown of prophage lytic transcripts 
should not be toxic to lysogenic cells per se. Meanwhile, fitness costs appeared to be 
completely abolished by mutation of cas10’s palm polymerase domain (Figure 3-10F). In 
addition, whereas this cas10DD palm domain mutation strongly impaired targeting with 
the gp16 spacer in prophage induction assays, ablation of the csm3 and csm6 RNase 
activities did not (Figures 3-10B & C). These data were in line with past reports 
indicating that both transcription-dependent DNA degradation and robust immunity to 
lytic infections by this system requires an intact palm polymerase domain (Samai et al., 
2015), and that its RNase activities are not required to disrupt the lytic cycle if the 
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phage’s target falls within an early-transcribed region, such as gp16 (Jiang et al., 2016). 
However, although the cas10DD palm domain mutation was not found to prevent target 
RNA cleavage by the type III-A complex in vitro (Samai et al., 2015), the possibility that 
this mutation could have pleiotropic effects in vivo has not been ruled out. Perhaps less 
expected was the finding that mutation of csm6’s HEPN RNase domain almost 
completely eliminated the costs associated with the gp16 spacer (Figures 3-10G & H). 
This RNase function is not strictly required to elicit severe growth defects associated 
with transcription-dependent chromosomal targeting, or targeting of DNA elements in 
general (Jiang et al., 2016). Hence, the nature of Csm6’s contribution to the growth 
defects described in this work remains unclear. Of potential relevance here, it was 
recently demonstrated that the HEPN RNase domains of RNA-guided type VI effector 
nucleases can mediate cleavage of non-target RNAs in trans, or ‘collateral’ RNA 
cleavage, upon binding of target RNAs (Shmakov et al., 2017). Furthermore, it was 
shown that type VI systems can cause growth defects in the presence of target RNAs, 
and this was proposed to result from off-target cleavage of cellular transcripts 
(Abudayyeh et al., 2016; Smargon et al., 2017). It’s possible that I’m observing a similar 
phenomenon in my experiments (and the results presented in Figure 3-13 would 
support this notion), but an analogous mechanism for coupling Csm6’s activity to 
transcription-dependent targeting by the type III-A complex has yet to be established. 
Current evidence suggests that binding of nascent target transcripts in cis is a pre-
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requisite for both localizing type III complexes to specific DNA elements and for 
regulating their DNase activity (Estrella et al., 2016; Goldberg et al., 2014; Kazlauskiene 
et al., 2016; Samai et al., 2015). Binding of target RNAs, nascent or otherwise, could 
likewise be a pre-requisite for recruitment or regulation of Csm6’s RNase activity, and 
this recruitment or regulation would presumably involve biophysical (and/or 
biochemical) interactions between Csm6 and the Cas10-Csm complex during targeting 
(Jiang et al., 2016). Meanwhile, such interactions—if confirmed—might feed back on in 
vivo DNA targeting by the Cas10-Csm complex in a more direct manner. In other 
words, the partially Csm6-dependent fitness costs I’m observing might result from 
enhanced degradation of chromosomal DNA licensed by Csm6-mediated feedback on 
the complex (at least in instances where nascent target RNAs are bound in cis)—rather 
than Csm6-dependent collateral RNA degradation effects per se. Arguing against this, 
however, I found almost no reduction in the gp16 spacer’s fitness cost upon mutation of 
the cas10 HD domain (Figure 3-10E). HD domain mutations are thought to specifically 
inactivate the DNase activity of Cas10 proteins (Estrella et al., 2016; Kazlauskiene et al., 
2016). Testing of a cas10HD/csm6* double mutant would confirm whether the residual 
fitness costs observed in the csm6* mutant background are due to the HD domain’s 
DNase activity (and thus presumably the direct result of chromosomal degradation). 
Note that, in each scenario described above, transcription is assumed to be a pre-
requisite for the Csm6- and Cas10-dependent effects, so that the wild type system 
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would still be expected to tolerate sufficiently repressed prophage targets. However, 
given the potential for incomplete tolerance of leaky targets, it is tempting to speculate 
that further layers of regulation could evolve to fine-tune type III-A targeting nuclease 
activities and provide more complete prophage tolerance while still ensuring robust 
immunity during lytic infections. 
The results presented in this work suggest that, among natural lysogenization-
prone lineages of S. aureus (Aanensen et al., 2016; Goerke et al., 2009), enrichment for 
certain temperate-phage-targeting spacers could serve as an ad hoc mechanism of 
evolutionary fine-tuning for type III-A CRISPR-Cas systems. Different fitness costs were 
observed for spacers matching different regions of the ɸNM1 prophage (Figures 3-3, 3-
4, & 3-9B) and fitness costs were potentially more severe in double lysogens if the 
spacer targeted both prophages (Figure 3-11E). Presumably, this latter phenomenon 
would be particularly relevant in natural environments where encounters with 
heteroimmune phages are common. Under these conditions, CRISPR-adapted lineages 
could gain a short-term survival advantage over non-adapted lineages (lysogenic or 
otherwise) when the population is infected by heteroimmune phages with identical or 
partially divergent target sequences. However, as my results illustrate, CRISPR-adapted 
cells that become lysogenized or polylysogenized during these subsequent infections 
may also incur constitutive fitness costs. In one case, a perfectly matching spacer was 
found to license curing of its ɸNM1 prophage target (Figure 3-7). This effectively 
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remedied the host’s immunopathology in a manner that did not compromise the 
CRISPR-Cas system itself. While a phenomenon such as this could be detrimental in 
environments where the host relies on its prophage(s) for beneficial traits, it might 
enhance the stability of a CRISPR-Cas system in environments where immunity to lytic 
infection conferred by its spacer(s) is sufficient for survival. In contrast, I found that the 
other CRISPR-Cas systems with perfectly matching spacers eventually succumbed to 
genetic inactivation (data not shown). Finally, the prophage-curing phenomenon could 
also promote the stability of a CRISPR-Cas system by preventing the accumulation of 
target prophages, which—as I’ve demonstrated (Figures 3-11E & 3-14D)—may further 
jeopardize host fitness. 
Importantly, costs were found to be reduced in the presence of sufficient spacer-
target mismatching, and in certain cases even when the mismatching did not abrogate 
immunity during the lytic cycle (Figures 3-3, 3-5A, 3-5B & 3-14). For these reasons, I 
speculate that conditionally tolerant lysogens harboring mismatched spacers could be 
generally more stable in natural populations than those with perfectly matched spacers. 
In line with this possibility, a putative conditionally tolerant isolate of S. aureus was 
recently identified, and it contains mismatches in each prophage target relative to a 
spacer in its type III-A CRISPR-Cas system (Cao et al., 2016). Type III-A systems have 
also been found to display signatures of horizontal acquisition within S. aureus genomes 
(Cao et al., 2016; Golding et al., 2010; Kinnevey et al., 2013). Hence, I further speculate 
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that the genetic stability afforded by conditional tolerance, and by extension spacer-
target mismatches, could facilitate horizontal dissemination of prophage-targeting type 
III-A systems throughout natural lysogenic populations. Currently, it is unclear to me 
why the type III-A CRISPR-Cas plasmids employed in this work do not undergo 
detectable CRISPR adaptation, despite various conditions tested by me and other 
members of the lab (data not shown). Once rectified, investigation of type III-A CRISPR 
adaptation could be useful in clarifying the extent to which spacer diversity and 
incomplete prophage tolerance influence the stability of these systems in temperate-
phage-infected populations at large. 
Lastly, it should be emphasized that additional phenotypic consequences of 
conditional tolerance, or of incomplete tolerance, have not been ruled out. For example, 
it was previously found that low-grade chromosomal targeting by a type I CRISPR-Cas 
system, made possible by certain spacer-target mismatches, is sufficient to trigger a 
host-controlled response in Pseudomonas aeruginosa PA14 which prevents biofilm 
formation without an overt growth defect (Heussler et al., 2015). This phenotype was 
originally identified using a lysogenic derivative where the target was chromosomally 
integrated via a prophage, although these mismatches also abolished immunity during 
lytic infections (Cady et al., 2012; Cady et al., 2011). It remains to be seen whether 
immunopathological ‘costs’ associated with type III-A systems in lysogenic hosts could 
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be similarly exploited to provide a phenotype in certain environments, without 
necessarily compromising resistance to lytic infections. 
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3.7  Tables associated with Chapter 3 
Table 3-1. Selection coefficients determined in fitness assays. 
Prophage(s) Spacer(a) Figure Mean s(b) s.d.(c) Median s 
ɸNM1 gp32* 3-3B 0.1088 0.0561 (n = 3) 0.1162 
ɸNM1 gp32 [5 mm] 3-3C 0.0522 0.0476 (n = 3) 0.0530 
ɸNM1 gp5 3-4B 0.1036 0.0394 (n = 6) 0.1062 
ɸNM1 gp16 3-4C 0.0822 0.0663 (n = 6) 0.0680 
ɸNM1 gp43 3-4D 0.0327 0.0283 (n = 6) 0.0192 
ɸNM1 Parent vector 3-4E 0.0077 0.0344 (n = 6) 0.0005 
ɸNM1Pcro- gp5 3-4G 0.0137 0.0256 (n = 6) 0.0168 
ɸNM1Pcro- gp16 3-4H 0.0531 0.0098 (n = 6) 0.0557 
ɸNM1Pcro- gp43 3-4I 0.0334 0.0262 (n = 6) 0.0373 
ɸNM1ind- gp16 3-5F 0.1029 0.0498 (n = 6) 0.0981 
ɸNM1ind- gp43 3-5G 0.0356 0.0118 (n = 6) 0.0335 
ɸNM1Pcro- gp32* 3-7B 0.1449 0.0644 (n = 3) 0.1117 
ɸNM1Pcro- gp32* 3-7B 0.1051 0.0682 (n = 6) 0.1078 
ɸNM1 gp8 3-9B 0.0045 0.0074 (n = 6) 0.0047 
ɸNM1 gp16 (csm3) 3-10D 0.0745 0.0504 (n = 6) 0.0844 
ɸNM1 gp16 (cas10HD) 3-10E 0.0667 0.0166 (n = 6) 0.0681 
ɸNM1 gp16 (cas10DD) 3-10F 0.0055 0.0170 (n = 6) 0.0083 
ɸNM1 gp16 (csm6) 3-10G 0.0113 0.0177 (n = 6) 0.0088 
ɸNM1 gp16 (csm3/csm6) 3-10H 0.0258 0.0189 (n = 6) 0.0233 
ɸNM4+ɸNM1 gp5 3-11E 0.1059 0.0441 (n = 3) 0.1288 
ɸNM4+ɸNM1 gp16 3-11E 0.3341 0.0775 (n = 3) 0.3396 
ɸNM4+ɸNM1 gp43 3-11E 0.0581 0.0528 (n = 3) 0.0300 
ɸNM4 gp16 3-12A -0.0030 0.0262 (n = 6) 0.0045 
ɸNM4 gp16 3-12B 0.0868 0.0209 (n = 6) 0.0919 
ɸNM1 gp16 3-14C 0.1080 0.0404 (n = 3) 0.1076 
ɸNM1 gp16 [2 mm] 3-14C 0.0722 0.0320 (n = 3) 0.0689 
ɸNM1 gp16 [4 mm] 3-14C 0.0115 0.0474 (n = 3) 0.0198 
ɸNM1 gp16 [6 mm] 3-14C 0.0268 0.0163 (n = 3) 0.0210 
ɸNM1 gp16 [8 mm] 3-14C -0.0191 0.0355 (n = 3) -0.0133 
ɸNM1 gp16 [10 mm] 3-14C 0.0002 0.0111 (n = 3) 0.0003 
ɸNM1 gp16 [12 mm] 3-14C 0.0038 0.0147 (n = 3) 0.0110 
ɸNM1 gp16 [14 mm] 3-14C -0.0206 0.0393 (n = 3) -0.0122 
ɸNM1 gp16 [16 mm] 3-14C 0.0056 0.0139 (n = 3) 0.0115 
ɸNM4+ɸNM1 gp16 3-14D 0.2155 0.0780 (n = 3) 0.1902 
ɸNM4+ɸNM1 gp16 [2 mm] 3-14D 0.2090 0.0289 (n = 3) 0.1949 
ɸNM4+ɸNM1 gp16 [4 mm] 3-14D 0.0812 0.0224 (n = 3) 0.0939 
ɸNM4+ɸNM1 gp16 [6 mm] 3-14D 0.0494 0.0238 (n = 3) 0.0604 
ɸNM4+ɸNM1 gp16 [8 mm] 3-14D -0.0192 0.0201 (n = 3) -0.0098 
ɸNM4+ɸNM1 gp16 [10 mm] 3-14D -0.0089 0.0043 (n = 3) -0.0090 
ɸNM4+ɸNM1 gp16 [12 mm] 3-14D 0.0201 0.0604 (n = 3) -0.0051 
ɸNM4+ɸNM1 gp16 [14 mm] 3-14D -0.0212 0.0216 (n = 3) -0.0181 
ɸNM4+ɸNM1 gp16 [16 mm] 3-14D -0.0145 0.0139 (n = 3) -0.0117 
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(b) Selection coefficients, ‘s’, determined from the change or average change (where 
available) in relative frequency after each transfer interval in fitness assays. 
Values were extracted from the equation, dq/dt = –q(1 – q)s, where q is the relative 
frequency of the spacer being assayed, and t = 9.97 generations is assumed for 
1:1000 dilutions at each transfer interval. Positive selection coefficients (s > 0) 
suggest that the spacer is associated with a fitness cost. 
(c) Standard deviation. 
(a) For spacers possessing mismatches relative to their prophage target, the number 
of mismatches (mm) is written in brackets. For spacers present in CRISPR-Cas 
plasmids with one or more mutant cas genes, the mutated gene is written in 
parentheses.  
Table 3-1. Selection coefficients determined in fitness assays (continued). 
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Table 3-2. Sequences of putative ɸNM1 promoter elements depicted in Figure 3-6. 
Promoter(a) Sequence (5’-3’)(b) 
Pcro AAAATAATTACGAAAAATACTTGCAATCGTATTCTAATTACGATATACTTTGATCAGAACTTAA 
Pssb(1) AGTCACGATCTAAAAGATATTTAACTGTATTCAAAATTTTCATATCTTGTTGAGCTTTTAAGC 
Pssb(2) TTTCCAAGAAAAACAATTGATTGAATTAGTTACTCGATTAGGTATTAAGTTAAATCTTCCTAG 
Prep TTAAATTGTTCTTTGAATTTTTCAAATTCTACTTCTCTTTGATAAATAACTTTATCCACATAA 
Pdut ACCAACAAGCAATTGTTATAGTGATAGACATAGCTTACAACTTATATTCTATCGACCAACTCA 
PterS TGACAGTAAAATGACAGTTTTTGACACCTATAACGAGGTATTATGATAGCGTAAGATATTGA
Pportal GAAAAAGAAGTTATACATCATTGAAGAGTATGTTAAACAAGGTATGCTGAATGATGAAATAGC 
Pcapsid ACAGCGTAAGGTCGGCAGTATTAGCCGATAAAGAAAAATCGAAATATAATGAACCTCTCTTTTAA 
(a) Promoters are named after the nearest encompassing or downstream ORF with a 
known or predicted function, according to the ɸNM1 annotation (Accession: 
NC_008583.1).  
(b) Candidates were selected from among prokaryotic promoters predicted using a 
neural network promoter prediction (Reese, 2001) tool available online at: 
http://www.fruitfly.org/seq_tools/promoter.html. Published E. coli promoter 
consensuses (Shimada et al., 2014; Shultzaberger et al., 2007) were consulted for 
additional reference to manually curate the initial hits. Putative -35 and -10 
elements are underlined. A putative operator binding site palindrome is 
italicized in the Pcro promoter. Putative RinA-interacting direct repeat elements 
(Ferrer et al., 2011; Quiles-Puchalt et al., 2013) adjacent to the PterS promoter are 
bold-faced. 
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Table 3-3. Spacers tested in Chapter 3. 
Spacer(a) Sequence (5’-3’)(b) Plasmid Name 
Parent vector TGAGACCAGTCTCGGAAGCTCAAAGGTCTC pGG79 
gp5 ATGTCTTAGCAATTCTAAAAGCATCTCTAGGTTTA pGG126 
gp8 TTGCCAGGTTCACTACGTTGAATCATTGCAATCTC pGG124 
gp16 TAGAACAGTCGCGCAGACTGATTTCTTCATAACCT pGG102 
gp32 [5 mm] TTAAATCTTTGATTGCTCTTAGCTCTAGTTATGTAT pGG122 
gp32* GTAAACCTTTGATTGCTCTTAGCTCGAGTTATGTGC pGG100 
gp43ori ATTCGTCATCTTCAAGTAATGCCTCTAAATCAATAA pGG104 
gp43 ATTCGTCATCTTCAAGTAATGCCTCTAAATCAATA pGG165 
gp16 [35 mm] GCTCCACTGATATACTCAGTCGGGAGGACGCCAAG pGG153 
gp16 [2 mm] TCGAACAGTCGCGCAGACTGATTTCTTCATAACAT pGG154 
gp16 [4 mm] TCGCACAGTCGCGCAGACTGATTTCTTCATACCAT pGG155 
gp16 [6 mm] TCGCAAAGTCGCGCAGACTGATTTCTTCAGACCAT pGG156 
gp16 [8 mm] TCGCAAATTCGCGCAGACTGATTTCTTAAGACCAT pGG157 
gp16 [10 mm] TCGCAAATTAGCGCAGACTGATTTCGTAAGACCAT pGG158 
gp16 [12 mm] TCGCAAATTAGAGCAGACTGATTGCGTAAGACCAT pGG160 
gp16 [14 mm] TCGCAAATTAGAGAAGACTGAGTGCGTAAGACCAT pGG161 
gp16 [16 mm] TCGCAAATTAGAGAATACTTAGTGCGTAAGACCAT pGG162 
(a) ‘gp’ numbers correspond to open reading frames with a matching target 
sequence in ɸNM1 (Accession: NC_008583.1). Mismatched variants are also 
listed, with the number of mismatches (mm) denoted within brackets. Each 
spacer is located between repeats 2 and 3 of the CRISPR array. A placeholder 
sequence with two opposing BsaI restriction sites is present at this position in the 
parent vector. 
(b) In order to avoid excessive matching between the 5’ crRNA tag and the target’s 
corresponding flanking sequence, which has been shown to abrogate DNA 
targeting by the type III-A system (Marraffini and Sontheimer, 2010b; Samai et 
al., 2015), spacer-target combinations were selected such that no more than 1 bp 
of complementarity was present at flanking sequences in each case.  
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Table 3-4. Oligonucleotides used in Chapter 3. 
Name Sequence Primary Purpose 
oGG281 GTATCGATCGAGACCTTTGAGCTTCCGAGAC Construction of pGG79 control/parent vector 
oGG282 CCACCCCGAAGAAAAGGGGACGAGAACTAAATCTAACAACACTCTAAAAAATTG Construction of pGG79 control/parent vector 
oGG330 GAACGTAAACCTTTGATTGCTCTTAGCTCGAGTTATGTGCG Construction of pGG100 
oGG331 CGATCGCACATAACTCGAGCTAAGAGCAATCAAAGGTTTAC Construction of pGG100 
oGG332 GAACTAGAACAGTCGCGCAGACTGATTTCTTCATAACCTG Construction of pGG102 
oGG333 CGATCAGGTTATGAAGAAATCAGTCTGCGCGACTGTTCTA Construction of pGG102 
oGG334 GAACATTCGTCATCTTCAAGTAATGCCTCTAAATCAATAAG Construction of pGG104 
oGG335 CGATCTTATTGATTTAGAGGCATTACTTGAAGATGACGAAT Construction of pGG104 
oGG351 GAACCAGGTGCAGTTACACCAATCATCAAACCTTTACCAAG Construction of pGG115 
oGG352 CGATCTTGGTAAAGGTTTGATGATTGGTGTAACTGCACCTG Construction of pGG115 
oGG385 GAACTTAAATCTTTGATTGCTCTTAGCTCTAGTTATGTATG Construction of pGG122 
oGG386 CGATCATACATAACTAGAGCTAAGAGCAATCAAAGATTTAA Construction of pGG122 
oGG393 GAACTTGCCAGGTTCACTACGTTGAATCATTGCAATCTCG Construction of pGG124 
oGG394 CGATCGAGATTGCAATGATTCAACGTAGTGAACCTGGCAA Construction of pGG124 
oGG397 GAACATGTCTTAGCAATTCTAAAAGCATCTCTAGGTTTAG Construction of pGG126 
oGG398 CGATCTAAACCTAGAGATGCTTTTAGAATTGCTAAGACAT Construction of pGG126 
oGG435 GAACGCTCCACTGATATACTCAGTCGGGAGGACGCCAAGG Construction of pGG153 
oGG436 CGATCCTTGGCGTCCTCCCGACTGAGTATATCAGTGGAGC Construction of pGG153 
oGG437 GAACTCGAACAGTCGCGCAGACTGATTTCTTCATAACATG Construction of pGG154 
oGG438 CGATCATGTTATGAAGAAATCAGTCTGCGCGACTGTTCGA Construction of pGG154 
oGG439 GAACTCGCACAGTCGCGCAGACTGATTTCTTCATACCATG Construction of pGG155 
oGG440 CGATCATGGTATGAAGAAATCAGTCTGCGCGACTGTGCGA Construction of pGG155 
oGG441 GAACTCGCAAAGTCGCGCAGACTGATTTCTTCAGACCATG Construction of pGG156 
oGG442 CGATCATGGTCTGAAGAAATCAGTCTGCGCGACTTTGCGA Construction of pGG156 
oGG443 GAACTCGCAAATTCGCGCAGACTGATTTCTTAAGACCATG Construction of pGG157 
oGG444 CGATCATGGTCTTAAGAAATCAGTCTGCGCGAATTTGCGA Construction of pGG157 
oGG445 GAACTCGCAAATTAGCGCAGACTGATTTCGTAAGACCATG Construction of pGG158 
oGG446 CGATCATGGTCTTACGAAATCAGTCTGCGCTAATTTGCGA Construction of pGG158 
oGG447 GAACTCGCAAATTAGAGCAGACTGATTGCGTAAGACCATG Construction of pGG160 
oGG448 CGATCATGGTCTTACGCAATCAGTCTGCTCTAATTTGCGA Construction of pGG160 
oGG449 GAACTCGCAAATTAGAGAAGACTGAGTGCGTAAGACCATG Construction of pGG161 
oGG450 CGATCATGGTCTTACGCACTCAGTCTTCTCTAATTTGCGA Construction of pGG161 
oGG451 GAACTCGCAAATTAGAGAATACTTAGTGCGTAAGACCATG Construction of pGG162 
oGG452 CGATCATGGTCTTACGCACTAAGTATTCTCTAATTTGCGA Construction of pGG162 
oGG461 GAACATTCGTCATCTTCAAGTAATGCCTCTAAATCAATAG Construction of pGG165 
oGG462 CGATCTATTGATTTAGAGGCATTACTTGAAGATGACGAAT Construction of pGG165 
oGG320 GAACGTTTTGGTCGTAGAGCACACGGTTTAACGACTTAAG Construction of pGG91 
oGG321 CGATCTTAAGTCGTTAAACCGTGTGCTCTACGACCAAAAC Construction of pGG91 
oGG432 GAACCCAGTTGCACCACATGCAATATACGATACTAGTTTG Construction of pGG152 
oGG433 CGATCAAACTAGTATCGTATATTGCATGTGGTGCAACTGG Construction of pGG152 
L6 AAAGGTACCAAATTTAATGCTATTTTCCTTCGC Type III CRISPR array sequence verification 
L50 AAAAGATCTAATAATGTATTTACGCTGGGGC Type III CRISPR array sequence verification 
PS153 GGTAAATCAAAACTAACTAACAAATACATTAGTTTCCCACCTCTATCATC Construction of pPS95 
PS154 GATGATAGAGGTGGGAAACTAATGTATTTGTTAGTTAGTTTTGATTTACC Construction of pPS95 
PS465 GAATCTAGTATGATTGGAGCAATTGCTTCTCCTGTAGTTAGAGATTTGCAAACC Construction of pPS95 
PS466 GGTTTGCAAATCTCTAACTACAGGAGAAGCAATTGCTCCAATCATACTAGATTC Construction of pPS95 
W852 CCAACAAACGACTTTTAGTATAACC Construction of other mutant type III plasmids 
W614 GGTTATACTAAAAGTCGTTTGTTGG Construction of other mutant type III plasmids 
PS565 GTTAGAGTATTATATTTATCAAATAAGGGAG Construction of pGG99 and pGG89 
PS566 CTCCCTTATTTGATAAATATAATACTCTAAC Construction of pGG99 and pGG89 
oGG457 GAGCACAAATTAAGTATTAAAGAAG Construction of pGG167 
oGG458 CTTCTTTAATACTTAATTTGTGCTC Construction of pGG167 
oGG424 CATATTGCCTGATGAAGTGAATAG Construction of pGG139 
oGG425 CTATTCACTTCATCAGGCAATATG Construction of pGG139 
oGG270 TAAAATGTGGTTTGACAAACGAAAATTGGATAAAGTGGG Additional type III plasmid sequencing 
L36 AAAGGTACCTTATTACTACCTAAGATGATAGAGG Additional type III plasmid sequencing 
W14 ATCAATTTTTGTCCCAATTTTCAG Additional type III plasmid sequencing 
W15 CAAATTACTGCTATATATTCAGGC Additional type III plasmid sequencing 
W16 TTAAATTTTATTATGAAGCAGGACG Additional type III plasmid sequencing 
W19 CTACTTTAATAATTGAAAAAGATGG Additional type III plasmid sequencing 
PS566 CTCCCTTATTTGATAAATATAATACTCTAAC Additional type III plasmid sequencing 
W125 ATTTAGCGTCTATAGTAAAGGTG Construction of pAV71 
PS557 CCATGCACCGATTAAAAATAAAGCGGCACCGCCTGAATATATAGCAG Construction of pAV71 
PS556 CTGCTATATATTCAGGCGGTGCCGCTTTATTTTTAATCGGTGCATGG Construction of pAV71 
W762 CAAATCACCTTTACTATAGACGC Construction of pAV71 
W1169 CCGATTAAAAATAAAGCTGCACCGCCTGAATATATAGCAGTAATTTG Construction of pWJ291 
W1170 TATTCAGGCGGTGCAGCTTTATTTTTAATCGGTGCATGGGATG Construction of pWJ291 
JW398 GAACGTCTCATAATTTGAAATAGTAGCTTTTTTAGTGTT Construction of JW233’s type III plasmid 
JW399 TTTAAACACTAAAAAAGCTACTATTTCAAATTATGAGAC Construction of JW233’s type III plasmid 
JW443 CTTTAGGTAACTCATAAGTGAATGGTTG Sequencing of the ɸ11γ2 deletion 
JW444 GCCACTCTGTTAAATCAGTAACTTTG Sequencing of the ɸ11γ2 deletion 
oGG387 GTGTTGAACTTGAACAAAGTCAC Sequencing of the ɸ11γ2β1 deletion 
oGG388 TCATCAACTTTTATCCACGAGTC Sequencing of the ɸ11γ2β1 deletion 
AV205 ATACAAAACCACATACCTATCAACGTGATGAGCTTATTGGGG Construction of pAV43  
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AV202 GAAGTATATAAATCATCAGTACAAAGGTTTACGTCCTGTTGAATCTTTG Construction of pAV43 
AV203 GATGATTTATATACTTCGGCATACGTAGTCGTTGAGGCAGAGAGTA Construction of pAV43 
AV185 CTGTTATGTGGTTATCGATTCCTAGCTTGTATGTCTGCGC Construction of pAV43 
AV186 AATCGATAACCACATAACAGTCATAAAAC Construction of pAV43 
AV204 ATAGGTATGTGGTTTTGTATTGGAAT Construction of pAV43 
oGG38 AAGATAAAGAATTTGCTCAAGACG ɸNM4γ4α2 sequence verification 
oGG40 ACCATTAAAACTCGTCATTCTTTC ɸNM4γ4α2 sequence verification 
oGG297 GCAAAATTCATATAAACAAATTAAAGAGGGTTATAATGAACG Construction of pE194-tyc1 
oGG298 CCCTCTTTAATTTGTTTATATGAATTTTGCTTATTAACGATTC Construction of pE194-tyc1 
oGG315 AGTGATCGTTAAATTTTAATCAAATATGTTCATAGCTTGATG Construction of pGG90 
oGG316 CGCATCCGATTGCAGCGATGCAGGTCTTTCTGTTGGC Construction of pGG90 
oGG314 AACATATTTGATTAAAATTTAACGATCACTCATCATGTTC Construction of pGG90 
oGG317 GAAAGACCTGCATCGCTGCAATCGGATGCGATTATTG Construction of pGG90 
oGG192 TCTACTTAATCTGATAAGTGAGC ɸNM1-ErmR2 sequence verification 
oGG191 GAAGCTTTAGCTTTGCAGTGG ɸNM1-ErmR2 sequence verification 
W277 CTGTAATAGACATCGTTCGCAG TB4::ɸ11 attL junction verification 
oGG342 CATCTTAAAGGAGACATAACAAATG ɸ11-specific amplification 
oGG343 CCAGCTCTCGCTCACATCTG ɸ11-specific amplification 
oGG338 CTTGTTCAAATTACTTTCGTCTG Multiplex PCR for SaPI1tst::tetM 
oGG339 CTTAAAATTATTCGTTGATGCAGG Multiplex PCR for SaPI1tst::tetM 
oGG340 CCTTGAACTTCCTTGATAATCTG Multiplex PCR for SaPI1tst::tetM 
oGG341 ATTCTCACGTTACTGAACAGATG Multiplex PCR for SaPI1tst::tetM 
oGG6 TACCCTAGTTAACGTCTCTTG ɸNM1 prophage genotyping 
oGG7 GATATCAACTTGTAGTGCATCG ɸNM1 prophage genotyping 
oGG10 GCTGACTTACAAGAAGGTGGAC ɸNM4 prophage genotyping 
oGG11 GTTGTAATTGGATTAAATTCAGTC ɸNM4 prophage genotyping 
JW809 GTTGTACAAGGGTTACAATTCTTAATGC Construction of pGG170 and pGG172 
JW810 CCATCTTCATCAGCTGACATTAGAG Construction of pGG170 and pGG172 
oGG467 AATAACTCTAATGTCAGCTGATGAAGATGGGTTTACGACCGTTAAAAGCAAATG Construction of pGG170 
oGG468 AGTTCTGATCAACGTACATCGTAATTAGAATACGATTGCAAG Construction of pGG170 
oGG469 TTCTAATTACGATGTACGTTGATCAGAACTTAACAAGGAGG Construction of pGG170 
oGG470 TTGCATTAAGAATTGTAACCCTTGTACAACGAAAACCCTTTAACTTTTGATGTTG Construction of pGG170 
oGG471 AATAACTCTAATGTCAGCTGATGAAGATGGTTCAACTACATATTTGTAGCCTTC Construction of pGG172 
oGG472 AATAAACGGAGATGCCATGAATAAAATACTCGCTAACGGTTC Construction of pGG172 
oGG473 GTATTTTATTCATGGCATCTCCGTTTATTTTTAGTGCTATAC Construction of pGG172 
oGG474 TTGCATTAAGAATTGTAACCCTTGTACAACGCTTTCAAAAATTCCATAAAAGAAATC Construction of pGG172 
W1250 TTCAAAGAGTTGGTAGCTCAGAG pGG170/pGG172 homology arm sequencing 
oGG455 CATACCCATTCTAGGTTCAGTTC pGG170 homology arm sequencing 
W1245 GACAAAAATCACCTTGCGCTAATGCTCTGTTACAGCTGTTAGATTATGAAAGCCGATG Sequencing of the repA(ts) region 
W354 GTTTTTCAAAATCTGCGGTTGCG Sequencing of the repA(ts) region 
B266 TGGAATAATAGTAATATTATACAAAATGGA Sequencing of the repA(ts) region 
W653 ATTTACCGCTATCTTTACAGGTAC Sequencing of the repA(ts) region 
oGG509 TGGAAAGAAAAATTAGAGAGTTTGGGCGTATCTATGGC Construction of pGG170ts and pGG172ts 
oGG510 TACGCCCAAACTCTCTAATTTTTCTTTCCAATCATTAGGAATTG Construction of pGG170ts and pGG172ts 
oGG32 GTATTTTAAGGGTTGCAATTACG Verification of pGG172ts integrants 
oGG33 GTATCTGTTTTCAACTACATATTTG Sequencing of GWG7 
oGG475 AATAACTCTAATGTCAGCTGATGAAGATGGCGTAGTAAATAGATGTGTAATAAATG Sequencing of GWG9 
oGG31 TACCATCAACAGTTAAAGACAATG Verification of ɸNM1ind- escaper plaques 
Table 3-4. Oligonucleotides used in Chapter 3 (continued). 
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3.8  Materials and methods used in Chapter 3 
Bacterial strains and growth conditions. 
Unless otherwise noted, cultivation of RN4220 (Nair et al., 2011) or TB4 (Bae et al., 2006) 
and their derivatives was carried out in sterile 15 or 50 ml conical-bottom Falcon tubes 
(Corning) containing DifcoTM TSB liquid media from BD (volume ≤ 14% tube capacity), 
or on sterile petri dish plates containing DifcoTM TSA solid media from BD. Media was 
supplemented with erythromycin (Erm) at 10 μg/ml or tetracycline (Tet) at 5 μg/ml only 
when streaking out single colonies of marked TB4 lysogens containing pE194 
(Horinouchi and Weisblum, 1982b) or pT181 (Khan and Novick, 1983) plasmids, 
respectively, and during the construction of these strains as needed. When cultivating 
TetR strains that harbor the SaPI1tst::tetM element in their chromosome, media was 
supplemented with tetracycline at 2.5 μg/ml instead of 5 μg/ml. All media was 
supplemented with chloramphenicol (Cm) at 10 μg/ml when cultivating strains with 
CRISPR-Cas plasmids. Unless otherwise noted, plates were incubated at 37 °C for 12-18 
hours and then stored at 4 °C for up to a week. Overnight liquid cultures were 
inoculated from single colonies (biological replicates), grown for 12-16 hours at 37 °C 
with shaking, and then stored at 4 °C for 3 hours or less before briefly vortexing and 
subculturing at a 1:100 dilution as needed. Where applicable, subcultures were treated 
with Mitomycin C (AG Scientific) to a final concentration of either 0.5, 1.0, or 2.0 μg/ml, 
as indicated in the figure legends. When the overnight cultures were to be used in 
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competition experiments, 24 hours of growth was instead allowed, followed by 
immediate vortexing, mixing of aliquots, and passaging at a 1:1000 dilution. When 
streaking out lysogens with targeting spacers, aberrantly large colonies were presumed 
to have lost conditional tolerance either via genetic inactivation of CRISPR-Cas 
plasmids or prophage deletion, and not studied further in this work. 
DNA preparation and cloning. 
Plasmid DNA of E. coli DH5α was purified from 4-6 ml overnight cultures using 
plasmid miniprep reagents from Qiagen, according to the manufacturer’s protocol. 
DNA from S. aureus RN4220 or TB4 was purified similarly except that 2 ml overnight 
cultures were used, and cells were treated with 10-15 μl lysostaphin (1 mg ml-1) at 37 °C 
for 1.5 h immediately after resuspension in P1 buffer. Minipreps were carried out with 
either Qiagen or EconoSpin columns. For PCR-based cloning procedures, DNA was 
amplified with Phusion polymerase (Thermo) and purified using Qiagen reagents and 
EconoSpin columns. When generating amplicons for Sanger sequencing, TopTaq 
polymerase (Qiagen) was often used for amplicons smaller than 750 bp, and DNA was 
not necessarily purified after the PCRs. 
Electrocompetent RN4220 cells (described previously, (Goldberg et al., 2014)) 
were used for cloning in S. aureus. The pGG79 parent vector is a derivative of pGG3-
BsaI, (Goldberg et al., 2014) with the BsaI placeholder sequence at position two trimmed 
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at its 3’ end by one base pair, and a CRISPR repeat inserted immediately downstream. 
This was accomplished by ‘round-the-horn PCR (Moore and Prevelige, 2002) using 
primers oGG281/oGG282, followed by blunt ligation. The pGG78 plasmid was 
constructed similarly, except that the pGG-BsaI plasmid was used in place of pGG3-
BsaI to template the PCR. Their CRISPR arrays were sequenced by Sanger as described 
previously (Goldberg et al., 2014), and expected plasmid sizes were verified via 
analytical digestion during subsequent manipulations. The immune functionality of 
pGG79 in S. aureus was later also confirmed by resistance to infection with ɸNM4γ4α2, 
a derivative of ɸNM4γ4 (Heler et al., 2015) possessing a target for the nes spacer in 
position 1 of its CRISPR array. Except where noted, all other CRISPR-Cas plasmids with 
wild type cas genes were constructed via scarless insertion of spacers between CRISPR 
repeats 2 and 3 of the parent vector, pGG79. This was accomplished by restriction 
digesting the two oppositely oriented BsaI sites and then ligating them with an 
annealed oligonucleotide pair possessing compatible overhangs and the desired spacer 
sequence (see Supplementary Table 3). CRISPR array modifications were then verified 
again as described previously (Goldberg et al., 2014). CRISPR-Cas plasmids with the 
gp16 spacer and one or more cas gene mutations were also constructed by the annealed 
oligo cloning method in most cases, and checked similarly, except that mutant BsaI 
parent vectors were used as backbones for insertion of the spacer. The csm3* (D32A) 
mutant vector, pPS95, was constructed via 2-piece Gibson assembly of PCR products 
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(Gibson et al., 2009) amplified from pGG79 using primers PS153/PS465 and 
PS154/PS466. The csm6* (R364A,H369A) mutant vector, pGG99, as well as the 
csm3*/csm6* double mutant vector, pGG89, were also constructed via 2-piece Gibson. 
For pGG99, the fragment containing the CRISPR array was amplified from pGG79 
using primers W852/PS566, while the rest of the backbone including the csm6* 
mutations was amplified from pWJ241 (Jiang et al., 2016) using primers PS565/W614. 
The same was done for pGG89, except that pWJ242 (Jiang et al., 2016) was used for 
templating the backbone with both csm3* and csm6* mutations. To construct the 
pGG164 cas10HD (H14A,D15A) HD domain mutant plasmid harboring the gp16 spacer, 
2-piece Gibson was performed with a CRISPR-containing fragment amplified from 
pGG141 using primers W852/oGG458, and a backbone fragment amplified from pGG79 
using primers oGG457/W614. The pGG167 cas10DD (D586A,D587A) palm domain 
mutant plasmid harboring the gp16 spacer was constructed similarly, except that the 
CRISPR-containing fragment was amplified from pGG102, and the backbone fragment 
was amplified from pGG139. The pGG139 BsaI parent vector contains cas10 mutations 
in both the HD (H14A,D15A) and palm polymerase (D586A,D587A) domains, and was 
itself constructed via 2-piece Gibson of a fragment amplified from pGG79 with 
W852/oGG425 and a fragment amplified from pAV71 using primers oGG424/W614. 
Following Gibson assembly of these vectors, the expected plasmid size was confirmed 
by restriction digest, and regions of interest were sequenced by Sanger using primers 
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listed in Supplementary Table 3 (Gibson assembly junctions, CRISPR arrays, and in 
select cases the relevant cas nuclease active sites). The pAV71 vector was constructed via 
2-piece Gibson of a fragment containing the HD domain mutation amplified from 
pLM546 (Hatoum-Aslan et al., 2014) with W125/PS557, and a fragment containing the 
palm domain mutation amplified from pWJ291 with PS556/W762. The pWJ291 vector 
was constructed via 2-piece Gibson of fragments amplified from pWJ30β (Goldberg et 
al., 2014) using primer pairs W852/W1169 and W1170/W614. In turn, the pGG141 
plasmid was constructed by inserting the gp16 spacer into the pGG139 vector via the 
oligo cloning method described above. JW233 is a derivative of RN4220 with a type III 
CRISPR-Cas plasmid that targets ɸ11’s cI-like repressor gene. This plasmid was 
constructed from pGG3-BsaI according to the annealed oligo cloning procedure 
described previously (Goldberg et al., 2014), using oligos JW398 and JW399 for insertion 
of the spacer. The pAV43 plasmid was constructed by 3-piece Gibson assembly of two 
homology fragments amplified from ɸNM4γ4 (AV205/AV202 and AV203/AV185), 
along with a backbone fragment amplified from pC194 (AV186/AV204). The pE194-tyc1 
plasmid was constructed by 1-piece Gibson assembly of PCR products generated with 
primers oGG297/oGG298. The presence of an intact assembly junction, including the 5’ 
UTR SNP in ermC, was subsequently confirmed by Sanger sequencing with primers 
oGG191/W235. The pGG90 plasmid was constructed by 2-piece Gibson assembly of 
PCR products; its integrase homology fragment was amplified from ɸNM1 with 
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primers oGG315/oGG316, while its backbone fragment including ermC homology was 
amplified from pE194-tyc1 using primers oGG314/oGG317. Intact assembly junctions 
were verified by PCR and Sanger sequencing with primers W234/W235.  
 Chemically competent DH5α cells were used for cloning pWJ327-derived vectors 
in E. coli, each constructed via 3-piece Gibson assembly of PCR products. The pGG170 
plasmid contains homology to ɸNM1 with mutations in the Pcro promoter, while the 
pGG172 plasmid contains homology to ɸNM1 with mutations in its cI-like repressor. A 
backbone fragment was amplified from pWJ327 using primers JW809/JW810, while the 
homology arms were amplified from ɸNM1 using primer pairs oGG467/oGG468 and 
oGG469/oGG470 for pGG170, or oGG471-oGG472 and oGG473-oGG474 for pGG172. 
The expected size of the resulting plasmids was confirmed by restriction digest, and 
homology arm sequences were confirmed by Sanger using primers listed in 
Supplementary Table 3 (W1250, oGG455, and oGG469 or W1250, oGG471, and 
oGG473). Unexpectedly, the plasmids failed to transform RN4220. PCR and Sanger 
sequencing of the region encoding elements required for replication in S. aureus at 28 °C 
revealed a SNP within the temperature-sensitive repA gene, resulting in a premature 
stop codon. The SNP was corrected in each case to create “pGG170ts” or “pGG172ts” 
via 1-piece Gibson of PCR products amplified from pGG170 or pGG172 using primers 
oGG509/oGG510, followed by electroporation directly into RN4220 and plating at 28 °C.  
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Estimation of phage lysate titers.  
As needed, phage lysate titers were estimated according to the procedure described 
previously (Goldberg et al., 2014). 
 
Preparation of transducing lysates.  
Overnight culture aliquots (100 ul) of RN4220 or TB4 derivatives harboring a plasmid of 
interest were infected with ‘clear’ mutant (lytic) derivatives of either ɸNM1, ɸNM2, 
ɸNM4, or ɸ11 (MOI ~0.1-10) in HIA soft agar supplemented with CaCl2 at 5mM, and 
incubated overnight at 37 °C to produce a lysed lawn. Within 48 hours of storage at 4 
°C, soft agar was hydrated with 600 μl fresh HIB, scraped and decanted into a 50 ml 
conical-bottom Falcon tube, supplemented with an additional 600 μl fresh HIB, and 
then centrifuged at 4303g for 8-10 min. Filtered supernatants containing the phage and 
transducing particles were stored in autoclaved 1.5 ml tubes (Eppendorf) at 4 °C. When 
the plasmid of interest carried a CRISPR-Cas system, care was taken to lyse its host with 
a suitable non-targeted phage, among the following: ɸNM1γ6 (Goldberg et al., 2014), 
ɸNM2γ1, ɸNM1γ6α1, ɸNM4γ4 (Heler et al., 2015), or ɸ11γ2β1. Phages not described 
previously were procured via CRISPR-assisted editing as outlined below.  
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CRISPR-assisted editing of phages.  
Recombinant phages were isolated by using type III CRISPR-Cas plasmids to counter-
select against different target sequences, essentially as described for the isolation of 
CRISPR-escape mutant phages in Chapter 2. The ɸ11γ2β1 phage is a mutant of ɸ11γ2 
isolated during infection of lawns harboring the pGG102 plasmid (gp16). After an 
additional round of counter-selection with pGG102, the presence of a 357 bp deletion 
encompassing the target site was confirmed by PCR and Sanger sequencing with 
primers oGG387/oGG388. ɸ11γ2 is a clear mutant of ɸ11 that was isolated during 
infection of JW233 lawns harboring a type III plasmid targeting its cI-like repressor 
gene. Following plaque re-isolations, a 791 bp deletion was confirmed by PCR and 
Sanger sequencing with primers JW443/JW444. The ɸNM1γ6α1 phage is a mutant of 
ɸNM1γ6 that was similarly isolated while infecting lawns harboring the pGG100 
plasmid (gp32*), although the presence of a target site deletion was not confirmed after 
plaque re-isolations. ɸNM2γ1 is a clear mutant of ɸNM2 that was isolated during 
infection of lawns harboring the pGG152 type III plasmid targeting its cI-like repressor 
gene, although the presence of a target site deletion was not confirmed after plaque re-
isolations. The original two ɸNM2 γ-series escapers of spacer 2B described in Chapter 2 
were never analyzed for plaque phenotypes, and were ultimately discarded. For 
homology-directed editing of phages, we used a variation of phage editing methods 
described previously (Kiro et al., 2014; Martel and Moineau, 2014). Briefly, phages were 
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propagated on hosts containing homology plasmids for recombination with phage 
genomes, and the resultant lysates were used to infect soft agar lawns containing a 
suitable CRISPR-Cas plasmid that can counter-select against parental genotypes. 
Homologies were designed such that recombinant phages would lack a target sequence 
for the type III CRISPR-Cas plasmid used in counter-selection. The ɸNM4γ4α2 phage 
was created by replacing a 40 bp sequence containing the gp32 spacer’s partially 
matched target in ɸNM4γ4 with a perfectly matched target sequence for the nes spacer 
(Marraffini and Sontheimer, 2008). ɸNM4γ4 was first propagated on lawns of RN4220 
containing the homology plasmid, pAV43, and recombinants were subsequently 
selected during infection of lawns containing the pGG12 (Goldberg et al., 2014) CRISPR-
Cas plasmid. After an additional round of counter-selection with pGG12, a single 
ɸNM4γ4α2 plaque was isolated, and the presence of its recombinant target was 
confirmed by Sanger sequencing of PCR products generated with primers 
oGG38/oGG40. The ɸNM1-ErmR2 phage was constructed similarly by first propagating 
the ɸNM1-ErmR phage (Goldberg et al., 2014) on lawns containing the pGG90 homology 
plasmid, which includes the tyc-1 allele SNP in the 5’ UTR of ermC, and subsequently 
selecting for recombinants lacking a nearby 182 bp fragment that encompasses the 
target for the pGG91 CRISPR-Cas plasmid. The presence of the recombinant sequences 
in ɸNM1-ErmR2 was confirmed by PCR and Sanger sequencing with primers 
oGG192/oGG191.  
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Transduction.  
Subcultures were grown at 37 °C in TSB supplemented with CaCl2 at 5mM for 1 hour 25 
minutes (~0.5-1.0 attenuance, D600 nm), and 990 μl aliquots were subsequently mixed with 
10 μl of transducing lysate containing the plasmid or SaPI of interest in autoclaved 1.5 
ml tubes (Eppendorf). After 15 minutes of growth at 37 °C, infected cultures were 
treated with filter-sterilized sodium citrate to a final concentration of 40 mM, and then 
pelleted by centrifugation at 16100g for 2 min with refrigeration (4 °C). When 
transducing pE194, pT181, or SaPI1tst::tetM, an additional 1 hour 45 minutes of growth 
was allowed immediately after treatment with citrate and prior to centrifugation. 
Following centrifugation, fresh TSB supplemented with sodium citrate (40 mM) was 
used to resuspend and dilute pellets for plating on solid media supplemented with both 
sodium citrate at 20 mM and antibiotics to select for the transductants. To avoid 
residual free phage, an additional re-streak was performed on solid media in the 
presence of citrate (20 mM) and antibiotics to select for the strain’s plasmid(s).  
 
Streak-test (phage-sensitivity) assays. 
Throughout cloning and strain construction procedures, or as otherwise needed, clones 
were readily checked for sensitivity to a phage of interest according to the streak 
method previously performed with ɸNM2 (Goldberg et al., 2014), except that clear 
mutants described above were used in place of their parental temperate phages to 
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facilitate scoring, and chloramphenicol-supplemented TSA without added CaCl2 was 
usually used in place of HIA. 
 
Construction of lysogens and derivative strains.  
TB4::ɸNM1-ErmR2 and TB4::ɸ11 single lysogens were obtained by mixing 100 μl of a 
TB4 overnight culture with either ɸNM1-ErmR2 or ɸ11 (MOI ~0.1-10) in HIA soft agar 
supplemented with CaCl2 at 5mM, incubating overnight at 37 °C, and re-streaking from 
the resulting turbid lysate lawns. After an additional re-streak from single colonies 
(plates were supplemented with erythromycin in the case of TB4::ɸNM1-ErmR2), a clone 
was selected for each and saved. The TB4::ɸ11 single lysogen was verified further via 
PCR with primers oGG342 and oGG343 to amplify a specific internal sequence not 
present in my other phages, and also via PCR with primers oGG191 and W277 to 
amplify across its integrated attL junction. Other TB4::ɸNM1-ErmR2 single lysogens 
were obtained by lysogenizing TB4 derivatives harboring CRISPR-Cas plasmids via the 
erythromycin selection protocol for lysogenization described in another section below.  
TB4::ɸNM1 or TB4::ɸNM4 single lysogens were likewise obtained by mixing 100 μl of a 
TB4 overnight culture with either ɸNM1 or ɸNM4 (MOI ~0.1-10) in HIA soft agar 
supplemented with CaCl2 at 5mM, incubating overnight at 37 °C, and re-streaking from 
the resulting turbid lysate lawns. After an additional re-streak from single colonies, a 
clone was selected for each, and immunity groups were confirmed by assaying for 
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sensitivity to clear mutants (ɸNM1ɣ6 (Goldberg et al., 2014) or ɸNM4ɣ4 (Heler et al., 
2015)). Both clones were also typed via PCR using ɸNM1- or ɸNM4-specific primer 
pairs, oGG6/oGG7 or oGG10/oGG11, respectively. The TB4::ɸNM1+ɸNM4 double 
lysogen was constructed and typed similarly, except that an overnight culture of 
TB4::ɸNM4 was mixed with ɸNM1 in soft agar to produce the turbid lysate lawn. ɸNM1 
prophage mutants were constructed via CRISPR-assisted genome editing as outlined 
below. All plasmid-containing derivatives of TB4::ɸNM1, TB4::ɸNM4, or 
TB4::ɸNM1+ɸNM4 were subsequently generated via transduction. 
 
CRISPR-assisted genome editing of S. aureus.  
Homology-directed allelic exchange coupled with CRISPR-Cas counter selection was 
performed essentially as described previously for the pWJ327 allelic replacement 
system (Modell et al., 2017), with modifications. pWJ327-derived vectors containing 
homology to ɸNM1 and the prophage mutation of interest were used to transform 
electrocompetent RN4220 non-lysogens instead of RN4220::ɸ12, and a subsequent 
transduction step was used to transfer the plasmids from RN4220 to TB4::ɸNM1. 
Transduction was performed with ɸNM4γ4 as described above, except that transducing 
lysates were raised and injected at 28 °C, with 2 hours 30 minutes of growth allowed for 
the recipient subculture. After isolating putative co-integrants via two consecutive re-
streaks at 37 °C in the presence of chloramphenicol and verifying them with PCR using 
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primers W1250/oGG7 (pGG170ts) or W1250/oGG32 (pGG172ts), clones were inoculated 
overnight in plain media at 37 °C instead of 28 °C. Subcultures were grown at 28 °C in 
plain media supplemented with CaCl2 at 5mM to obtain logarithmic-phase cultures for 
treatment with the pWJ326 phagemid, but treated cultures were plated at 30 °C on 
media containing erythromycin after 3 hours of growth at 30 °C rather than 1 hour. An 
additional re-streak at 30 °C was performed in the presence of erythromycin before 
clones were checked by PCR and Sanger sequencing with primers oGG455/oGG470 
(pGG170ts) or oGG471/oGG474 (pGG172ts) for the presence of the desired mutation 
(ɸNM1Pcro or ɸNM1ind-, respectively). Clones which had also lost the integrated pWJ327 
amplicon (again determined by PCR with primers W1250/oGG7 or W1250/oGG32) were 
inoculated overnight in plain media but grown at 42 °C instead of 37 °C in order to cure 
the strain of pWJ326. Dilutions were plated on plain media at 37 °C, and single colonies 
were replica-plated at 37 °C on both plain and erythromycin-supplemented media to 
confirm plasmid loss. After re-streaking an erythromycin-sensitive clone on plain 
media, a PCR amplicon spanning the entire homology region was procured with 
primers oGG33/oGG7 (pGG170ts) or oGG475/oGG32 (pGG172ts), and sequenced by 
Sanger using additional primers listed in Supplementary Table 3. The clone was also re-
streaked on media supplemented with chloramphenicol as a final check for sensitivity 
to the antibiotic; and, checked for sensitivity to ɸNM1γ6 to ensure that lysogenic 
immunity had not been lost. The pGG170ts- and pGG172ts-derived strains were 
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renamed GWG7 and GWG9, respectively. TSB and TSA media were used in place of 
BHI throughout. The pWJ326 phagemid lysate used in this work was procured using 
the method described previously (Modell et al., 2017). 
 
Enumeration of plaque-forming units liberated from lysogenic cultures. 
‘Spontaneous’ particle release from single lysogens was measured essentially as 
described previously (Goldberg et al., 2014), except that filtered supernatants were 
collected immediately after 12 hours of growth overnight (or as otherwise noted in the 
figure legend). For quantification of particles released from MMC-induced cultures, 
overnight cultures were grown for 15 hours and subcultures were grown for 1 hour 15 
minutes (~0.3-0.6 attenuance, D600 nm) before treatment with MMC (or as otherwise noted 
in the figure legend). Following 4 hours of growth post-treatment, subcultures were 
pelleted by centrifugation at 4303g for 6 min, and filtered supernatants were collected 
for serial dilution and spotting on lawns of TB4 harboring the CRISPR-Cas parent 
vector. Where applicable, filtered supernatants derived from double lysogens were 
spotted in parallel on TB4::ɸNM4 and TB4::ɸNM1 lawns harboring the CRISPR-Cas 
parent vector in order to quantify the fraction of PFU derived from ɸNM1 or ɸNM4, 
respectively. 
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Plate reader high-resolution growth curves.  
Biological replicates were subcultured as described above, except that 200ul culture 
volumes were used in 96-well microplates, and incubation at 37 °C with shaking was 
performed with an Infinite M200 PRO plate reader (TECAN) measuring attenuance 
(D600 nm) every 10 minutes. Following 70 minutes of growth, subcultures were treated 
with MMC to a final concentration of 2.0 μg/ml. For each biological replicate, an 
additional subculture was performed in parallel to monitor growth in the absence of 
MMC treatment. 
 
Pairwise competition assays with marked lysogens.  
Aliquots of overnight cultures were mixed 1:1 by volume and then diluted for 
passaging and selective plating on tetracycline (5 μg/ml) and chloramphenicol or 
erythromycin (5 μg/ml) and chloramphenicol. Passaging and plating was repeated in 
this manner every 24 hours for 6 days, and relative frequencies were calculated at each 
interval as the number of TetR+CmR colony forming units (CFU) divided by the sum of 
ErmR+CmR CFU plus TetR+CmR CFU. 
 
Batch competition of unmarked lysogens for deep sequencing.  
Aliquots of overnight cultures were mixed in equal proportions by volume and then 
diluted for passaging as described above. The remaining culture (~2 ml) was pelleted by 
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centrifugation at 4303g for 6 min. Supernatants were discarded, and pellets were stored 
at -20 °C after drying for 10 min at benchtop. Passaging and storage of pellets was 
repeated in this manner every 24 hours for 3 days. 
 
Preparation of DNA for deep sequencing.  
Frozen pellets were thawed on ice for 20 minutes and then miniprepped as described 
above. 100 ng of miniprepped DNA from each sample was used as the template for 
barcoded PCRs to amplify a region of the CRISPR array that fully spans spacer position 
2, using forward and reverse primers with identical barcode pairs. Barcoded PCR 
products were gel purified and then pooled at roughly equal proportions by 
normalizing to the least-concentrated NanoDrop Spectrophotometer (Thermo) reading. 
Library preparation was subsequently carried out on the pooled sample using a TruSeq 
Nano DNA LT kit (Illumina). 
 
Deep sequencing and analysis.  
Single-read deep sequencing (321 cycles) was performed on an Illumina MiSeq 
essentially as described in the manufacturer’s protocol for low-complexity amplicon 
sequencing with the v3 reagent kit (~25% PhiX spike-in). Using a custom Python script, 
output files (.fastq) were parsed using the Biopython package for Python, and reads 
containing the expected sequences with 100% identity (either forward or reverse) were 
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tallied for each barcode set. Relative frequency datapoints are plotted as the number of 
reads containing a particular barcode and the perfect or partially matching spacer of 
interest divided by the sum of that count plus reads containing the fully mismatched 
spacer with the same barcode.  
 
Efficiency of plaquing.  
Assays were performed as described previously (Goldberg et al., 2014), except that the 
sensitive control lawns were prepared with a TB4 derivative harboring the pGG79 (non-
targeting) parent vector. 
 
Lysogenization with ermC(tyc-1)-marked ɸNM1.  
Lysogenization was performed essentially as described previously (Goldberg et al., 
2014), except that overnight cultures were always grown for 14 hours, TSB broth was 
used in place of HIB, multiplicity of infection was ~1, and incubation times were 
reduced to 10 minutes on ice and 20 minutes at 37 °C. Following the 20 minute 
incubation, cultures were supplemented and plated with citrate as described for the 
transduction protocol above, except that chloramphenicol was maintained in all media 
and plates were also supplemented with erythromycin (5 μg/ml) to quantify acquisition 
of the marked prophage. The ɸNM1-ErmR2 phage used for infections is a derivative of 
ɸNM1-ErmR (ref. (Goldberg et al., 2014)) with a modified ermC 5’ UTR that includes the 
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SNP found in the tyc-1 allele previously reported (Gryczan et al., 1980) to improve 
constitutive expression of the cassette’s gene product in B. subtilis. To estimate the 
concentration of total recipients harboring CRISPR-Cas systems, serial dilutions of the 
untreated overnight cultures were plated in the presence of chloramphenicol alone.  
 
Mitomycin C survival assays. 
Overnight cultures were grown for 14 hours and then subcultured for 1 hour 15 
minutes (~0.3-0.6 attenuance, D600 nm). Subcultures were split into an untreated or treated 
tube where MMC was added to a final concentration of 0.5 μg/ml. After an additional 
45 minutes of growth, treated and untreated cultures were vortexed, diluted, and plated 
to quantify CFUs. 
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CHAPTER 4: PERSPECTIVES ON TOLERANCE TO FOREIGN ELEMENTS
 THROUGH THE LENS OF PROKARYOTIC IMMUNE SYSTEMS 
 
Although an organism may be defined by its genomic content in a strict genetic sense, 
the classical evolutionary definition is concerned most with its phenotype (Doolittle and 
Sapienza, 1980). The descriptive power of a genome sequence is therefore limited, in 
part, to the extent that phenotypes can vary independently of a particular genotype. 
Presumably, phenotypic variability can more predictably be accounted for, given a 
better understanding of how multicellular organisms are shaped by environmental 
factors, including the microbiota that colonizes them (Amaral et al., 2008; Backhed et al., 
2004; Li et al., 2008; Rakoff-Nahoum et al., 2004; Stappenbeck et al., 2002). Collectively, 
the genetic repertoire of a multicellular organism, along with the microbiomes of its 
resident microbiota, can be conceptualized as a metagenome. Hence, there is increasing 
effort to define metagenomic information, such as microbiomes, that could be correlated 
with organismal phenotypes (Bruls and Weissenbach, 2011). 
Similar in a sense to how microbiome analyses have uncovered substantial 
metagenomic variation among multicellular organisms within a species, comparative 
genome analyses of prokaryotes have revealed a surprising degree of genomic 
variability among related strains that were traditionally classified as members of the 
same species (Murray et al., 2001; Tettelin et al., 2005). Accordingly, a modern view of 
246 
prokaryotic genomes has emerged that distinguishes ‘core’ genome sequences, which 
are common to most or all strains of a particular group, from the ‘accessory’ genome 
sequences, which are not universally sampled (Lan and Reeves, 2000; Mira et al., 2010). 
Accessory sequences typically comprise no more than 10–20% of a given genome 
(Makarova et al., 2014), but their gene diversity across strains can be substantially 
greater than that observed for core sequences (Koonin and Wolf, 2008). Furthermore, it 
has been found that prophages, plasmids and various predicted MGEs are usually 
associated with accessory rather than core sequences of the genome (Cortez et al., 2009; 
den Bakker et al., 2013; Di Nocera et al., 2011; Lindsay and Holden, 2006; Ozer et al., 
2014). Thus, by analogy to mammal-associated microbiomes, the accessory genomes of 
prokaryotes may represent a transient repository for horizontally derived foreign 
genetic information that can contribute to adaptability. However, as both microbiomes 
and prokaryotic accessory genomes are also liable to harbor parasitic elements, the host 
organism may employ its selective defenses to keep these elements in check while 
participating in symbiotic interactions or HGT. In turn, the flux of genetic information 
in prokaryotic genomes can be selectively moderated by both CRISPR–Cas and R–M 
systems through their influence on MGEs and accessory genomic content encountered 
via HGT. Although the selectivity of these systems is tied to their resistance 
mechanisms, it can be reinforced by tolerance in certain contexts, as I explain below. 
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4.1 CRISPR-Cas 
As outlined in Chapter 1, a CRISPR–Cas system resists diverse MGEs according to its 
spacer content, and this can have evolutionary consequences for lineages that acquire 
different spacers. For example, cells that acquire immunity to parasitic elements can 
gain a selective advantage (Barrangou et al., 2007), whereas those that target favorable 
or ‘self’ elements can be put at a disadvantage and potentially be lost from the 
population (Bikard et al., 2014; Bikard et al., 2012; Jiang et al., 2013b; Marraffini and 
Sontheimer, 2008). However, just as the risk imposed by particular microorganisms can 
be niche- or context-dependent within a mammalian host (Hube, 2004; Stecher et al., 
2007; von Eiff et al., 2001), the fitness contributions associated with a particular MGE are 
not always clear-cut in the prokaryotic domain. Temperate phages are a prime example 
(Figure 1-5). Although toxic during lytic infections, they can be maintained as 
prophages in an alternative, lysogenic state that does not necessarily reduce their host’s 
fitness and can even be advantageous (Brüssow et al., 2004; Dykhuizen et al., 1978; 
Edlin et al., 1977). Notwithstanding, indiscriminate CRISPR–Cas targeting of temperate 
phage DNA compromises the stability of the lysogenic state in addition to preventing 
lytic infection (Edgar and Qimron, 2010; Goldberg et al., 2014). This is because the 
transition between the two states does not involve genetic alteration of the phage DNA 
sequence (Lwoff, 1953) but instead results from changes in its transcriptional activity 
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within the host; in fact, most of a lambdoid prophage’s genes are typically repressed 
during lysogeny (Ptashne, 2011).  
These properties of lambdoid temperate phages, it would appear, allow a 
staphylococcal type III CRISPR–Cas system to distinguish between each of their 
infection states (that is, lytic versus lysogenic) via transcription-dependent targeting 
(Goldberg et al., 2014). Type III CRISPR–Cas systems only initiate an immune response 
 
Figure 4-1. Schematic diagram summarizing selectivity associated with conditional 
tolerance by type III CRISPR-Cas systems. 
(A) Transcription-dependent targeting by type III CRISPR-Cas systems is only directed 
at DNA elements with actively transcribed target sequences. In this example, type III 
targeting licenses conditional tolerance of a lambdoid temperate phage. During the 
phage’s lytic cycle, when most of its genome is transcribed, type III targeting occurs 
readily. During its lysogenic cycle, most prophage sequences are repressed in the host 
chromosome, and the prophage DNA may be spared from type III targeting. 
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when their target sequences are transcribed (Figure 4-1). As such, they can tolerate non-
transcribed prophage targets during lysogeny without withdrawing resistance to lytic 
infection by the same phage. Tolerance, at least for temperate phages, may thus be 
achieved in a context-dependent, conditional manner, as it is for microbiota in the gut of 
a healthy mammal (Belkaid and Hand, 2014). This prokaryotic phenomenon could be 
further viewed as a ‘disease tolerance’ paradigm (Gozzelino et al., 2012; Medzhitov et 
al., 2012; Soares et al., 2014), insofar as it averts the ‘immunopathology’ associated with 
targeting of prophages in the host chromosome without elimination of the target 
element. Alternative strategies for disease tolerance, aimed at neutralizing parasite-
derived toxins (Playfair et al., 1990; Schofield et al., 2002) rather than the parasites 
themselves, might also exist in the prokaryotic domain. Past and recent work have 
demonstrated that type III CRISPR–Cas systems can cleave RNA targets both in vitro 
(Hale et al., 2009; Jiang et al., 2016; Samai et al., 2015; Staals et al., 2014; Tamulaitis et al., 
2014; Zhang et al., 2012) and in vivo (Hale et al., 2012; Jiang et al., 2016; Samai et al., 2015; 
Tamulaitis et al., 2014; Zebec et al., 2014) and thus offer the potential to reduce the 
toxicity associated with certain viral transcripts. It is currently unclear whether DNA 
degradation can be uncoupled from RNA cleavage during canonical type III targeting 
circumstances. If this were found to occur, however, cleavage of RNA in the absence of 
DNA degradation could potentially represent another avenue for tolerating certain 
types of MGEs. To this end, the potential of the recently discovered type VI systems 
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might also be explored, since they do not possess any known DNase activities 
(Shmakov et al., 2017). 
 
4.2 Restriction-Modification 
In certain contexts, R–M systems can also tolerate the insertion of foreign DNA into the 
chromosome. Owing to their intracellular, double-strand cleavage mechanism, REases 
do not eliminate the DNA of unmodified target elements per se. In fact, it has been 
shown that fragments of restriction-sensitive DNA encountered through transduction 
or conjugation can be rescued by recombination with the chromosome (McKane and 
Milkman, 1995; Milkman et al., 1999; Wood, 1966). This was proposed to contribute to 
the genomic mosaicism observed among natural isolates of Escherichia coli (Milkman 
and Bridges, 1993). Furthermore, evidence indicates that R–M systems are ineffective at 
blocking natural transformation with otherwise restriction-sensitive DNA, at least when 
homologous sequences are introduced (Bron et al., 1980; Cohan et al., 1991; Harris-
Warrick and Lederberg, 1978; Lacks and Springhorn, 1984; Trautner et al., 1974). These 
results have been explained in light of the findings that DNA enters the cell through a 
single-stranded intermediate during natural transformation (Lacks, 1962; Piechowska 
and Fox, 1971), which remains stable (Eisenstadt et al., 1975; Morrison and Mannarelli, 
1979; Mortier-Barriere et al., 2007) before recombination with a methylated 
complementary strand (Figure 4-2). Interestingly, an R–M system in Streptococcus  
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pneumoniae was found to encode an auxiliary MTase that is upregulated during 
competence and allows even non-homologous sequences to be protected from 
restriction during natural transformation (Cerritelli et al., 1989; Johnston et al., 2013a). 
Known as modification methylase DpnIIB (encoded by dpnA), this MTase 
 
Figure 4-2. Schematic diagram summarizing the selective resistance and tolerance 
activities associated with Restriction-Modification.  
(A) Intracellular restriction endonuclease enzymes (REases) can recognize and 
inactivate double-stranded DNA (dsDNA) of unmodified phages and other mobile 
genetic elements but do not recognize single-stranded DNA (ssDNA) intermediates of 
natural transformation. Successful homologous recombination may result from pairing 
of unmethylated (red) ssDNA with a methylated (red & blue) homologous sequence in 
the host chromosome, which promotes rapid modification and tolerance of the newly 
incorporated strand. The red ‘x’ represents arbitrary degradation of a donor DNA 
strand upon uptake of dsDNA during natural transformation. 
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preferentially methylates single-stranded DNA and may thus promote natural 
transformation without compromising the ability of the system to resist phages that 
enter double stranded. In its absence, replication of non-homologous, unmethylated 
single-stranded DNA that has integrated into the chromosome can give rise to 
unmethylated double-stranded DNA that is susceptible to the REase (Johnston et al., 
2013b). Hence, I’m suggesting that the specialized action of DpnIIB exemplifies another 
disease tolerance strategy in that it is only required to protect the chromosome from 
immunopathological damage when foreign, non-homologous sequences are 
introduced. Non-homologous fragments of DNA that are introduced through phage 
transduction might also be processed to single strands before recombination. The effect 
of DpnIIB on transduction efficiency from an unmodified donor should therefore be 
examined in future work. Finally, it should be emphasized that the tolerance scenario 
observed with DpnIIB closely mirrors that observed with the type III CRISPR–Cas 
system, in which a substantial stretch of non-homologous DNA—the prophage—is 
allowed to integrate into the chromosome.  
 
4.3 General implications and concluding remarks 
Surveillance by both R–M and CRISPR–Cas systems can be optimized for selective 
incorporation of foreign genetic information in a manner that reduces the risks of 
parasitism and immunopathology. This is similar to the pattern observed for 
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multicellular organisms, in which an optimal balance of resistance and tolerance must 
be struck to accommodate commensal microbiota without succumbing to infection or 
compromising health (Ayres and Schneider, 2012). Mammalian strategies for pathogen 
resistance have been studied extensively in the field of immunology. Meanwhile, host 
strategies for tolerance of non-self elements, especially as an alternative or, at least, 
auxiliary immune function with respect to resistance, have been far less explored in 
animal models (Ayres and Schneider, 2012; Howick and Lazzaro, 2014; Raberg et al., 
2009). Efforts to understand tolerance mechanisms hold the promise of revitalizing our 
grasp on clinical problems, in which vaccination, antibiotics and other therapeutic 
interventions aimed at bolstering resistance have fallen short. Alternative therapeutic 
approaches could be aimed at exploiting or reinforcing tolerance (Soares et al., 2014). Of 
particular relevance to this discussion, it has been postulated that tolerance strategies 
can lead to more stable (or at least more homogeneous) evolutionary outcomes(Miller et 
al., 2006; Roy and Kirchner, 2000; Schafer, 1971) that are distinct from the arms race 
dynamics that typically result from resistance to pathogens (for further discussion of the 
latter, see (Brockhurst and Koskella, 2013)). The outcomes observed for CRISPR–Cas 
targeting of temperate phages in prokaryotes are ostensibly consistent with this notion, 
as tolerance during lysogeny does not lead to genetic alteration of either the host or its 
target prophage. In the absence of tolerance, lysogenization was less frequent and only 
occurred in genetic mutants that had either lost their prophage target sequence or 
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dismantled their CRISPR–Cas immunity (Goldberg et al., 2014). This latter propensity to 
abandon CRISPR–Cas immunity (Bikard et al., 2012; Jiang et al., 2013b; Vercoe et al., 
2013; Yosef et al., 2011) might in part explain the absence of these systems in about half 
of sequenced bacteria, especially considering that mechanisms for non-self tolerance 
have yet to be identified for most of the CRISPR–Cas types. In these cases, other 
mechanisms that allow for phage defense and resistance to MGEs could be helping 
these bacteria to survive without CRISPR-Cas systems (Labrie et al., 2010; Ram et al., 
2014). Another point to consider is that the abundance of CRISPR-Cas systems within a 
population could also be diminished by fitness costs associated with CRISPR-Cas 
immunopathology, even if the systems are intrinsically capable of tolerance. This point 
was expressly demonstrated in Chapter 3 for type III-A CRISPR-Cas systems in 
lysogenic populations of S. aureus. Chapter 3 also established that type III-A systems 
which provide broad-spectrum immunity to diverse temperate phages can put their 
host at a greater risk of immunopathology in the event of (poly)lysogenization. At least 
in part, however, this increased risk was found to be alleviated by the presence of 
spacer-target mismatches that are expected to occur in natural populations. Analogous 
immunopathological complications faced by mammalian lineages are dealt with 
through well-conserved central and peripheral tolerance mechanisms. The latter 
tolerance mechanisms appear to be particularly crucial during encounters with 
innocuous non-self elements, including food-derived products and commensal 
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microorganisms that are highly abundant in the gut (Pabst and Mowat, 2012). Insofar as 
tolerance strategies can work to curb — or even replace — resistance strategies that 
would otherwise reduce a particular microbial burden, tolerance may, in turn, influence 
microbiome compositions and stability. Therefore, in addition to leading us towards 
novel therapeutics for dealing with the complications of infection and 
immunopathology (Soares et al., 2014), knowledge of tolerance mechanisms that fulfil 
these criteria could prove insightful when attempting to develop clinical interventions 
aimed at manipulating specific members of the commensal microbiota. 
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